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Abstract
At the time of writing this thesis, the overall 5 year survival from pancreatic cancer 
was 3%, mainly due to late presentation. The European Registry of Hereditary 
Pancreatitis and Familial Pancreatic Cancer was established to identify individuals at 
high risk of pancreatic cancer and to offer them screening. At the time the work 
described in this thesis was initiated, relatively few individuals had been offered 
screening, which combined with the low number of prospective cancers in the 
registered high risk families made a reasonable diagnostic yield from screening 
unlikely.
The primary aim of this work was, therefore, to improve risk stratification on an 
individual basis for members of both hereditary pancreatitis and familial pancreatic 
cancer kindreds and to pilot a trial of secondary screening in individuals with an 
increased risk of pancreatic cancer.
The aims relating to risk stratification were met. Better primary screening led to 
increasingly in depth characterisation of high risk kindreds. A computer model was 
devised that calculated survival on an individual basis in familial pancreatic cancer 
and the possible utility of glucose to aid early diagnosis was investigated. In the 
hereditary pancreatitis kindreds, the clinical phenotype produced by the p.A16V 
mutation of the PRSS1 gene was characterised for the first time. A multi-centre study 
of secondary screening for early pancreatic cancer in high risk individuals was also 
established, though at time of writing, the world’s first curable pancreatic cancer has 
yet to be detected by screening.
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1 Introduction 
1.1 Physiology of the Pancreas
The pancreas has two physiological functions, an exocrine function involved in 
digestion and an endocrine function relating to glucose metabolism. These actions 
are performed by different cells that operate as separate functional units. This 
section will focus on pathways leading to pancreatitis and the development of 
diabetes. As will be described later in the thesis, the development of diabetes could 
be a crucial element in identifying both early tumours and high risk individuals.
The majority of the pancreas is made up of lobules which contain multiple spherical 
clusters (acini) made up of acinar cells which are joined to ductal cells in a 
continuous epithelial layer. The intra-lobular ducts drain into a central intra-acinar 
terminal ductule. These contribute to progressively larger ducts until the main 
pancreatic duct of Wirsung and accessory duct of Santorini are formed, which empty 
into the duodenum1.
The primary function of the ductal cells is to produce water and bicarbonate which 
neutralise the low pH of chyme. The role of the acinar cells is more complex. They 
produce pancreatic enzymes, which have a crucial role in digestion. The enzymes 
are produced within the acinar cells’ rough endoplasmic reticulum and are transiently 
stored in an inactive form within zymogen granules1. They are released into the 
duodenum via the ductal system in response to acetylcholine and cholecystokinin, 
which are released by local nerves and the duodenal mucosa respectively. Once in
13
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the duodenum, trypsinogen is converted to trypsin, triggering activation of the other
pancreatic enzymes1.
The exact aetiological process/processes leading to acute pancreatitis remain 
unclear but a general feature is thought to be either premature activation of 
trypsinogen to trypsin or the failure to eliminate active trypsin within the pancreas2. 
The triggers for this are most commonly gallstones and heavy alcohol consumption3. 
Chronic pancreatitis is characterised by fibrosis of the gland. It has been hotly 
debated whether this chronic disease is a completely separate condition from acute 
pancreatitis (in much the same way as cirrhosis of the liver and hepatitis are 
considered as separate entities) or whether this is just a natural progression from 
recurrent (possibly sub-clinical) acute attacks4. Most cases of chronic pancreatitis 
have traditionally been seen in those with a high intake of alcohol but there is an 
increasing understanding of the role of genetic factors in chronic pancreatitis2, with 
mutations in, for example, the Cystic Fibrosis Transmembrane Receptor (CFTR) 
gene apparently increasing an individual’s susceptibility5,6.
An understanding of Hereditary Pancreatitis (HP) is important as it will be discussed 
repeatedly in this thesis. There are 3 different types of human trypsinogen, termed 
cationic, anionic and meso-trypsinogen. These are coded for by the genes PRSS1, 
PRSS2 and PRSS3 respectively7. PRSS1 mutations cause pancreatitis8, 9, but it 
appears that PRSS2 and PRSS3 mutations do not10'12.
There is still dispute and scope for further work on the biochemical effects of 
trypsinogen mutations, and it may prove to be the case that most reported 
‘mutations’ actually have no effect and that they are actually artefactual13. In contrast
14
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the main mutations seem to have pleiotropic effects in vitro. Sahin-Toth performed
molecular analysis on recombinant trypsinogen with a range of mutations and 
showed that most of them, including the most common mutations, led to increased 
auto-activation of trypsinogen7, but it is equally clear that the most common mutation 
p.R122H reduces self-inactivation of trypsin14. A novel mechanism, the ‘Unfolded 
Protein Response’15, was recently revealed in a p.R116C kindred. It is unclear which 
of these mechanisms has the greatest effect in vivo.
The endocrine function of the pancreas is performed by specialised cells that form 
the Islets of Langerhans. The human pancreas contains 1-2 million islets, 
predominantly within the body and tail, organised around small capillaries which act 
as the mechanism for release of the cell products into the systemic circulation1.
The islets contain 5 known cell types. Alpha cells produce glucagon1; beta cells 
produce insulin1 and islet amyloid polypeptide16; delta cells produce somatostatin1; 
and pancreatic polypeptide cells produce pancreatic polypeptide16. Epsilon cells 
were discovered in mice in 200417 and produce Ghrelin. The description of 
mechanisms of the different cell products will focus on those related to diabetes.
Insulin production by the beta cells is triggered by a complex series of feedback 
loops. The one relating to serum blood glucose is the best understood18. The main 
function of insulin is facilitating the storage of energy, whenever there is an excess of 
energy substances within the body. Excess carbohydrates are stored as glycogen 
within the liver and muscles, excess fats are stored in the adipose tissues and any 
carbohydrates that are unsuitable for glycogen production are converted to fats 
under the stimulus of insulin for storage1. Insulin directly promotes amino acid uptake
15
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and conversion into protein as well as inhibiting the breakdown of proteins that have
already been produced1. Glucagon, produced by the alpha cells, has several 
functions that are diametrically opposed to those of insulin. Glucagon’s production is 
again closely related to serum blood glucose and it’s principle effects on glucose 
metabolism are the promotion of glycogenolysis (which increases serum blood 
glucose within minutes) and the promotion of gluconeogenesis in the liver from 
amino acids19. Diabetes results from either inadequate production of insulin, which 
can result from pancreatic damage, or a reduction in the systemic response to 
glucose, which is the main pathway in the development of late onset diabetes in the 
obese1.
16
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1.2 Pancreatic Ductal Adenocarcinoma
The most common form of pancreatic cancer is pancreatic ductal adenocarcinoma 
(PDAC). Other malignancies occur in and around the pancreas but for the purposes 
of this thesis, whenever the term pancreatic cancer is used, this will refer to PDAC 
unless explicitly specified.
Pancreatic cancer is the tenth most common malignancy in males but the fourth 
leading cause of cancer death in both men and women20. The latest published 
figures available for England and Wales are for the year 20 0021. These show the 
incidence for the year 2000 to be 10.5/100,000 and 7.9/100,000 in males and 
females respectively, with 17,919 patients diagnosed between 1996 and 1999. 
Incidence is falling slightly in both sexes, with the gap between men and women 
reducing. These changes may be due to changes in smoking behaviour.
The only hope of cure is surgical resection but the high rate of locally advanced and 
metastatic disease at time of presentation means that surgical treatment is only an 
option for a small minority at the time they are diagnosed. The best estimates of the 
proportion of all those that are suitable for resection come from population based 
studies and varies from 2.6%22, through 4.2%23, 9%24 to 13.4%25. The resection rate 
tends to be higher with more recent data24,25 and has been estimated to be as high 
as 15-20%26, but definite calculations remain difficult.
If resection is possible, five year survival at a single centre has been reported to be 
as high as 32%27. Even better figures have been reported for early stage disease28, 
but the results from the ESPAC-1 (European Study Group of Pancreatic Cancer 1)
17
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trial29 of 21% are more typical. Latest figures from the Mayo clinic give a five and ten
year survival of 18% and 13% respectively30, with five year survival at Johns Hopkins 
being 17%31. As only the minority of those affected can be treated surgically, overall 
survival remains poor, with 12 and 60 month survival for all those diagnosed in 
England and Wales being 12% and 2% respectively21.
The general trend in post resection survival is improving32 but the progress may not 
be as dramatic as some authors claim33. Progress is likely to be multi-factorial. 
Concentration of pancreatic services within tertiary centres will have contributed34'36, 
and trial evidence has helped to clarify aspects of clinical care29. More radical 
surgery has not been shown to make a significant difference to long term survival37.
This thesis is based on the assumption that screening (and so earlier surgery) will 
offer better survival. It is therefore of great importance to note that post-operative 
chemotherapy has shown survival benefit in the ESPAC-1 trial, a large randomised 
controlled trial (RCT), although there was no discernable benefit in a chemo- 
radiotherapy group29. A second large RCT also showed no survival benefit from 
adjuvant chemo-radiotherapy38. This suggests that poor survival results from a 
systemic disease that is at least partially treatable. It can be reasonably 
hypothesised that the metastatic burden will at least be lower with earlier detection 
and so easier to treat. The findings of ESPAC-1 have been accepted in Europe but 
have not been universally accepted in the US26 where chemo-radiotherapy remains 
in use.
The chemotherapeutic agent used in ESPAC-1 was Fluorouracil (5-FU) and this 
remains in widespread use, delivered orally as the pro-drug Capecitabine. The
18
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ESPAC 3 trial has shown no survival difference between 5-FU and Gemcitabine in
the adjuvant setting39 although Gemcitabine is now the established agent of choice 
when chemotherapy is being used with palliative intent40. Combinations of agents 
are an area of ongoing research, particularly in the palliative setting. The addition of 
cisplatin to gemcitabine has been shown to be beneficial in advanced biliary tract 
carcinomas41 but this benefit was not shown in advanced pancreatic cancer42. The 
combination of capecitabine with gemcitabine showed a significant increase in both 
the objective response rate and progression-free survival and was associated with a 
trend toward improved overall survival compared with Gemcitabine alone43. Chemo- 
radiotherapy has also been considered pre-operatively44 and agents such as the 
epidermal growth factor receptor inhibitor, Erlotinib, have become available although 
their role remains limited45. One major question which still needs to be addressed is 
whether there is a role for neo-adjuvant treatment in pancreatic cancer, although the 
answer is likely to be some years away.
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1.2.1 Types of Pancreatic Lesion and the PanIN Model
This thesis will propose that in screening for pancreatic cancer in high risk groups 
the ideal result will be the identification of precancerous lesions (in preference to 
identification of adenocarcinoma). The arguments for this will be made later, but it is 
necessary to first understand the nature of these lesions.
In 2000 a progression model was proposed where normal pancreatic ductal cells 
developed through an adenoma-carcinoma sequence in a transition towards 
malignancy46. There was already good evidence for this in colorectal cancer47 but it 
took several years to achieve an acceptance of a similar pathway for pancreatic 
cancer. The classification system for pancreatic lesions that was first proposed in 
199448 was built upon in 199949 when pancreatic intraepithelial neoplasia (or PanIN) 
was split into three sub-groups; PanIN 1 (divided into types A and B), PanIN 2 and 
PanIN 3. Definitions were tightened in 200350 but the underlying system was not 
altered and the definitions have been increasingly accepted with time.
Normal tissue was defined as having normal ductal epithelium, ranging from cuboidal 
to low-columnar epithelium with amphophilic cytoplasm and no evidence of 
mucinous cytoplasm, nuclear crowding or atypia. The next step beyond normal is 
squamous (transitional) metaplasia, which was defined as the replacement of normal 
cuboidal ductal epithelium by mature stratified squamous or pseudo-stratified 
transitional epithelium, in the absence of cytological atypia50.
PanlN-1A lesions were defined as flat epithelial lesions comprising tall columnar 
cells with basally located nuclei and abundant supranuclear mucin. They have small 
nuclei which are round-to-oval in shape. If oval, these are oriented perpendicular to
20
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the basement membrane. The difference between a PanlN-la and a PanlN-1b was
defined as the presence of papillary, micropapiiiary, or basally pseudostratified 
architecture50.
PanlN-2 lesions were defined as mucinous epithelial lesions that can be flat but are 
mostly papillary, with some nuclear abnormalities. These abnormalities might include 
loss of polarity, nuclear crowding, enlarged nuclei, pseudo-stratification, and 
hyperchromatism, but falling short of the abnormalities seen in PanlN-3. Mitoses are 
rare, but when present are non-luminal and are not atypical60.
A diagnosis of PanIN 3 was suggested by true cribriforming, the appearance of 
‘budding off of small clusters of epithelial cells into the lumen and luminal necrosis. 
The lesions are generally papillary or micro-papillary, though they can still be flat. 
Cytologically, PanIN 3 lesions have lost nuclear polarity, with the presence of 
dystrophic goblet cells, mitoses, nuclear irregularities, and prominent (macro) 
nucleoli. Overall, cellular appearances were in keeping with carcinoma, but without 
invasion of the basement membrane50. These changes are presented visually in 
figure one.
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Figure 1: Histological images of benign pancreatic ductal epithelial cells, progressive 
PanIN lesions and invasive carcinoma, with associated genetic alterations.
Reprinted (with consent) from P Ghaneh eta/(2007), Gut 56 (8) 1134-5251.
Figure illustrates a progression from left to right from normal ductal epithelial tissue through 
to invasive adenocarcinoma, through a series of histologically defined precursor lesions. The 
genetic mutations associated with each stage are also shown.
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The evidence to support the theory that PanINs are the precursors of invasive 
pancreatic adenocarcinoma results from large pathological studies, case studies and 
identification of genetic markers.
Pathological evidence includes the original study by Cubilla and Fitzgerald52, who 
analysed more than 1000 pancreatic specimens. They identified histologically 
distinct proliferative lesions in pancreatic ducts and ductules adjacent to infiltrating 
pancreatic adenocarcinoma. The lesions were initially dubbed ‘hyperplasias’ and 
were shown to be more common in the specimens with cancer than in those without. 
A similar study, Kozuka et a/53, corroborated the findings. PanINs are more common 
in the pancreatic head and increase in frequency with age. Luttges and Kloppel54 
pointed out that this is the same pattern seen in pancreatic ductal adenocarcinoma.
Additional evidence was provided by Brat et a/55, where three cases of infiltrating 
ductal adenocarcinoma were reported 17 months to 10 years after the identification 
of atypical papillary duct lesions within the pancreas. Similarly, Brockie et a/56 
described two patients with atypical papillary lesions who subsequently developed 
invasive pancreatic ductal adenocarcinoma.
The genetic analysis of PanINs provides strong evidence of a link to 
adenocarcinoma and generally supports the progression model. The genetic 
mutations associated with each stage of the Pan IN model have been shown above 
in figure one51. There are well established genetic abnormalities associated with 
PanINs on the K-RAS2 gene (which codes for the K-Ras oncoprotein)57'61 and the 
tumour suppressors CDKN2A (which codes for p16)62,63 and Tp53 (which codes for
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p53)61,64. Mutations of these three genes are all tested for as part of EUROPACs 
secondary screening study outlined later in this thesis. As figure one shows, there 
are a large number of other PanIN associated gene mutations affecting members of 
the ErbB family of receptor tyrosine kinases such as HER1 and HER2)61,65, other 
tumour suppressor genes such as SMAD466, and caretaker gene mutations such as 
BRCA267. In addition to gene mutations, other genetic factors associated with PanIN 
lesions include telomere shortening68, aberrations in ceil cycle control mechanisms 
such as over-expression of p2iWAF/GIP169) growth factor signalling changes such as 
over-expression of COX-2 and inappropriate activation of embryonic signalling 
pathways such as Hedgehog70,71 and Notch71.
It is widely accepted that pancreatic cancers can also develop from precursor 
lesions other than PanINs. These include both mucinous cystic neoplasms (MCN), 
and intraductal pancreatic mucinous neoplasms (IPMN). The definitions relating to 
IPMN were defined in a WHO publication in 200072, and the associated genetic 
changes are becoming increasingly well characterised73"79. In time this may permit 
clinicians to differentiate between mucinous lesions that will follow a benign course 
and those that will undergo malignant change.
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1.2.2 Symptoms and Signs of Pancreatic Cancer
The symptoms and signs of pancreatic cancer are relevant to this thesis as although 
they are generally non-specific and normally occur, as stated already, when the 
cancer is already incurable. They certainly play a part in any vigilance system and at 
present represent the bench mark against which any screening system must be 
judged. In particular diabetes will be discussed in this thesis as it may, in time, open 
new opportunities for screening and earlier diagnosis.
The classical presentation is of epigastric pain which radiates to the back, weight 
loss, and painless obstructive jaundice80. Pain originating from a pancreatic tumour 
can be felt anywhere in the T6 to T10 dermatomes. It is initially difficult to localise, 
although it can be more pronounced in body and tail tumours and is the most 
common presenting complaint in larger tumours81. Weight loss is often a relatively 
late symptom and is more common in tumours of the pancreatic head. A proportion 
of the weight loss associated with pancreatic cancer will be due to exocrine 
pancreatic failure and the associated reduction in absorption of nutritional intake, but 
this will be exacerbated by increased metabolic requirements of malignant cells as 
the primary grows and metastatic disease progresses. The weight loss associated 
with malignant disease accelerates as the tumour mass increases. Obstructive 
jaundice can be the trigger that leads to presentation in those with potentially 
resectable disease81. Should the tumour develop in the pancreatic head (the 
commonest site for pancreatic cancer), obstruction of the biliary tree may occur 
relatively early and trigger diagnosis, whilst the tumour is still potentially curable.
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Occasionally individuals may experience other symptoms. An estimated 1% of newly 
diagnosed diabetics aged greater than 50 years have developed diabetes as a direct 
result of an emerging pancreatic cancer82 and there may be non-specific symptoms 
such as nausea and vomiting. Nausea and loose stools could develop as a result of 
exocrine pancreatic failure. Gastric outlet obstruction would obviously lead to 
vomiting, but this would normally be expected to only occur in those with locally 
advanced disease83.
By far the most common physical sign associated with potentially curable pancreatic 
cancer is jaundice84. Less commonly, one may see left supra-clavicular 
lymphadenopathy (Troisier’s sign), or other signs associated with jaundice, liver 
failure or portal venous hypertension such as pruritus, spider naevi or caput 
medusae respectively.
Attempts have been made to characterise the symptoms and signs associated in 
pancreatic cancer, but except for those related to cholestasis, these are of limited 
clinical application84,85.
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1.2.3 Diagnosis
The investigative process may be triggered by the presence of the symptoms or 
signs described in the previous section or, as cross sectional imaging becomes 
increasingly common, more pancreatic cancers are being diagnosed incidentally86. 
Logically, a greater proportion of individuals with these tumours will be potentially 
curable as the tumour has been detected before clinical signs and symptoms have 
become apparent. The most common initial investigations if a patient presents and 
pancreatic cancer is suspected is serum CA19-9 and a computed tomography (CT) 
scan of the abdomen. If the results of either of these tests showed evidence of a 
pancreatic tumour, in the United Kingdom (UK) at least, the case would be referred 
to a multi disciplinary team (MDT) meeting. The outcome of the discussion at this 
meeting would be: referral to a resectional centre; palliative oncology after the 
confirmation of the diagnosis; or best supportive care, if the patient was not a 
candidate for either of the first two treatment modalities.
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1.2.4 Current Treatment
All potential resections in the UK are put through the supra-regional MDT meetings 
at the relevant regional centre. Once all appropriate investigations have been 
performed and cytological evidence obtained wherever possible, a decision is taken 
as to what the most likely diagnosis is and the most appropriate treatment. For 
pancreatic cancer, the key decision is whether the tumour is resectable. This is 
guided by the degree of local invasion and the presence of metastatic disease. At 
the Royal Liverpool University Hospital, which is the centre which performs the 
pancreatic surgery for patients from Merseyside and much of North Wales, this 
decision is informed by the CA19-9 level. If the CA19-9 is greater than 150 kU/L, a 
laparoscopic ultrasound is performed87. This is a more sensitive method of assessing 
vascular encasement, looking for small liver metastases and finding small peritoneal 
deposits than staging CT. Those that still have potentially curable disease are 
subsequently listed for resectional surgery.
Those that have unresectable disease on presentation, or are shown to have 
incurable disease after either laparoscopy or laparotomy, are put forward for 
palliative chemotherapy. Palliative surgery or stenting is also performed as 
appropriate.
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1.2.5 Prognosis
There has been some progress in one year survival of pancreatic cancer. This has 
been a result of regionalisation of services and the addition of adjuvant 
chemotherapy to surgical resection, but with only 10-15% of pancreatic cancers 
being suitable for surgical cure at presentation, overall five year survival remains in 
the region of 2-3%20. The low 5 year survival rate makes it imperative that pancreatic 
cancers are detected earlier in their developmental process, when they are still 
potentially curable. One of the problems with earlier detection by screening is that 
the sensitivity and specificity of the available imaging modalities is reduced, altering 
the balance of potential risk and benefit. The incidence of pancreatic cancer in the 
general population is low. As the specificity of the available imaging modalities falls, 
it becomes inevitable that the number of false positives increases. At some (as yet 
undetermined) point, there will be a crossover between the morbidity and mortality 
that is involved in operating on the inevitable false positives that result from 
screening and the lives saved by the earlier detection of pancreatic cancer. This is a 
difficult and as yet unresolved problem, but one way of optimising the risk to benefit 
ratio is to optimise the necessary screening protocols to groups at greatest risk of 
pancreatic cancer.
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1.3 The High Risk Groups
Relatives of pancreatic cancer patients have an elevated risk of pancreatic cancer. 
This risk is mostly accounted for by a few families with multiple cases88, with an 
estimated 5-10% of pancreatic cancer cases occurring as part of familial cancer 
syndromes associated with known mutations89. A recent meta-analysis shows the 
relative risk of a family history to be 1.80 (95% Cl 1.48, 2.12), although the 
heterogeneity of the studies limited the sub-group analysis90.
The cause of clustering of cancer cases within families will vary. The cancers may 
result from an inherited predisposition to a cancer associated condition such as 
hereditary pancreatitis91'93 or diabetes82. Other families can be shown to carry known 
pancreatic cancer associated genetic mutations, such as CDKN2A94, 95; whilst others 
have been classified as belonging to the group Familial Pancreatic Cancer (FPC), 
where the causative mutation for the vast majority of families remains unknown96,97. 
As this thesis will largely focus upon FPC, this will be the first of the groups to be 
discussed.
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1.3.1 Familial Pancreatic Cancer
Familial Pancreatic Cancer (FPC) is the name given to the cancer syndrome where 
multiple cases of pancreatic cancer are clustered within a single family. Such 
clusters of cancers were originally thought to be due to common environment or 
coincidence, but seminal work by Henry Lynch and co-workers (initially with 
colorectal cancer) resulted in the gradual acceptance of a genetically determined 
predisposition with the first cohort of pancreatic cancer families presented in 198998. 
The potential implications of genetic predisposition prompted the establishment of 
registries around the world, including the European Registry of Hereditary 
Pancreatitis and Familial Pancreatic Cancer (EUROPAC), with which the author is 
associated.
The term FPC is used to describe multiple cases of pancreatic cancer within families 
in a pattern consistent with autosomal dominant inheritance. This definition has 
gradually been strengthened by the registries to exclude families that belong to other 
cancer syndromes, which carry a predisposition to pancreatic cancer (e.g. Breast- 
Ovarian Syndrome), or hereditary illnesses such as Hereditary Pancreatitis (HP), 
which carry an associated increased risk of pancreatic cancer".
The causative gene in Familial Pancreatic Cancer (FPC) kindreds remains 
unidentified but segregation analysis of families on registries suggests a rare major 
gene conferring predisposition100, 101. Autosomal dominant transmission is not 
universally accepted but is the most likely form of transmission given a single major 
gene. An inherited predisposition for cancer is usually the result of a heterozygous
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defect in a tumour suppressor, with loss of the second copy of the tumour 
suppressor being the second ‘hit’. Genetic instability is part of the ageing process 
and so the second hit will be inevitable if an individual lives long enough.
1.3.1.1 The Evidence for FPC
Epidemiology
The sheer number of families that are included in registries provides strong evidence 
pointing towards FPC as a genuine genetically defined syndrome, with EUROPAC’s 
figures shown in the first part of the results section of his thesis. At the time of data 
guillotine for this thesis, EUROPAC had registered more than 170 families with an 
apparent autosomal dominant predisposition to pancreatic cancer, with scores of 
other families where there are multiple cases of pancreatic cancer and no evidence 
for another genetic cause. Some of these families could be explained by 
confounding factors which will be described in section 1.3.1.2, equally the inclusion 
of some artefactual families cannot be ruled out, but the rigorous evidence required 
to meet the strict inclusion criteria may result in omission of genuine families, 
meaning the incidence of the syndrome may well be an underestimate.
Although, on average, age of onset is similar to that seen in sporadic disease, one 
phenomenon that has been discovered is ‘anticipation’ 102, 103. In simple terms, the 
age of onset of pancreatic cancer within FPC families occurs at an increasingly 
young age in consecutive generations. The fact that average age of onset remains 
consistent with the sporadic disease is explained by later age of onset in earlier
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generations balancing out the younger onset in their offspring. This could be 
explained by various forms of bias, but meticulous statistical analysis suggests that 
the phenomenon is real101.
Genetics
Identification of the gene responsible for FPC requires a mutation that segregates 
with the disease. For most genetic syndromes linkage analysis has been used to 
identify such mutations, but FPC presents particular problems when applying such 
an approach. Pancreatic cancer is a late onset disease making it difficult to 
distinguish a carrier who is yet to develop cancer, from a family member who is not 
carrying the mutation. Ethical and logistical reasons make it impractical to obtain 
samples from every family member prior to an individual developing the disease. 
Once a family member is diagnosed, there is only a very short window of opportunity 
for research groups to approach patients for DNA, at a time of great stress for those 
affected. This makes conventional linkage studies extremely difficult and as a 
consequence most work has concentrated on candidate genes. Various candidate 
genes have been suggested, but these have either been found not to be mutated in 
FPC kindreds (such as STK'/'/104, RA/ase/105 and various Fanconi anaemia 
genes106), or they are only associated with pancreatic cancer as part of more general 
cancer syndromes (such as CDKN2A94 and mismatch repair genes107). The only 
exception has been a small number of families which are entirely consistent with 
FPC and which carry BRCA2m or PALB2 stop mutations109, which have recently 
been shown to be associated with hereditary pancreatic cancer. It is noteworthy that
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the protein product of BRCA2'U0 has been shown to be a binding partner for the 
PALB2 protein111.
The lack of progress made using candidate genes has prompted a return, despite its 
problems, to conventional linkage analysis and association studies. To overcome the 
problem of identifying carriers, Brentnail and colleagues used a surrogate of 
pancreatic dysplasia for pancreatic cancer. Patients with dysplasia were identified by 
screening within ‘Family X’, a large family characterised by a high incidence of 
diabetes as well as pancreatic cancer. Using this approach they were able to identify 
a region at the end of chromosome 4 which gave two point LOD scores of greater 
than 3, with three point LOD scores reaching a maximum value of 5.36112. A LOD 
score (logarithm (base 10) of odds) is a statistical test often used for linkage analysis 
and compares the likelihood of obtaining the test data if two loci are linked, to the 
likelihood of observing the same data by chance alone. The minimum defined area in 
Family X was 4q32-34 and the same group have now provided evidence that the 
disease mutation for this family lies within the Palladin gene113.
The other FPC registries (which will be discussed in section 1.5.1 of this thesis) 
assessed their own families and showed that it was not just unlikely that the 4q32-34 
locus accounts for a significant proportion of their registered FPC families114,115, but 
that the Palladin mutation was also absent in these kindreds116"118. Work is ongoing 
in a number of institutions, exploiting novel mathematical models to account for the 
ambiguity in defining carrier status101 and new technology, such as SNP arrays, to 
increase the efficiency of linkage and association studies119.
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1.3.1.2 Arguments Against FPC:
There are a number of arguments that have been put forward criticising and even 
questioning the existence of FPC as a true genetic syndrome. The arguments have 
been discussed in full in a recent review of FPC96 and are summarised below.
Misclassification and Chance
The overall lifetime risk of developing pancreatic cancer for the general population is 
0.5-1 %120. It is, therefore, not inconceivable that large kindreds (with scores of at risk 
individuals) could have two cases by chance alone.
Selection Bias
Pancreatic cancer patients in the USA were asked to report any other cases in first 
degree relatives. Approximately one in ten were able to do so103,121. In these studies 
all the families will include at least one pancreatic cancer case (the proband). This 
means that the chance of two cases in one of these families is roughly equivalent to 
the chance of finding a single case in an unselected kindred. Case-control studies 
are desirable and these are discussed in more detail in the review96.
Genetic Factors
The relative influence of genes and environment is a notoriously difficult area. 
People who share common genetic backgrounds often have similar diets, 
occupations and customs. Pancreatic cancer has been shown to be more common
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in black than white Americans122; this could be due to low penetrance or multi-gene 
susceptibility, or simply that black Americans lead a lifestyle that is more ‘high risk’. 
In support of an environmental rather than genetic link, migration studies show that 
pancreatic cancer risk amongst Japanese migrants moving to the US increases and 
overtakes the level of cancer risk of white Americans123. The most likely cause of this 
is the Japanese adopting the ‘Western’ high meat, high fat diet, although a direct link 
between Western diet and pancreatic cancer has not been proven, despite large 
cohort studies124. An indirect link via obesity and diabetes (see below) cannot be 
ruled out, but neither is there any evidence that it explains the migration studies.
Gender
Analysis of the Surveillance Epidemiology and End Results (SEER) data120 shows a 
slightly greater incidence of pancreatic cancer in men than women in all age groups. 
The situation in high risk groups is less well understood and EUROPAC data and the 
SEER data were compared as part of the analysis of primary screening. The findings 
can be seen in figure 14 in the results section of this thesis.
Environmental and Lifestyle Factors
The best evidence for a link between an environmental risk factor and incidence of 
pancreatic cancer exists for tobacco smoking125. Overall, smoking increases the risk 
of pancreatic cancer by two-fold126, with some evidence for a dose-response 
relationship127. The risk posed by passive smoking remains unproven, thus 
clustering of pancreatic cancer within families is more likely to be related to a
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common habit shared by family members, than contamination of the family home by 
a single heavy smoker. Analysis of the EUROPAC database has shown no direct 
evidence for smoking as the cause of familial clusters of pancreatic cancer101.
A link has been shown between pancreatic cancer and obesity128. Obesity shows 
familial clustering, thought to be due to shared behaviours, so this may contribute to 
some cases classified as FPC.
There has been particular emphasis on searching for a link between pancreatic 
cancer and occupations that lead to contact with chlorinated hydrocarbons, 
especially dichlorodiphenyltrichloroethane (DDT), though, again, no definite link has 
been established ,29' 13°.
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Diabetes and Other Associated Medical Conditions
There are two major illnesses linked to pancreatic cancer; diabetes mellitus and 
chronic pancreatitis. Some 80% of pancreatic cancer patients have impaired glucose 
metabolism. Tumours can induce production of diabetogenic peptides which result in 
insulin resistance reminiscent of type 2 diabetes131, which can often be alleviated by 
resection of the tumour132. In sporadic disease, development of higher baseline 
fasting glucose levels appears to be a very early symptom of pancreatic cancer133 
but this has not been shown in familial pancreatic cancer patients. It is also possible 
that diabetes is a risk factor, as well as a symptom, of pancreatic cancer but this 
remains unproven132. Diabetes shows familial clustering and as stated previously is a 
feature of Family X, one of the best characterised of all FPC families112. It is possible 
that diabetes could explain some cases classified as FPC on the EUROPAC 
database, but an analysis has failed to show an increased incidence of diabetes 
mellitus, above that expected as a symptom of pancreatic cancer.
An additional possible cause of artefactual familial clusters of pancreatic cancer 
could be multiple cases of chronic pancreatitis within a family. This could be caused 
by a shared tendency to heavy alcohol intake or the rare genetic syndrome, 
hereditary pancreatitis. Chronic pancreatitis has been shown to lead to a 15% 
lifetime risk of pancreatic cancer134 and the cumulative lifetime risk increases to 35- 
53% in hereditary pancreatitis families91"93, but given that EUROPAC also registers 
families with hereditary pancreatitis (HP) and most of the responsible mutations can 
be tested for, this is unlikely to be relevant in EUROPAC’s case.
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Interaction of Genetic and Environmental Factors
It is conceivable that multiple cases of pancreatic cancer in a family could be caused 
by genetic variations other than the elusive FPC mutation that could possibly 
increase the impact of environmental factors. Such variations, although inherited, 
would not justify the description of FPC, as the link is indirect. Genetic 
polymorphisms have already been linked to the development of pancreatic cancer 
and pancreatic adenocarcinoma has been shown to be associated with the 
UGT1A7*3 allele of UDP-glucuronosyltransferase, an enzyme known to be involved 
in detoxifying tobacco carcinogens135, however, with >90% of the population having 
a very small risk of pancreatic cancer, it is unlikely that any commonly occurring 
polymorphism could cause a sufficient increase in risk to account for FPC. A rare 
combination of multiple unlinked polymorphisms should not lead to a family history of 
pancreatic cancer covering more than one generation.
Cystic Fibrosis (CF) affects multiple systems by causing obstruction of ducts; one 
organ affected is the pancreas. Two early onset cases of pancreatic cancer were 
identified in 28,000 cases of cystic fibrosis (odds ratio 31.5 vs. control group)136 and 
there is a greatly increased risk of chronic pancreatitis5,6 in those with cystic fibrosis 
transmembrane receptor (CFTR) mutations. It is at least conceivable that a similar 
autosomal dominant inheritance of pancreatic cancer risk could be observed either 
under certain circumstances, or with specific CFTR mutations. A study of 166 early 
onset pancreatic cancer patients (under the age of 60) found 14 carriers of disease 
related CFTR mutations (8.4%) compared to 4.1% in controls (odds ratio 2.18, 95%
40
Modelling of risk in individuals with a possible genetic predisposition for pancreatic cancer
Cl: 1.24-3.29)137, but none of the 14 cancer patients had a family history of 
pancreatic cancer, which is unsurprising given the fairly modest increased risk.
Autosomal dominant inheritance of a predisposition to other forms of cancer is well 
known, for example colorectal cancer in hereditary non polyposis colorectal cancer 
or breast cancer in breast ovarian syndrome. It is conceivable, that by chance, a 
family with a more general syndrome could present with more than one pancreatic 
cancer case in the absence of other tumours. It should also be understood that 
although FPC is defined specifically in terms of pancreatic ductal adenocarcinoma, it 
is possible that ampullary tumours, extra-hepatic cholangiocarcinomas, acinar cell 
tumours and even pancreatic neuroendocrine tumours may have been included due 
to misdiagnosis. It is even possible that misdiagnosis, or misreporting of colorectal or 
gastric tumours could explain part of a cluster.
Other Cancer Syndromes that Predispose to Pancreatic Cancer
Registries such as EUROPAC, NFPTR and FaPaCa (described in full in section 
1.5.1) require reliable evidence of pancreatic ductal adenocarcinoma before 
registering a family. This means that high penetrant syndromes with known disease 
mutations are unlikely to be confused with FPC. For example, mutations in the VHL 
gene which cause von Hippel-Lindau syndrome are associated with pancreatic 
neuroendocrine tumours138, with only occasional pancreatic ductal adenocarcinomas 
reported in these families139. Li-Fraumeni Syndrome is associated with Tp53 and 
CHK2 mutations. At least 24 families have been reported with multiple cases of 
pancreatic cancer, which, superficially, would be consistent with FPC140. However, in
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the same study the families were followed for 10 years and over 200 cases of non- 
pancreatic cancer were reported140. It is unlikely that such an extreme cancer risk 
would be missed by even the most cursory family analysis and so such families 
would not be included as FPC by any of the large registries. Another example, is 
Peutz-Jeghers syndrome (PJS); the autosomal dominant inheritance of 
hamartomatous polyposis. The reported increased risk for pancreatic cancer is very 
great (132-fold)141 which is sufficiently high to produce a phenotype with multiple 
cases of pancreatic cancer within a family, but in the largest study of PJS to date, 
only 6 pancreatic cancer patients were reported. The reason for the small number of 
cases is the high mortality from other cancers in these families, so as for Li-Fraumeni 
it is very unlikely that a PJS family would be mistaken for FPC142, 143. EUROPAC 
originally had a policy of screening possible FPC families for the STK11 mutations 
that cause PJS, but no mutations were identified104.
Similarly, low penetrant cancer syndromes associated with well defined phenotypes 
other than cancer would be unlikely to be confused with FPC. For example, 
mutations in the ATM gene cause ataxia-telangiectasia, an autosomal recessive 
inherited disease characterised by oculocutaneous telangiectasias, cerebellar ataxia, 
and cellular and humoral immune deficiencies. People with ataxia-telangiectasia 
have increased cancer risk, estimated at 50 to 150-fold, but this would clearly be a 
recessive risk. Heterozygotes for ATM mutations have an approximately 3-fold 
increase in risk144. The specific risk for pancreatic cancer is, at most, marginal145. It is 
unlikely that such a low increased risk would give many familial clusters of pancreatic 
cancer and even if this did occur, a familial history of ataxia would be likely. Familial
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adenomatous polyposis (FAR), which is caused by a mutation of the tumour 
suppressor gene APC, is characterised by the presence of multipie adenomatous 
polyps within the gastrointestinal tract. The coion is the most commonly affected site 
and there is a high incidence of colonic cancer. The elevation in risk of pancreatic 
cancer is relatively small, 4.46 (95% Cl: 1.2-11.4) or 21.4 cases per 100,000 person 
years146. Although it is possible that a family would contain multiple cases of 
pancreatic cancer, due to the numbers of colonic cases, an FAR family would be 
unlikely to be diagnosed as a FPC kindred.
Although the majority of cancer syndromes are unlikely to be confused with FPC by 
major registries, there appears to be heterogeneity in the phenotype associated with 
certain mutations. For example, Hereditary Non-Polyposis Colorectal Cancer 
(HNPCC) can be divided into two groups (Lynch syndromes I and II). Both 
syndromes result from mutations in mismatch repair genes but Lynch syndrome I is 
almost exclusively associated with colorectal cancer, whilst Lynch syndrome II 
features extra-colonic tumours in sites such as the stomach, breasts, uterus, bladder 
and small bowel. This second group shows a clearly elevated risk for pancreatic 
cancer147. Another example is the phenotype that can result from mutations of the 
BRCA2 gene. This can lead to an autosomal recessive syndrome associated with 
lymphomas and hepatomas (Fanconi’s Anaemia). In most cases these families have 
no noticeable increased risk for pancreatic or breast cancer148. In other families 
BRCA2 mutations are associated with autosomal dominant predisposition to breast 
and ovarian cancer149, with other families having an autosomal dominant 
predisposition towards pancreatic cancer without an elevated risk of breast cancer.
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The latter example includes families that have been defined as FPC108. Mutation of 
the CDKN2A (Ink4ap16) gene is associated with multiple naevi and cases of 
melanoma, a syndrome known as Familial Atypical Multiple Mole Melanoma 
(FAMMM)150. In other CDKN2A families there are also one or more cases of 
pancreatic cancer, this has been described as a separate syndrome (FAMMM-PC, 
OMIM #606719). To date, all FAMMM-PC families have included cases of 
melanoma, hence the probability of confusion with FPC is low. Testing of genuine 
FPC families has yet to identify any CDKN2A mutations94. A summary of the genes 
with germline variants associated with pancreatic cancer is presented below in table 
one, which is taken (with permission) from a review written by my MD supervisors97.
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Table 1: Genes with germline variants associated with pancreatic cancer
aLoss of function means that the germline mutation stops an allele working, leading to 
dependence on the other allele for the gene function.
Gain of function means that the mutation has a phenotype even when present in a 
heterozygote with a wild type copy of the gene.
Polymorphism means that the variant associated with cancer is present in a substantial 
proportion of the population with no overt phenotype, but may cause a subtle decrease (or 
increase) in the efficiency of the gene.
bProteins often have multiple functions, this list just describes a category which best fits each 
gene. DNA repair is described in basic terms, recombination is meant to include any 
mechanism used to repair double strand breaks, NER is nucleotide excision repair and BER is 
base excision repair.
cSyndromes are defined clinically, some syndromes result from more than one mutation and 
some mutations are causative of more than one syndrome. Syndromes are autosomal 
dominant unless otherwise stated.
Principal cancers other than pancreatic ductal adenocarcinoma linked to germ line variants in 
the gene.
eWhere cancer risk is associated with another disease state and the other disease is 
associated with the variant in the gene.
fMonogenic if at least one family has been shown to have cancer predisposition that 
segregates with the mutation. Polygenic if the variant is associated with apparently sporadic 
disease or with cancer in only a single generation.
9Defined as independent unless the association with a genetic variant is only seen in 
combination with specific environmental exposures.
With kind permission from Springer Science+Business Media: figure 24-1 from Greenhalf etal; 
Chapter 24: Genetic Susceptibility; 2010; 565-600; In: Handbook of Pancreatic Cancer; J. P. 
Neoptolemos, R. Urrutia, J. L. Abbruzzese, M. W. Buchler, eds97
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1.3.1.3 The Cancer Risk in FPC Kindreds
The definition of FPC as an autosomal dominant condition suggests that risk is 
equivalent to penetrance; however, this is complicated by the issues of classification 
(as discussed above) and the lack of a recognised disease mutation in most families. 
It is assumed that penetrance in FPC is high, but less than 100%. If penetrance in 
FPC were 80% to 75 years, then lifetime risk for a mutation carrier would be 80%. 
The risk to an individual in the same family without a mutation would be that of the 
general population (0.5-1 %)184. In the absence of a test for mutation status in most 
families, the lifetime risk can only be estimated on the basis of some form of 
probability calculation giving the perceived chance that the individual is a mutation 
carrier. For example, half of all first degree relatives of pancreatic cancer patients in 
a genuine FPC family would be mutation carriers; on the basis of 80% penetrance 
they would therefore be estimated to have a 40% lifetime risk. On the discovery of a 
disease mutation, the estimation of risk for these same individuals would rise to 80% 
or fall to that of the general population depending on whether the individual was 
shown to be a gene mutation carrier. This does not take into account the possibility 
that the family only appears to be a FPC kindred.
An attempt at risk quantification was performed by Klein et a/185. A prospective 
registry-based analysis showed that members of families with one confirmed 
pancreatic cancer death had a 4.6-fold increase in risk over the general population. If 
there were two confirmed cases the risk increased to 6.4-fold and was increased 32- 
fold in families with three affected members. Ignoring low penetrance conditions, this
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equates to estimation of the likelihood that an individual is a member of a FPC 
family. Despite the obvious weaknesses that could be levelled at these calculations, 
these were the best data available on risk within FPC kindreds at the start of my 
period of research. The risk in EUROPAC’s FPC kindreds is shown in figure 13 in 
the results section of this thesis.
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1.4 Hereditary Pancreatitis
Hereditary Pancreatitis (HP) was first described in 1952 by Comfort and Steinberg186 
but it was not until 1996 that Whitcomb et a/8 isolated the first mutation in the cationic 
trypsinogen gene (PRSS1) on the long arm of chromosome seven (7q35). It is an 
autosomal dominant disease with penetrance that is generally accepted to be 
=80%186,187 and further work on this will be presented in the results section of this 
thesis. HP is characterised by frequent attacks of epigastric pain, which is normally 
associated with nausea and vomiting. Symptoms may start shortly after birth but 
onset varies greatly, with some individuals not exhibiting symptoms until adulthood. 
There is usually progression to chronic pancreatitis with endocrine and exocrine 
failure and an increased risk of pancreatic cancer91'93. The natural history of HP 
follows a similar pattern to alcohol associated chronic pancreatitis, but there are 
important differences, for example, HP has an earlier age of onset of pancreatitis 
although malabsorption and diabetes mellitus occur at a later stage in the disease91'
93
Families are defined as having HP if the phenotype is consistent with highly 
penetrant autosomal dominant inheritance. In simple terms, this would require two or 
more first degree relatives (or three or more second degree relatives) to have 
unexplained recurrent-acute or chronic pancreatitis in two or more generations and 
this is the definition that has been adopted by EUROPAC92.
The vast majority of the cases of HP are caused by mutations of the cationic 
trypsinogen gene {PRSS1), which lies on the long arm of chromosome seven.
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Substitutions, at base 365 (c.365G>A) and base 86 of the cDNA (c.86A>T), were 
discovered in the late 1990s by conventional linkage analysis8, 9. They are now 
known as p.R122H8 and p.N29l9 according to the amino acid substitution and 
position in the protein sequence.
These mutations are rarely identified in general screens of patients with idiopathic 
disease188"191 and the phenotype of p.R122H and p.N29l is now well characterised91" 
93. There are many other rare mutations or polymorphisms of PRSS1 that are less 
well understood192 and not all HP families have had the responsible genetic mutation 
identified. EUROPAC calls families with a phenotype consistent with HP, but no 
identified mutation (after sequencing of PRSS1), ‘Neg All HP’. Their presence 
implies that there is at least one further mutation to be identified.
As stated in section 1.1, the mechanism by which these genetic mutations cause 
pancreatitis is incompletely understood but it is thought to be due to increased 
autoactivation7 or reduced deactivation of trypsinogen, or a combination of the two.
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1.4.1 Diabetes in Hereditary Pancreatitis
This subject has been the focus of much recent work by the EUROPAC study group. 
Data were analysed from 750 individuals (614 affected and 136 obligate carriers) 
from 145 families. There were a total of 191 individuals that developed endocrine 
pancreatic failure, with a total of 37 cancer cases, 35 in affected individuals and 2 in 
unaffected carriers. A Cox proportional hazard model showed that diabetes was an 
independent risk factor for pancreatic cancer, allowing for familial clustering using a 
gamma shared-frailty model, hazard ratio of 2.9 (95% confidence intervals of 1.47, 
5.85). In short, diabetes was shown to be a risk factor rather than a symptom of 
cancer in most patients (Greenhalf et al, unpublished).
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1.4.2 The Cancer Risk in Hereditary Pancreatitis Kindreds
A diagnosis of hereditary pancreatitis carries a substantial cancer risk. Lifetime risk 
has been variously calculated as 35-54% 91‘93 to the age of 75 years. This is 
sufficient to merit secondary screening but the overall risk of pancreatic cancer in 
those affected by HP in the EUROPAC population is 4-5 times less than the cancer 
risk in FPC families as will be shown in figures 13 and 21 of this thesis.
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1.4.3 Non-Causative Pancreatitis Associated Mutations
Both p.R122H and p.N29l are high penetrance mutations. Other genetic mutations 
have been identified which have been shown to have an associative rather than a 
causative relationship with pancreatitis. The two most common will be discussed 
below.
1.4.3.1 Cystic Fibrosis Transmembrane Receptor Mutations
As previously mentioned cystic fibrosis (CF) is an autosomal recessive condition with 
an incidence in the Caucasian population of 1:2500 live births. The causative gene, 
the cystic fibrosis transmembrane receptor (CFTR) gene, was located in 
1989{Kerem, 1989 #35333}. The most striking effects (normally pulmonary) are seen 
in homozygotes, though 1-2% of homozygotes have been shown to develop chronic 
pancreatitis193, 194 Interestingly this predisposition to pancreatitis is also seen in 
heterozygotes. There are >1500 known mutations, although only a handful have 
been proven to be associated with pancreatitis. Much of this work has been 
performed in the past decade6,195,196, with the most common mutation found to be 
p.F508del which comprises 66% of all mutated alleles197. The resultant phenotype 
can vary greatly from young onset idiopathic chronic pancreatitis with complete 
exocrine and endocrine pancreatic failure to later onset disease and almost normal 
pancreatic function, even for those with the same mutation.
The exact pathway by which CFTR mutations cause chronic pancreatitis is 
incompletely understood5,198'202. The presence of a mutation does not inevitably lead
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to chronic pancreatitis, suggesting either an environmental trigger, or that CFTR 
mutations contribute to a multigenic predisposition to pancreatitis. It has been argued 
that compound heterozygous CFTR mutation carriers have an even greater risk of
chronic pancreatitis, which is increased further if a SPINK1 mutation is also present5,
200
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The degree of the cancer risk in CFTR related chronic pancreatitis is also 
incompletely understood. The overall lifetime risk of pancreatic cancer in individuals 
with chronic pancreatitis has been calculated at 15%134. There are insufficient data 
available to say whether the cancer risk in CFTR mutation associated chronic 
pancreatitis is greater or less than this. As stated previously, two early onset cases 
of pancreatic cancer have been identified in 28,000 cases of cystic fibrosis (odds 
ratio 31.5 vs. control group)136 and a study of 166 early onset pancreatic cancer 
patients (under the age of 60) found 14 carriers of disease related CFTR mutations 
(8.4%) compared to 4.1% in controls (odds ratio 2.18, 95% Cl: 1.24-3.29)137, 
although none of the 14 cancer patients had a family history of pancreatic cancer. At 
present, individuals with CFTR mutation associated chronic pancreatitis are not 
screened for early pancreatic cancer as the risk of cancer is deemed too low to merit 
the risk of experimental screening.
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1.4.3.2 SPINK1 Mutations
SPINK1 is a protease inhibitor which is thought to inactivate intra-pancreatic trypsin. 
This occurs by the formation of a covalent bond between SPINKTs carboxyl group 
and the catalytic serine residue of trypsin. Despite recent progress203, the exact 
mechanism by which the most common mutation (p.N34S) causes chronic 
pancreatitis remains unresolved. Mutations in the Kazal type 1 serine protease 
inhibitor gene (SP/A/Kf)204'213 have been shown to be associated with pancreatitis, 
with the p.N34S variant present in over 20% of idiopathic patients208, 210. Twenty 
seven percent of Indian alcohol-related chronic pancreatitis patients have also been 
shown to carry p.N34S mutations205, although it is not considered a causative 
mutation, being present in 1-2% of healthy controls.
The Cancer Risk in SPINK1 Mutation Associated Chronic Pancreatitis
It has been shown that p.N34S mutations of SPINK1 are not found in idiopathic 
pancreatic cancers214 but the cancer risk in those with SPINK1 mutation associated 
chronic pancreatitis is again poorly characterised and cannot be differentiated from 
the cancer risk in a cohort of chronic pancreatitis patients of all aetiologies134. 
Individuals with SPINK1 mutation related chronic pancreatitis do not fulfil the 
inclusion criteria for the screening studies.
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1.4.3.3 The p.A16V Mutation of PRSS1
One of the more significant steps from the work that went towards this thesis is the 
characterisation of the clinical phenotype produced by the third most common 
PRSS1 mutation on the EUROPAC registry. A cytosine (C) to thymine (T) missense 
mutation in exon 2 that leads to an alanine (GCC) to valine (GTC) substitution at 
codon 16191 is more simply known as p.A16V.
p.A16V is significantly associated with pancreatitis191 and was first identified in 
pancreatitics with no family history191. It has subsequently been reported by other 
groups in apparently idiopathic patients188 and is relatively rare in families with 
multiple cases of pancreatitis92, 188, 191. In contrast, rare instances of p.R122H in 
individuals without a family history may be explained by either a limited pedigree or 
by spontaneous mutation215.
Whilst p.R122H and p.N29l have both been linked to increased autoactivation (or 
reduced deactivation) of cationic trypsinogen{Sahin-Toth, 2000 #2054;Sahin-Toth, 
2000 #1707}, p.A16V lies at the edge of the signal peptide of trypsinogen and has 
previously been considered to influence secretion{Witt, 1999 #1605}. Secretion 
failure is still considered to explain the link between the p.R116C mutation of PRSS1 
and pancreatitis, but p.A16V mutant protein has been reported to be secreted 
normally{Kereszturi, 2009 #32374}. Other work has established that p.A16V 
increases the rate of chymotrypsin C (CIRC) activation of trypsinogen by
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approximately four-fold. This results in accelerated trypsinogen activation in vitro, 
possibly explaining the link with pancreatitis{Nemoda, 2006 #14447}.
In 1999 Witt et a/191 published the first report of p.A16V in a paper detailing the 
results of genetic testing of children with chronic pancreatitis. Of the 44 children 
tested, 30 had apparent sporadic disease with a further 14 having a family history. Of 
the 30 sporadic cases, p.A16V was detected in three individuals. It was also 
detected in one individual with a family history. One p.R122H mutation was also 
detected in the family history group. Further individuals from families with p.A16V 
were tested for the mutation, with just one of seven carriers being affected. This 
suggested that p.A16V is a low penetrance mutation, although the numbers involved 
were too low for firm conclusions to be drawn.
In contrast to Witt’s initial paper, EUROPAC has held data for many years on several 
families with p.A16V mutations and phenotypes consistent with HP, which would be 
indistinguishable from those of p.R122H or p.N29l. Prior to this thesis, p.A16V was 
poorly characterised in the literature and EUROPAC and the other registries held too 
few data in isolation for a meaningful analysis. It remained unclear whether p.A16V 
was a HP causative mutation in the same way as p.R122H and p.N29l or whether it 
was a pancreatitis associated mutation producing a similar phenotype to mutations in 
the CFTR and SPINK1 genes. The results from the multi-centre collaborative project 
relating to p.A16V will be presented in Chapter 3.
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The Cancer Risk in p.A16V Kindreds
The cancer risk due to chronic pancreatitis in p.A16V kindreds is uncertain. The 
occurrence of a single cancer case in a p.A16V family has already been published92 
but the data were too few for definitive conclusions and at the start of this thesis 
p.A16V pancreatitics were not entered into the trials of secondary screening.
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1.5 Primary Screening and Traditional Methods of Risk 
Stratification
Screening can be thought of as primary or secondary. Primary screening is the 
identification of individuals at known high risk of an event, e.g. identification of 
families with a genetic predisposition to pancreatic cancer. This is supplemented with 
risk stratification within these families on an individual basis. This contrasts with 
secondary screening which is the attempt to discover evidence of the event (e.g. 
cancer) in those high risk individuals identified by the primary screening process.
Primary screening involves the collection of large amounts of familial and personal 
data. It permits research into phenotype of pancreatic cancer within and between the 
different cancer syndromes and within and between the different HP mutation 
groups. The collection of DMA from both those at risk and controls permits research 
into identifying the causative genes both for FPC and for further HP genes.
Primary screening is a time consuming undertaking and is normally only formally 
undertaken by large registries. Some of the registries working in the field of 
pancreatic disease have already been mentioned in previous sections of the 
introduction, but they will now be discussed together in the following section.
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1.5.1 EUROPAC and Other Registries
The large registries that identify FPC families are administered from three centres in 
the United States (US) with a further two large registries in Europe. The US centres 
are the Johns Hopkins University and University of Washington groups and, more 
recently, the Moffitt Cancer Center in Florida. The National Familial Pancreas Tumor 
Registry (NFPTR) is the name given to the Johns Hopkins registry. In Europe the 
two large registries are The European Registry of Hereditary Pancreatitis and 
Familial Pancreatic Cancer (EUROPAC), coordinated from Liverpool, UK and the 
German National Case Collection of Familial Pancreatic Cancer or Nationale 
Fallsammlungt Familiares Pankreaskarzinom (FaPaCa) of Marburg, Germany.
EUROPAC was established in 1997. It works in close collaboration with both 
FaPaCa and the French national hereditary pancreatitis registry based in Clichy. 
EUROPAC is a collaboration of scientists and clinicians that aims to register and 
treat individuals with inherited pancreatic disease. The groups registered have an 
increased risk of developing pancreatic cancer giving a rare opportunity for research 
into the pathogenesis of early pancreatic cancer.
The aims of EUROPAC are: to describe the phenotypes of Hereditary Pancreatitis 
(HP) and Familial Pancreatic Cancer (FPC), to establish risks to family members of 
developing these diseases, to identify the gene (or genes) predisposing to the 
development of pancreatic cancer and to develop methods of screening for early 
pancreatic cancer in individuals from families considered to be at high risk of 
developing the disease.
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EUROPAC is unique in the volume of personal and environmental data that it 
collects. Of the North American registries, the one that most closely follows the 
EUROPAC model is the NFPTR. The University of Washington registry was set up 
after the incidental recruitment of a family with an unnaturally large number of 
pancreatic cancers and cases of diabetes mellitus, the so-called ‘Family Xj219. 
EUROPAC matches all epidemiological and environmental data to DNA from family 
members wherever possible. If a relevant genetic test is available (see table 1) 
testing is performed as long as the individual gives informed consent after discussion 
with a genetic counsellor.
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1.5.2 Traditional Risk Stratification: Primary Screening
The familial and personal data are gathered by means of structured questionnaires, 
as detailed in the methods section of this thesis. At the completion of primary 
screening the family phenotype or pedigree can be assessed, either by an individual 
researcher or clinician, or by a multi-disciplinary team. This allows a subjective 
estimate of the degree of risk within the family to be made.
Estimation of individual cancer risk is more complicated. It is simpler to stratify 
cancer risk amongst individuals from HP kindreds as the phenotypes (including 
cancer risk) have been well characterised 91'93 and a genetic test is available for the 
most common mutations.
Determining cancer risk on an individual basis in FPC kindreds is more difficult as 
genetic testing is only available in a minority of cases. It was informed by the work of 
Klein et a/185 where risk amongst first degree relatives was determined to be 4.6-fold, 
6.4-fold and 32-fold that of the general population, depending on whether there were 
1, 2 or 3 family members affected by pancreatic cancer respectively. This study only 
issued a calculation of risk for a family as a whole. Assuming autosomal dominant 
inheritance, as previously described, risk is either very high or equivalent to that of 
the general population, depending on whether an individual is a gene mutation 
carrier or not. Determining cancer risk on an individual basis within FPC kindreds 
had never been done before the start of this thesis, and as such, became one of my 
primary aims.
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1.5.3 Current Adjuncts to Risk Stratification
One tool that is currently being used within EUROPAC’s trial of secondary screening 
is the analysis of pancreatic juice gathered at ERCP for cancer associated 
mutations. The methodologies were published in 2005220 and have slowly been 
refined by Dr Van since then. Molecular analysis of pancreatic juice has the 
advantage that it gives additional information on individual, rather than familial risk. 
Molecular analysis is currently used to phase the screening investigations performed 
as part of the EUROPAC study of secondary screening for early pancreatic cancer 
(see figure 4) and ultimately, if validated, could trigger prophylactic surgery before a 
mass becomes visible on conventional imaging. The modality will be described 
further in section 1.7.2.4.
64
Modelling of risk in individuals with a possible genetic predisposition for pancreatic cancer
1.6 Novel Modalities of Risk Stratification
To improve on the traditional stratification offered by careful primary screening and 
possible genetic testing, new ways of identifying those at risk must be considered. 
The ideal outcome would be to use a combination of family and individual data 
(supplemented by basic investigations and genetic testing where available) to give a 
defined calculation of the risk of cancer to an individual within a set time period. This 
value, once validated, could become a central part of the decision making process 
before an individual enters a trial of secondary screening. It should improve the cost 
effectiveness of screening by avoiding the screening of low risk individuals. It could 
be used to phase investigations and should reduce the overall number of false 
positives by targeting screening investigations most appropriately. One way of 
achieving this outcome is mathematical modelling, possibly with the addition of 
serum glucose data. Both of these novel modalities will now be examined in turn.
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1.6.1 Mathematical and Statistical Models in Pancreatic 
Cancer
Increasing numbers of mathematical models are being produced to try to stratify or 
predict risk and guide management in many areas of medicine and surgery. These 
range from calculations of risk of a myocardial infarction221, to help guide general 
practitioners how aggressively risk factors should be treated, to tools such as 
POSSUM scoring to predict peri-operative death following colorectal bowel 
resection222. Nothing similar has ever been developed in familial pancreatic disease 
although a model has been produced in Breast-Ovarian syndrome223.
The volume of EUROPAC’s personal, familial and genetic data puts it in a unique 
position to develop a mathematical model for stratification of risk in high risk groups. 
Similar models have been developed in other cancers where sufficient volumes of 
accurate data have been available224. Ideally a mathematical model gives a 
prediction of cancer risk over a fixed time period and needs to be sufficiently user 
friendly that it can be completed online, (with a calculated level of cancer risk derived 
from the entered data), within the time frame of a typical clinical consultation.
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1.6.2 Serum Blood Glucose
Many studies have shown diabetes to be a risk factor for idiopathic pancreatic 
cancer. Both retrospective case-control225,226and prospective cohort studies 227,228 
have shown a link, although other studies229,23°, which excluded those with a short 
latency period between diagnosis of diabetes and pancreatic cancer, have shown 
the risk to be more moderate. Overall, two meta-analyses of 20231 and 36232 studies 
have shown a relative risk of 2.0 and a combined summary odds ratio of 1.82 (1.66- 
1.89) respectively. Not all studies, however, have shown a relationship229 with one 
even suggesting diabetes to be protective230.
In the high risk groups, there is also some evidence of an increased level of risk 
incurred by diabetes as set out in section 1.4.1 of this thesis. The as yet unpublished 
EUROPAC research shows diabetes to be an independent risk factor for pancreatic 
cancer, with a hazard ratio of 2.9 (95% confidence intervals of 1.47, 5.85) in HP 
kindreds. There is less evidence to prove that diabetes is either a risk factor or a 
symptom of pancreatic cancer in FPC kindreds, but ‘Family X’219 does show a very 
high number of cases of diabetes and diabetes status was used as a surrogate 
marker of carrier status in the Palladin paper113.
There is strong evidence that hyperglycaemia can be a symptom of pancreatic 
cancer. Up to 80% of those diagnosed with pancreatic cancer have glucose 
intolerance233'235 with 40% formally meeting the criteria for diagnosis of diabetes236. 
A greater proportion of new onset diabetics subsequently developed pancreatic 
cancer up to three years prior to their eventual diagnosis. It has also been shown
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that hyperglycaemia often regresses after surgery132, 234. The reason or reasons for 
this remain incompletely understood, but it could be that pancreatic cancer 
associated diabetes is the result of secretion of diabetogenic peptides by the tumour, 
with S100A8 having been proposed as a possible agent131.
Damiano237 imaged 115 patients aged >50 years over ten years that were admitted 
with new onset diabetes. Six of the 115 (5.2%) were shown to have adenocarcinoma 
of the pancreas. A further four patients had either a benign pancreatic tumour or 
other malignancies involving the pancreato-biliary system, with a further three 
incidentally detected cancers. The data indicated that new onset diabetes 
necessitating admission is likely to indicate advanced pancreatic cancer. Of the six 
pancreatic adenocarcinomas found by Damiano237, only one was classed as ‘early’.
As part of this thesis serum random glucose levels were collected from those with 
sporadic pancreatic cancer and fasting levels were collected in high risk individuals. 
Initial results will be shown in chapter 3 of this thesis.
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1.7 Secondary Screening
The identification of high risk families raises an ethical dilemma as to how individuals 
from these families should be managed. This is exacerbated by the low sensitivity of 
the imaging modalities, meaning that screening could identify as many, or even 
more, false positives as actual cancers.
Consensus recommendations for secondary screening of high risk groups were 
proposed at the Fourth International Symposium on Inherited Diseases of the 
Pancreas238. It was concluded that secondary screening should only be carried out 
on a research basis and only in patients with hereditary pancreatitis, individuals from 
Peutz-Jeghers kindreds or families with a history of pancreatic cancer. In the latter 
case the family history should include at least two first degree relatives (or three 
more distant relatives) unless the participant requesting screening has a mutation in 
either of the BRCA genes or CDKN2A (p16).
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1.7.1 The Rationale Behind Secondary Screening
Successful screening will depend on adequate risk stratification both on a familial 
and individual level, the advantages of which have been discussed in the previous 
section. There is already evidence to show that screening for early pancreatic cancer 
will not be successful if this primary screening is not performed239, 24°. Serum tests 
have already been used in both symptomatic and asymptomatic populations and 
been shown to be ineffective due to poor positive predictive values239,24°.
The aim of secondary screening of members of high risk groups is to identify 
pancreatic cancers at a sufficiently early stage in their development that treatment 
produces an increase in the five year survival rate. This aim will obviously require 
sufficient numbers of early pancreatic cancers to be detected and treated before a 
retrospective analysis of prospectively gathered data can be performed. The need 
for five year survival data, by definition, means that this aim is beyond the scope of a 
single MD project and will take many years to complete. Secondary aims or 
additional benefits of detecting and resecting earlier cancers are: firstly, an 
improvement in our understanding of the development of pancreatic 
adenocarcinoma; secondly, the elucidation of the stepwise genetic micro-cellular 
changes that occur as pancreatic cancers develop; thirdly, the proving, refining or 
rejection of the PanIN model of pancreatic cancer development; and finally, the 
identification of the ideal time for surgical intervention to maximise chances of 
survival.
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Screening for early pancreatic cancer is only happening on any significant scale 
within trials organised by a few centres using high risk individuals identified by the 
registries.
High risk individuals are used, as lives saved by screening must be balanced against 
the inevitable false positives of screening. Logically, a false positive result of 
screening for pancreatic cancer must prompt the offer of resection. The mortality of 
major pancreatic surgery is in the region of 4%, even at large centres241. There is 
also associated morbidity, including endocrine and exocrine pancreatic failure. One 
study showed a deterioration in glycaemic control in 41% and steatorrhea in 58.6% 
of all those having Whipples procedure (n=80)242.
The incidence of pancreatic cancer is below 10 in 100,000 in the general 
population20,243, so if 100,000 individuals were screened with a modality that had 
98% specificity there would be 2,000 false positives and only 10 possible lives saved 
by early detection (even assuming 100% sensitivity). The pre-test incidence of 
cancer would have to be at least 2% in order for a screening programme with this 
level of specificity to potentially benefit more people than it harmed.
Only the high risk groups described above offer the possibility of this level of 
incidence within a reasonable screening window. For example, a 50 year old 
individual in an FPC family would have a 5% chance of developing pancreatic cancer 
within a 5 year period based on a 120-foid constant increase in risk over the SEER 
population96 (see figure 14a and 14b).
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The changes associated with HP detrimentally affect the sensitivity and particularly 
the specificity of blood testing and imaging, making false positives more likely244. 
However, in other ways, individuals affected by HP are an attractive population for a 
secondary screening study. The risks of surgery are ameliorated as any resection 
would be of diseased pancreatic tissue, with affected individuals likely to already 
have endocrine and exocrine pancreatic failure. Individuals with chronic pancreatitis 
are also likely to be at a lower risk of an acute episode of pancreatitis following 
endoscopic retrograde cholangiopancreatography (ERCP) than patients with a 
normal pancreas245, making them more suitable for investigation by ERCP than 
members of FPC kindreds.
Screening also offers important potential research benefits. The early pathogenesis 
of pancreatic cancer is poorly understood as early tumours are so rarely found. As 
more small tumours are resected, tissue analysis should lead to the elucidation of 
the stepwise intracellular changes that take place as tumours develop246. The 
screened population also provide a bank of clinical samples, including blood, urine, 
saliva and possibly pancreatic juice. These samples can be used retrospectively to 
test novel molecular screening modalities.
There is limited evidence to guide the age at which screening should commence. 
The incidence of pancreatic cancer in individuals with HP increases exponentially 
with age and is negligible before the age of 4092. Older patients are more likely to 
have a cancer at the time of screening, but a younger patient may have more to gain 
from successful treatment.
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In FPC kindreds, the age dependent risk is heavily dependent on family structure. 
Later generations tend to have an earlier onset of cancer101, thus maximum risk is at 
approximately the age of onset in affected siblings and is somewhat lower than the 
age of onset in affected parents. As the disease mutation is not known, in most FPC 
families, risk reduces after the age of onset in affected siblings or parents because 
the probability of being a carrier decreases.
There is little point in screening for early pancreatic cancers, unless there is at least 
the potential to cure the tumours detected. Two studies from Japan247, 248 have 
shown that small cancers (<1cm diameter, no lymph nodes involved), result in a 50- 
100% 5-year survival rate following resection. These data are inevitably limited by 
low numbers due to the low incidence of early tumours. There is also some less 
positive evidence246 with a retrospective South Korean study showing a 5 year 
survival of just 23.3% in the 11 stage 1a pancreatic cancers resected as part of their 
series of 542 cases. Small pancreatic cancers do not necessarily equate to ‘early’ 
cancers, but overall these studies show that there is at least the hope of surgical 
cure when the screening studies detect a malignant lesion.
Once the modalities and protocols have been tested and pancreatic cancer is better 
understood, screening may, in time, become justifiable in lower risk groups such as 
new onset diabetics82 or those with chronic pancreatitis134.
73
Modelling of risk in individuals with a possible genetic predisposition for pancreatic cancer
1.7.2 The Potential Screening Modalities
There is no single screening tool that offers 100% specificity and sensitivity for the 
detection of early pancreatic cancer. Combinations of modalities may offer adequate 
positive and negative predictive values in high risk patients, although this has yet to 
be proven. The five pilot screening programs that are in progress (Johns Hopkins, 
Washington, Moffitt, EUROPAC and FaPaCa), all use endoscopic ultrasound (BUS) 
with most centres supplementing this with serum bloods tests. The blood tests will be 
discussed first, followed by the other potential modalities.
1.7.2.1 Blood Tests
Ideally any screen should be safe and non-invasive. In practice the closest that is 
possible to this ideal, is a serum test. The two collected by EUROPAC are detailed 
below.
CA19-9
At least four of the five pilot studies measure CA19-9, a sialylated Lewis antigen 
produced by patients with digestive tract cancers, particularly those of the pancreas 
and biliary tree. There is, however, limited evidence supporting its use. Estimates of 
sensitivity in the literature range from 67-92%, with specificity ranging from 68- 
92%249'252. These values were all obtained using samples from symptomatic 
patients; when used as a screening modality these figures would be far worse. 
CA19-9 has never been shown to be effective in detection of tumours in 
asymptomatic individuals{Kim, 2004 #1829}. Only 50% of cancers less than 2 cm are
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associated with a rise in CA19-9253 and it is rarely elevated in the presence of 
dysplasia254. In a study of 71,000 patients described as asymptomatic undergoing 
trans-abdominal ultrasonography, CA 19--9 was found to have a positive predictive 
value of less than 1 %240.
Other Tumour Markers
Other serum tumour markers such as carcinoembryonic antigen (CEA), DU-PAN-2, 
CA 50, SLX (sialyl difucosyl Lex), ST-439 (sialyl Lex-Tn) and CA125 could all be 
used but have the same drawbacks as CA19-9255.
Fasting Serum Blood Glucose
The interest in glucose as a possible marker for an emerging pancreatic cancer 
outlined earlier in this chapter has prompted EUROPAC to gather fasting glucose 
data in high risk individuals as an additional trial modality. It is unclear whether 
glucose levels collected within a screening study will be shown to be able to detect 
potentially curable pancreatic cancers or have a role in risk stratification. In time the 
results may inform clinical decisions based on imaging, with retrospective analysis of 
results clarifying their utility. Work continues to develop new serum markers for 
(early) pancreatic cancer, but there are currently no serum tests that can detect 
pancreatic cancer at a potentially curable stage.
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1.7.2.2 Imaging
Endoluminal Ultrasound (BUS)
BUS is low risk and has a very high sensitivity (>90%) for the detection of pancreatic 
masses, even in patients with very early tumours256'258. It is employed as the primary 
imaging modality in all the large trials of secondary screening in high risk groups. It 
has been claimed that it can even detect parenchymal heterogeneity caused by 
PanIN lesions259 and that intraductal papillary mucinous neoplasms (IPMNs) can be 
visualised as cystic masses50. BUS therefore meets many of the criteria as the ideal 
imaging modality in screening, but it does have limitations. BUS is not good at 
distinguishing between benign lesions and cancers. In a small study (n=85) aimed at 
distinguishing between chronic pancreatitis and pancreatic cancer, positive 
predictive value was only 60% based on imaging alone260. To improve specificity, 
BUS has been used to guide fine needle aspiration (FNA) or Tru-cut’ biopsy from 
pancreatic lesions. Although, this may still have limited specificity in the presence of 
abnormal parenchyma261.
Computed Tomography (CT)
Computed Tomography (CT) produces a three dimensional image of the pancreas 
using a computer to convert information obtained using conventional Roentgen 
principles. Interpretation of images is often aided by the use of intravenous and/or 
gastrointestinal tract contrast. Diagnostic accuracy for CT has been calculated to be 
as high as 85-90%262. A retrospective study showed that abnormalities were
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detectable up to 18 months before formal diagnosis with pancreatic cancer263, but, 
by definition, these abnormalities can be missed in routine clinical practice. 
Sensitivity for detecting early cancers is reasonable, but not ideal, with studies 
having shown sensitivity to be between 69 and 83% and specificity to be between 59 
and 93%264'266. The problem becomes more acute in the presence of chronic 
pancreatitis and CT has insufficient resolution to detect PanIN lesions. Tumours 
below 1cm have been shown to be almost impossible to detect267. Clearly this 
depends on the evaluation of the scans. As the threshold for defining abnormal 
scans decreases sensitivity will increase but specificity will fall. CT has the further 
disadvantage that each scan carries a dose of approximately 10 millisieverts (mSv) 
of radiation for each abdominal CT performed268. With some FPC kindreds shown to 
have a DNA repair defect (BRCA2)108, the repeated use of ionising radiation to 
image the pancreas needs to be considered carefully.
1.7.2.3 Other Potential Screening Modalities
Trans-abdominal Ultrasound
A variety of other imaging modalities are used by the screening groups alongside 
BUS. The simplest imaging modality available is trans-abdominal ultrasound (TUS). 
It is non-invasive, readily acceptable and involves no ionising radiation, but the 
physical distance from the abdominal wall to the pancreas and the number of tissue 
interfaces involved requires the use of low frequencies, limiting the picture quality. 
Whilst the sensitivity of trans-abdominal ultrasound in the detection of pancreatic
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cancer is 95% in tumours >3 cm, it reduces dramatically with smaller tumours 269,27°. 
Nevertheless, the advantages of TUS mean that it has already been assessed as a 
screening modality. Periodic TUS checks were performed by Tanaka et a/271 in a 
group of high-risk patients. Patients over 35 years old were recruited on the basis of 
pancreatic duct dilatation, pancreatic cysts and common bile duct dilatation. Serum 
amylase, elastase-l, alkaline phosphatase, bilirubin, fasting glucose, CA19-9, CEA 
and a pancreas-specific TUS were carried out every three or six months. Any 
abnormality prompted a CT or ERCP with pancreatic juice collection. Of the 393 
patients enrolled, pancreatic cancer was diagnosed in 41 patients. Eighteen patients 
had a surgical resection, three of which turned out to be false positives. Despite 
these encouraging figures, screening was not necessarily of benefit to these 
patients. Only four patients had stage I disease at diagnosis and one of these died 
within three years despite treatment271.
Magnetic Resonance Imaging (MRI)
Magnetic Resonance Imaging (MRI) is fast and non-invasive and produces a three 
dimensional image of the anatomy of the pancreas without exposing the individual to 
ionising radiation. The reported sensitivity of MRI ranges from 83-87% and specificity 
from 81-100%{Muller, 1999 #902;Vellet, 1992 #1802;Mu!ler, 1994 #852). It has even 
been reported that Ti weighted spin-echo MRI can be superior to spiral CT imaging 
for detection of small lesions257, 274, particularly when combined with the contrast 
agent mangafodipir trisodium, which enhances normal pancreatic parenchyma but 
not neoplasms257, 275. Despite these considerable advantages, low resolution and
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movement artefacts have previously limited its use267, although this may change 
over the next ten years as more modern studies are published.
Magnetic Resonance Cholangio-Pancreatography (MRCP)
Magnetic Resonance Cholangiopancreatography (MRCP) is a non-invasive method 
of imaging the biliary tree and avoids the risks associated with ERCP. In a 
prospective study of MRCP using 124 patients referred with a suspicion of 
malignancy (37 of whom went on to develop pancreatic cancer), Adamek et al 
showed sensitivity to be 84% and specificity to be 94%276. Some studies have 
stressed the value of secretin administration in improving pancreatic ductal details in 
MRCP277, but whilst MRCP is a useful, non-invasive tool in the diagnosis of 
pancreato-biliary obstruction, it has not been fully evaluated in the context of 
secondary screening. The limited sensitivity even with symptomatic tumours 
suggests it has limited use as a modality in this context.
Endoscopic Retrograde Cholangio-Pancreatography (ERCP)
Endoscopic retrograde cholangiopancreatography (ERCP) has traditionally been 
used as both a diagnostic and therapeutic modality in advanced pancreatic cancer 
with the potential to both obtain cytology and place stents. When used as an imaging 
modality to identify early pancreatic cancers, its use is less clear cut. It has been 
used for imaging in both the US secondary screening studies with the emphasis 
being on the identification of irregular or ectatic ducts with sacculations, which are 
said to be associated with PanINs259. These changes normally occur in the side
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branches or in the tail of the pancreas and require an expert radiologist to perform 
and interpret.
EUROPAC does not use ERCP for imaging but does use it to gather pancreatic juice 
for molecular analysis for cancer related genetic mutations220. Pancreatic juice is the 
secretion most intimately in contact with tumours and so may contain either tumour 
cells sloughed from the duct or cell components, including deoxyribonucleic acid 
(DNA), from necrotic cancer cells. This approach is only suitable for selected 
patients on a research basis as the potential benefits must be weighed against the 
risk of inducing acute pancreatitis278,279.
During my period of research, administration of diclofenac was added as prophylaxis 
against post-ERCP pancreatitis. Diclofenac is a non-steroidal anti-inflammatory drug 
(NSAID) commonly used as an analgesic for patients with arthritis or other 
musculoskeletal pain. Its mechanism of action is incompletely understood but it 
inhibits prostaglandin synthesis by inhibition of cyclooxygenase (COX). Evidence of 
its efficacy for prophylaxis of post-ERCP pancreatitis is mixed280,281.
EUROPAC are now investigating the potential of performing molecular analysis of 
duodenal juice gathered after the administration of secretin to eliminate the risk of 
post-ERCP pancreatitis. This is beyond the scope of this project and no results 
relating to this will be presented.
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Positron Emission Tomography (PET) and CT PET
Positron emission tomography (PET) is a non-invasive method of characterising 
tissue by measuring the higher glycolytic rate of malignant compared to normal cells. 
The only PET agent where there is any volume of literature that has assessed 
clinical utility in pancreatic cancer is 18F-Fluorodeoxyglucose (FDG). Other 
radiotracers are available but the evidence base is very limited282.
A meta-analysis (n=387) has calculated the weighted average sensitivity and 
specificity of FDG-PET to be 94% and 90% respectively. This compares to 82% and 
75% for CT283. More modern work has, however, given conflicting results, showing 
FDG-PET to have lower sensitivity than CT284.
The main strength of PET is its quantitative nature. There is the potential to improve 
diagnostic accuracy with early work on quantifying tracer uptake285 or delayed 
imaging apparently showing malignant lesions to have greater retention of FDG than 
benign lesions286.
Despite the attractions of PET imaging there are some serious weaknesses, which 
are particularly relevant to screening for early pancreatic cancer. Firstly, sensitivity is 
low for small tumours, probably due to partial volume averaging of signals, although 
this can be partly addressed by combining PET with CT imaging.
Of particular relevance to the HP group, there is frequent uptake of FDG by 
inflammatory tissue287, meaning that PET is unlikely to be a useful screening test in
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this subgroup. The same authors also showed that C-reactive protein levels greater 
than 4 mg/I, could reduce the specificity of FDG-PET to 50%287.
As discussed in this thesis, hyperglycaemia is frequently seen with pancreatic 
adenocarcinoma. High serum glucose levels are thought to compete with FDG for 
glucose transporter sites, reducing the sensitivity of FDG-PET in detecting malignant 
lesions. Zimny et al showed that the sensitivity of FDG-PET decreased from 98% in 
euglycaemic patients to 63% in hyperglycaemic patients288.
In summary, these weaknesses mean there is little evidence at present to support 
the use of PET or indeed CT PET as a screening test for early pancreatic cancer. 
Further research is required to prove the utility of PET and the specific indications for 
its use in the imaging of pancreatic disease.
1.7.2.4 Molecular Analysis
No single serum or imaging test is sufficiently sensitive and specific to be used in 
isolation for screening. The combination of investigations may improve the sensitivity 
and specificity of the overall process, but any method of sub-stratifying risk within 
high risk groups should be considered. One potential method is the testing for the 
presence of cancer related nucleic acid or protein changes in pancreatic juice of high 
risk individuals. The presence or absence of these cancer related nucleic acid or 
protein changes can be subjected to a Bayesian analysis to further stratify risk. This 
has the potential to indicate which individuals have an increased pre-test incidence
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and require regular imaging and which individuals can safely have the interval 
between screening investigations increased.
Modalities for molecular analysis of pancreatic juice have evolved since the early 
experiments showing that K-RAS2 mutations can be detected in cellular material 
obtained at ERCP289, K-RAS2 mutations are almost ubiquitous in pancreatic 
cancer290, but unfortunately it was soon established that K-RAS2 mutations are also 
common in the pancreatic juice of control patients291. Technical difficulties have 
restricted detection of Tp53 mutations as a modality for screening, despite a high 
proportion of Tp53 mutations in pancreatic tumours and an apparent high specificity 
for cancer292. Various other markers have been investigated including telomerase 
expression and methylation of specific promoter sequences. Most of these have 
shown promise, but this has not been sufficient to justify their inclusion as 
independent screening modalities293.
EUROPAC has proposed a combination of different molecular tests to phase their 
screening programme220. Cell free pancreatic juice samples are analysed for 
presence of K-RAS2 and Tp53 mutations and quantification of CDKN2A promoter 
methylation. It was proposed that a combination of results with the three molecular 
tests could stratify risk between negligible and 90% probability of cancer. 
Stratification is less marked in patient groups with a background of pancreatitis 
(approximately 0 to 50%), but molecular analysis may conversely have the most 
impact in HP patients where the sensitivity and specificity of conventional imaging is 
limited260. The techniques have yet to be proven in a prospective study. As things
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stand, there is no definite evidence that the molecular markers seen in the juice of 
sporadic cancer patients are also seen in patients who develop pancreatic cancer as 
a result of FPC and the risk of inducing post-ERCP pancreatitis goes against the 
basic principles of a good screening test. On the other hand, the analysis may 
significantly improve both the sensitivity and specificity of the screening process and 
inform the screening interval. This should reduce the number of investigations 
performed and reduce their associated radiation load, reduce the morbidity and 
mortality from false positives and reduce the financial costs per cancer detected. 
Initial results of the molecular analysis will be presented as part of this thesis.
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1.7.3 Initial Secondary Screening Results from Other Centres
Of the registries already mentioned, The Washington254,294, Johns Hopkins259,295,296 
and FaPaCa297 groups have already published initial results of the work on 
secondary screening. The Moffitt Cancer Center are in a similar position to 
EUROPAC, where they have published their methods and protocols298 but have yet 
to publish their full results. EUROPAC’s protocols have been published more than 
once96, 299 but data collection remains at a comparatively early stage. Initial results 
will, however, be shown in Chapter 3 of this thesis.
1.7.3.1 The Washington Group
The University of Washington group screens at risk individuals in FPC kindreds 
using EUS to provide baseline information. Screening commences ten years prior to 
the earliest pancreatic cancer death in each individual family. If no abnormality is 
detected, the EUS is repeated on a twelve monthly basis. If an abnormality is 
detected that is not thought to be due to pancreatitis, individuals are offered an 
ERCP after appropriate counselling. If this fails to show an abnormality, follow up is 
by EUS in twelve months. If both the initial EUS and the subsequent ERCP are 
abnormal, individuals are counselled and given the option of continuing with 
surveillance or obtaining a tissue diagnosis. This is achieved by performing a 
laparoscopic resection of the pancreatic tail296.
From a total cohort of 75 patients, 15 had abnormalities on EUS and ERCP, all of 
whom had surgery (12 total and 3 distal pancreatectomies). The three that had a
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distal pancreatectomy remain under surveillance. Histology results revealed PanlN-3 
lesions in ten individuals and the remaining five specimens contained PanlN-2. 
Although no cancers were detected in the resected participants, one individual 
developed an unresectable pancreatic malignancy whilst under imaging 
surveillance296.
1.7.3.2 The Johns Hopkins Group
The Johns Hopkins group aims to identify early pancreatic masses when the lesion 
is either pre-cancerous or a resectable malignancy. Patients from FPC and other 
cancer syndromes are screened using baseline EDS and CT with imaging repeated 
on an annual basis. Their screening cohort included 72 at risk members of FPC 
kindreds and six affected by Peutz-Jeghers syndrome. Primary imaging was by EUS 
and was performed in every participant. An abnormal scan prompted EUS guided 
FNA and 65 accepted the offer of an ERCP after appropriate counselling, which was 
successful in all but one case. Of the 64 ERCPs where the duct was successfully 
cannulated, there were five cases of ERCP induced pancreatitis and the Hopkins 
group have expressed the opinion that the benefits of imaging by ERCP do not 
justify the pancreatitis risk. Sixty seven participants had a spiral CT scan. From this 
investigative process, 61 participants were felt to have no significant abnormality, 
with suspected neoplastic lesions present in 17 cases. Of these, 10 continued with 
surveillance and seven proceeded to subtotal pancreatectomy. The histology from 
the resections showed IPMNs and PanIN lesions but no cancers. One participant
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had a cyst on CT and developed metastatic pancreatic cancer in the interval 
between imaging and clinical follow up295.
1.7.3.3 FaPaCa
Langer et al 297 reports on seventy six high risk individuals screened between 2002 
and 2007 using annual clinical review, serum blood tests and both MRI and BUS. 
These modalities were supplemented by MR angiography and MRCP in selected 
cases. A total of 182 examination visits revealed an abnormality in 28 patients. Most 
of these were found by BUS (n=25), with a further 12 abnormalities visible on MR 
imaging. There were seven pancreatic fine needle aspirations for cytology and seven 
patients had operations, supplemented by intra-operative ultrasound. Of those seven 
individuals that went to theatre, six had a limited pancreatic resection, with the 
histology showing serous oligocystic adenomas in three individuals, with PanINI 
lesions; PanlN2 lesions; and a PanINI lesion plus a gastric type intraductal papillary 
mucinous neoplasm (IPMN) in the three remaining individuals. Initially, when lesions 
were detected, surgery was recommended, but the surgical approach became more 
conservative as the study continued. At the end of the 5 year period, a further 21 
were having visualised lesions monitored, rather than operated. Their overall 
conclusion was that although Pan IN lesions can be detected and resected, the low 
yield and high psychological and financial burdens mean that general screening, 
even of high risk individuals, cannot be justified at present and should remain limited 
to the trial setting.
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1.7.3.4 The Moffitt Cancer Centre
Klapman et a?98 published a paper in 2008 where they outlined their screening 
protocol but gave no numbers or results. Their approach is based around annual 
BUS, supplemented by FNA (for lesions >5mm) and CT. They do not report a role for 
any serum investigations and have not reported any detected lesions or surgical 
intervention to date.
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1.7.4 Cost Effectiveness
Risk and benefit cannot only be considered in terms of patient survival and risk of 
maleficence. Cost implications cannot be ignored. Papers have discussed the cost 
of cancer screening in HP264 and Peutz-Jeghers syndrome (PJS)300. Screening of 
hereditary pancreatitis patients has previously been declared as prohibitively 
expensive, with a calculated cost of $164,285 per pancreatic cancer detected264.
In PJS, the cost per life saved was estimated at just $50,000, which is economically 
viable, but only if all other causes of cancer death in PJS could be eliminated. With 
existing levels of cancer risk in this syndrome, the cost of screening would rise to a 
prohibitive $297,000. This cost model also assumed use of molecular analysis to 
phase screening; without this added element, costs would rise even further to 
$373,OOO300.
In FPC the only work on cost effectiveness301 came to the conclusion that 
endoscopic screening was cost-effective, with an incremental cost-effectiveness ratio 
of $ 16,885/life-year saved, but this was based on assumptions of a 20% prevalence 
of pancreatic dysplasia and 90% sensitivity of BUS and ERCP. There are some 
importance differences between the studies in FPC and PJS. The FPC paper was 
based on a single round of endoscopic investigations, rather than a protocol guided 
screening study with repeated investigations. Costs were also based on detection of 
PanIN lesions rather than on detection of cancers. Analysis of the initial results from 
the screening studies299 shows that abnormalities requiring surgery are much lower 
than the 20% in the Rulyak paper301 and whilst pre-malignant lesions have been
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resected, screening has yet to detect its first pancreatic adenocarcinoma at a curable 
stage. Estimation is complex, but with the use of molecular analysis, costs in FPC 
could be below $50,000 per life saved300. This will only become clear once several 
cancers have been detected and the results from the pilot screening programmes 
have matured. Estimates of financial outlay on screening investigations performed as 
part of the EUROPAC secondary screening study will be shown in the results section 
of this thesis.
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1.8 Aims and Objectives of this Project
1.8.1 Aims
1. To improve risk stratification on an individual basis in both the HP and FPC 
groups.
2. To pilot a trial of secondary screening in high risk individuals.
1.8.2 Objectives
la. To further characterise the phenotype associated with PRSS1 mutations.
lb. To investigate whether serum fasting glucose levels can differentiate between 
individuals with differing risk profiles.
lc. To develop a computer model capable of stratifying risk in high risk individuals 
from FPC kindreds.
2a. Obtain the necessary ethical approvals for a full trial of secondary screening.
2b. To develop a multi-centre collaborative screening network.
2c. To continue with effective primary screening to identify high risk individuals that 
would benefit from inclusion in the trial.
2d. To test and develop the EUROPAC secondary screening protocol.
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2 Materials & Methods
The materials and methods set out in this section are those that pertain to this 
project. In part, this includes work carried out on behalf of the project by service 
providers or other members of the research team, for example, imaging 
investigations were performed by relevant clinicians or NHS departments, serum 
blood samples were processed by NHS departments of biochemistry and the 
methods relating to the molecular analysis of pancreatic juice were primarily those of 
Dr Van of the School of Cancer Studies. Wherever the methods in this section are 
those of others, it will be clearly stated.
2.1 Primary Screening
EUROPAC’s methods have evolved since 1997 in light of scientific progress and 
new findings. The methods described are those used and developed during my time 
as the EUROPAC research fellow. In order to complete the primary screening I was 
assisted in both data collection and entry by Mr Matthew Marcus, the EUROPAC 
database manager during my time in post. Primary screening in FPC families 
received ethical approval from the North West Research Ethics Committee 
(reference 03/8/069) with the Scotland Research Ethics Committee (reference 
04/0/010) giving approval for primary screening in HP kindreds.
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2.1.1 Recruitment
Potential participants were either referred by a clinician or they self-referred by 
contacting the office directly, usually after researching pancreatic cancer on the 
internet after a death in the family. Referrals were invited from any clinician that had 
access to individuals at high risk of pancreatic cancer or with HP. This was 
supported by the EUROPAC study group publishing in peer reviewed journals, by 
poster presentations at relevant academic meetings and by maintaining close 
contact with collaborators. Irrespective of the manner of initial contact, after an initial 
discussion, a patient information sheet (PIS) and questionnaires were sent out for 
individuals to look through. If they wished to register, they had to provide written 
informed consent. Consent forms were supplied at the request of the potential 
participant. The written documentation was supported by either a face to face 
meeting at the Royal Liverpool University Hospital or collaborating site, or a 
telephone conversation with the consent form returned by post. One question on the 
consent form asked for permission to inform the participant’s general practitioner 
(GP) that they had joined the registry. If this consent was given, then a standard 
letter was sent out for the GPs information and records. Personal, epidemiological, 
medical and family data were collected by a series of questionnaires. Blood samples 
were collected from all consenting individuals and stored under the care of the 
Mersey Regional Genetics Service, based at the Liverpool Women’s Hospital. 
Patients were not recruited when there was any doubt as to their ability to give 
informed consent. Individuals self-referring to EUROPAC from North America were 
given contact details for US registries.
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2.1.1.1 Genetic Testing
DNA was collected and stored in compliance with the Human Tissue Act 2004 
(England and Wales), which was amended in 2006. This was under the care of the 
Mersey Regional Genetics Service, where all testing took place. In FPC families, if 
the history suggested the presence of a particular testable mutation (e.g. in the 
BRCA2, CDKN2A, orSTK11 gene), testing was offered after the individual had been 
referred to a clinical geneticist for a discussion about the potential implications of a 
positive result. Genetic testing in HP families, where the history suggested a highly 
penetrant mutation, started with testing for the common mutations in the PRSS1 
gene. If the common mutations were not found, the entire gene was sequenced. A 
proportion of HP families with a phenotype suggesting a highly penetrant mutation 
were shown to have a normal PRSS1 gene. EUROPAC classified these families as 
‘Neg All HP’. If PRSS1 testing was negative or the phenotype suggested a low 
penetrance mutation, individuals were tested for the 33 most common disease 
related Cystic Fibrosis Transmembrane Receptor (CFTR) mutations, as well as the 
p.N34S variant of SPINK1.
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2.1.2 Data Storage
All collected data were stored using Progeny software (version 7.01) on a password 
protected computer isolated from the internet. Data were stored in compliance with 
the Data Protection Act (2003). The ethical agreement permits a single copy of the 
database to be kept in a locked fireproof box in a second locked office. Access to the 
database was limited to the EUROPAC research fellow, the database manager and 
Dr W Greenhalf, the lead scientist on the project.
2.1.3 Outcome of Primary Screening
On completion of the initial process of primary screening, the Progeny software was 
used to construct a family tree summarising the phenotype and there was a multi­
disciplinary discussion by a team of clinicians, scientists, and where possible, a 
clinical geneticist. The purpose of the discussion was to use all available data to 
classify the kindred or suggest any further work that could be performed before the 
family was formally accepted onto the registry. In most cases I was one of the clinical 
representatives.
The diagnosis of FPC in a family is based on evidence of autosomal dominant 
inheritance of predisposition specifically for pancreatic cancer. Recruitment required 
at least two first-degree, or at least three second-degree, relatives in two or more 
generations with confirmed pancreatic ductal adenocarcinoma. Confirmation of 
cases was by: histological evidence, cancer registry confirmation, or good quality 
medical notes with death certificate evidence, in that order. The real purpose of the 
multi-disciplinary discussion outlined in the previous paragraph was to pick out
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kindreds where there were two or more cases of pancreatic cancer, but the 
causative genetic syndrome was something other than FPC. Some families with only 
one pancreatic cancer death were enrolled in the presence of a proven genetic 
mutation associated with an increased risk of pancreatic cancer (e.g. CDKN2A). 
Where a mutation was identified, families were classified according to the underlying 
cancer syndrome, irrespective of the number of pancreatic cancer deaths in the 
kindred.
Similarly, the classification of HP was based on autosomal dominant inheritance, in 
this case of pancreatitis. Recruitment required evidence of acute or chronic 
pancreatitis in at least two first-degree, or at least three second-degree, relatives in 
two or more generations. Diagnosis of chronic pancreatitis was made by: histological 
evidence, a low faecal elastase or evidence of pancreatic calcification on imaging, or 
on the basis of good quality medical notes, in that order. Classification was easier in 
HP kindreds as it was normally supported by the results of genetic testing and 
kindreds were largely classified by PRSS1 mutation. Families were enrolled as ‘Neg 
All HP’ if their phenotype indicated autosomal dominant aetiology and no genetic 
cause was identified after sequencing of the PRSS1 gene. Some individuals were 
recruited with a phenotype that suggested sporadic disease if genetic testing results 
indicated the presence of a chronic pancreatitis associated mutation such as the 
p.N34S mutation of SPINK1. Attempts were then made to register other family 
members. Individuals with apparent sporadic idiopathic pancreatitis were not 
registered in the absence of a proven genetic mutation.
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The FPC arm of the registry was divided into sub-groups. Pancreatic cancer families 
were grouped by phenotype as ‘FPC, ‘?FPC\ ‘With Gastric’, tBRCA2 FPC, and 
‘Other’. The true ‘FPC’ group contained families where the phenotype was definitely 
consistent with autosomal dominance, with multiple cases of pancreatic cancer in 
multiple generations, and the cancer cases had been proven. The group *?FPC 
contained families with multiple pancreatic cancers but the strict criteria laid down to 
be classified as ‘FPC’ were not met. This could be for a number of reasons, but in 
practice was most commonly because the cancer cases were in a single generation 
(suggesting a multigene or environmental cause) or sufficient numbers of cancer 
cases could not be proven. ‘With Gastric’ was the name given to a group of families 
that fully met the criteria for diagnosis as ‘FPC’, but also contained an additional 
case of gastric carcinoma. The cases could not be explained by any of the known 
genetic syndromes and the cancers in these kindreds may be the result of an as yet 
unidentified mutation, different to that causing the cancers in the FPC kindreds. At 
present, the data remain too few to investigate this further. BRCA2 FPC contained 
families where the phenotype was consistent with ‘FPC’ in the presence of a BRCA2 
mutation. These families did not have multiple cases of breast or ovarian cancer, or 
they would have been classified as being ‘Breast Ovarian’ (see below). One tBRCA2 
FPC’ family had a single case of ovarian cancer, but this individual proved not to be 
a BRCA2 mutation carrier. The ‘Other’ group contained any families registered that 
did not meet the criteria for any of the above groups. This group contained the rare 
cancer related syndromes, for example, FAMMM-PC and Breast-Ovarian families 
that contained a pancreatic cancer. Families with single cases of pancreatic cancer
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were not registered unless a genetic mutation associated with pancreatic cancer had 
been identified. Basic data relating to these classifications are set out in table 3 of 
the results section of this thesis.
The HP arm of the registry was also sub-divided. The sub-groups for the pancreatitis 
families were largely based around the results of genetic testing. True HP kindreds 
were classed as belonging to the ‘p.R122H\ ‘p.N29r, ‘p.AISV’, or the ‘Neg All HP’ 
groups. As stated above ‘Neg All HP’ was the name given to kindreds with a 
phenotype entirely consistent with HP but no cause had been identified in the 
PRSS1, CFTR or SPINK1 genes. Individuals with the p.N29T mutation were 
classified as belonging to the p.N29l group. At time of data guillotine for the primary 
screening results displayed in this thesis, individuals with a p.R122C mutation were 
included in a group entitled ‘Other’ mutation. This contained HP families with proven 
rarer PRSS1 mutations, for example p.R116C, or p.V39A. The reasoning for p.N29T 
being included with p.N29l is that biochemically the substitution of an isoleucine or a 
threonine is similar (both are small neutral amino acids). In contrast cysteine (given 
its propensity for formation of sulphur bridges) could result in very different activity. 
Simon et at302 have shown that p.R122C results in a very radical change in both 
autoactivation and autodegradation, which is far more dramatic than p.R122H. Two 
final groups on the HP database were ‘HP family’ and ‘HP problem’. The group ‘HP 
family’ contained kindreds where the phenotype was consistent with HP and genetic 
testing should have been possible but had not been initiated or was in process. ‘HP 
problem’ was where the proband wanted to be on the registry, but had declined
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genetic testing, normally after discussion with a genetic counsellor. Basic data on 
these classifications are set out in table 4 in the results of this thesis.
There were also a number of sub-groups that were relevant to non-HP kindreds. 
These were ‘FIR’, ‘Sporadic’, ‘IPCA’ and ‘CFPANC. ‘Familial Idiopathic Pancreatitis’ 
(FIP) was where there were several cases of pancreatitis in a family but these were 
restricted to a single generation or were in family members where the relationships 
are sufficiently distant that the cases were not in keeping with HP. ‘Sporadic’ was a 
single idiopathic case and included those with SPINK1 mutations. Families where 
there was one case of idiopathic pancreatitis with an additional pancreatic cancer 
case (IPCA) is self-explanatory. These families may or may not have a proven 
SPINK1 mutation. The final group ‘CFPANC’ (CFTR-related idiopathic pancreatitis) 
had one or more cases of pancreatitis in individuals with a proven CFTR mutation. 
Basic data on these classifications are set out in table 6 of the results section of this 
thesis.
Classification in both the FPC and HP arms of the registry was an ongoing process 
and in some cases the group in which a family had been placed changed as 
additional family members were recruited, further genetic testing was performed, or 
additional cancers developed or were proven. As consent was required before 
primary screening could take place, some families were subsequently shown to have 
neither FPC nor HP. During my time in post, the data on these families were kept in 
a ‘pending’ file and a file number was not allocated until they were formally classified.
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Informed pedigree analysis at time of classification identified the high risk individuals 
within kindreds. Efforts were then made to see whether these individuals were 
interested in registration via previously recruited family members, the process was 
repeated and the kindreds were characterised as fully as possible.
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2.2 Risk Stratification
2.2.1 Manual Methods of Risk Stratification
During the course of this work the methods employed for risk stratification improved 
in accordance with the aims of the thesis. However, recruitment of participants for 
screening was ongoing throughout this period using less sophisticated approaches. 
The manual method of risk stratification was the result of analysis of the phenotypes 
built up by the thorough primary screening described in the preceding section. 
Informed judgement was used to identify those family members at particular risk. For 
FPC families this was a subjective calculation dependent on the number of 
confirmed pancreatic cancer in the family, the likelihood that an individual was a 
carrier of an apparent predisposing genetic mutation, individual risk factors and 
genetic testing where available. In HP kindreds, there was a similar process but 
ultimately the final decision for each individual was less subjective because a 
diagnostic genetic test was available for all but the ‘Neg All HP’ kindreds and the 
cancer risk in HP is well characterised, at least in p.R122H and p.N29l kindreds91'93.
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2.2.2 Novel Modalities
2.2.2.1 Glucose
Serum glucose samples were collected from consenting asymptomatic members of 
FPC kindreds, with additional samples collected from high risk individuals (from both 
FPC and HP kindreds) as part of the secondary screening study. These were fasting 
samples, normally taken in a primary care setting and processed locally with the 
result sent by post or fax. Some samples were collected in the outpatient setting. 
Samples obtained from participants in the Liverpool area or from patients who were 
treated at the Royal Liverpool University Hospital were processed using NHS 
facilities at the hospital. There was obviously some variability in how fasting glucose 
samples were processed in different institutions depending on local infrastructure 
and standard operating procedures. The process used by the biochemistry 
department at the Royal Liverpool University Hospital is described in section 2.3.3.1 
alongside the other investigations used as part of the secondary screening study.
All results, whether processed locally or at collaborating centres were stored on the 
main EUROPAC Progeny database under the registry ethical agreements for FPC 
(MREC 03/8/069) and HP (MREC/04/0/010) respectively.
2.2.2.2 Computer Modelling
The desire to improve risk stratification and make this as objective as possible 
prompted the development of a computer model to stratify risk in FPC kindreds. This 
was done in collaboration with two members of the University of Liverpool Clinical
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Engineering Department (employed by the Royal Liverpool & Broadgreen University 
Hospital Trust) and a PhD student, Francesco Tortora, who worked alongside them. 
My role in this process was: primarily commissioning; but I also generated, checked 
and coded the dataset; acted as the link with the non-clinical members of the team; 
and tested the interface generated by Mr Tortora to identify any problems so that 
they could be resolved.
The dataset used to produce the model was formed from 85 families from the FPC 
database with three or more cancer cases. These kindreds contained 1251 
individuals, of whom 297 had been affected by pancreatic cancer. The specific fields 
used were the individual’s age, gender, the age of death of an affected parent and 
smoking status. Smoking data were only available for 380 individuals. The gender 
specific probability of smoking was calculated from these individuals for each year of 
birth. Dummy variables were then generated for smoking in the individuals with no 
data so as to maintain the same probabilities across the whole group. Together 
these data made up the primary inputs into the equation shown below in figure 2.
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Figure 2: The Equation Used in the Mathematical Model
log t, -yvo^r)
bfi~N(0,ri)
PrN(0,Vj)
VjT], t~G(1/1000; 1/1000)
This figure shows the mathematical equation developed using EUROPAC data to predict 
cancers in FPC families. The expressions on the first line describe the log of time (£,) being 
normally distributed, with (yv(^(,r)) being a normal distribution term. Within this term (N) 
describes the normal distribution, /xt is the mean and t is the inverse variance. The second 
line states that the mean (/it ) is defined as (*-) the scalar product « )) of the vector of the 
model co-efficients (p,) and the vector of the covariates (z^) plus a fixed term (/?0) plus the 
frailty or family clustering term (b^). The co-variates are individual values e.g. gender, 
smoking, age class for death of parent and the co-efficients are the values by which these 
covariates are multiplied. Line three describes the frailty term (b^() which is again normally 
distributed (N(0,t])), with 0 representing the mean and rj being the inverse variance. The 
fourth line describes the elements of the beta vector (J3j) as being normally distributed (Af), 
with 0 again being the mean and vj being the inverse variance. The fifth line states that nu (py), 
eta (tj) and tau (r) are gamma distributed (~G), meaning that the variables will always be 
positive.
Dr’s TakTak and Eleuteri both had experience in computer modelling in 
malignancy224, 303-305 and used the data to construct an accelerated failure time 
model. A frailty factor was used to account for familial aggregation306. The model 
was formulated in the Bayesian framework using WinBUGS software307'309. The
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specific covariates used were individual values for age class, gender, smoking, age 
class for time of death of an affected parent.
The model output was then multiplied by two factors that increased the model’s 
predictive power. These factors were the ‘family index’, and the ‘probability of being 
a carrier’. The family index was intended to account for the difference in family size, 
where some kindreds had a phenotype with three cancer cases out of a total of six 
on-kindred individuals and other kindreds had three cancers within a large family of 
perhaps 50 at risk individuals. Each affected individual makes it more likely the 
family has a genuine increased risk and each unaffected individual makes it less 
likely. The smaller family logically has a greater likelihood of a genetic cause for the 
cancer cases. The index was calculated by dividing the number of cancer cases in 
the family by the number of individuals at risk i.e. on kindred individuals greater than 
40 years, giving a result of between zero and one.
The probability of being a mutation carrier was derived manually by looking at the 
pedigrees, with a value entered for each individual. Assuming autosomal dominant 
inheritance, any first degree relative of an affected individual, where the cancer had 
resulted from a genetic mutation, had an even chance (a probability of 0.5) of 
carrying the responsible mutation themselves. If a first degree relative remained 
unaffected, then the probability of their offspring being a gene carrier reduced to 
0.25.
This equation in figure 2 was tested for its powers of ‘discrimination’ and ‘calibration’ 
and adjusted until it had been optimised. ‘Discrimination’ is the ability of the model to
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separate the subjects into two groups, in this case those that developed cancer and 
those that did not. It was tested using Harrell’s C-Index which is an extension of the 
Area Under the Receiver Operating Characteristic (AUROC) Curve. Harrell’s C-Index 
is thought to be better for survival analyses as it is threshold independent and can 
cope with censored data310, 311. It is calculated by pairing all samples that are 
comparable and calculating the probability of their concordance. For any given pair 
to be comparable, at least one of the subjects in the pair must have developed the 
event (e.g. pancreatic cancer) and the follow-up time period for this subject must be 
less than that of the second subject. For a pair to be considered concordant, the 
probability of survival predicted by the model for the second (unaffected) subject 
must be greater than that predicted for the first.
Figure 3: Harrell's C-Index
Probability of Concordance
C Index =
Probability of Comparability
Figure showing Harrell’s C Index, which was used to test the mathematical equation for its 
power of discrimination (its ability to differentiate between those that developed cancer from 
those that did not). Affected and unaffected individuals were paired and a numerical value was 
calculated by dividing the probability of a pair being concordant (the probability of survival 
predicted by the model for the unaffected subject had to be greater than that of the affected 
one) by the probability that the pair was comparable (at least one of the subjects in the pair 
must have developed pancreatic cancer and the follow-up time period for this subject had to 
be less than that of the second subject.)
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The second method used to test the model was ‘calibration’. This is the degree of 
correspondence between the probability of an event being predicted by the model 
and the probability of that event having actually occurred. It is tested using Hosmer- 
Lemeshow analysis which has previously been peer reviewed as suitable for this 
type of work312. Values derived from the model were first rank ordered and split into 
five groups, with the most likely to develop pancreatic cancer in group one and the 
least likely in group five. Predicted versus actual survival were then compared and 
tested for goodness of fit with the results quantified as a Chi-square statistic.
The Computer Interface
The interface was constructed by Mr Francesco Tortora, a PhD student, who was 
supervised by Dr’s TakTak and Eleuteri. My role in the creation of the interface was 
to devise an algorithm for how the data were to be collected, which he converted into 
an online interface using HyperText Markup Language (HTML). I used the interface 
to enter test data and noted any errors and problems, which Mr Tortora then 
corrected. At the end of data entry for each high risk individual, a summary of the 
data was produced. If this summary was accepted as correct by the individual 
entering the data, a survival curve was produced which gave a calculated estimate of 
risk from pancreatic cancer for that individual over the next five years.
Pseudo-Prospective Testing
Once the model had been tested and optimised, its ability to predict cancers was 
tested by backdating the EUROPAC FPC database to the year 2000. Between 2000
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and 2008, there had been a total of 27 cancers amongst FPC kindreds. MedCaic for 
Windows, version 9.5.0.0 (MedCaic Software, Mariakerke, Belgium) software was 
used to perform a Receiver Operating Characteristic (ROC) curve analysis to 
determine the optimum level of risk at which screening should be triggered. This was 
set so that all cancers were within the screened group, but unnecessary screening 
was minimised, as shown in table 8 of the results section of this thesis.
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2.2.3 Improving the Characterisation of p.A16V
Mutation type was used in this study as a variable in quantifying cancer risk in HP. 
Although p.R122H and p.N29l had previously been extensively studied little 
information was available on p.A16V. Therefore, as part of this work, the phenotype 
of pancreatitis, pancreatic failure and cancer in p.A16V kindreds were researched. 
The difficulty of characterising p.A16V at the start of this thesis was that this form of 
mutation was too rare for single centres to perform a meaningful statistical analysis. 
Most kindreds used in this study had already been recruited and characterised by 
EUROPAC with primary screening performed in the standard way. Additional 
participants were recruited by contacting all prominent researchers in the field of HP 
identifiable from the literature. I was ably assisted in this by my colleague Mr 
Matthew Harcus. Data and DMA were obtained wherever permitted using existing 
local ethical consents. No data were accepted without evidence of written informed 
consent that permitted transfer or sharing of data. The data obtained were analysed 
using SAS Institute Inc. StatView version 5.0. Endpoints including onset of 
pancreatitis and diagnosis of endocrine and exocrine pancreatic failure were 
analysed using the method of Kaplan-Meier, with differences assessed using the 
Mantel-Cox logrank test. Where an endpoint was not reached, censor times were 
taken as the age of last contact. Differences in median values for continuous data 
were tested using the Kruskall-Wallis (for comparison of multiple groups) and Mann- 
Whitney-U tests (for comparison of two groups).
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2.3 Secondary Screening
2.3.1 Recruitment and Inclusion and Exclusion Criteria
As part of this study I made two ethical applications for a trial of secondary 
screening, one in the FPC group and a second in HP kindreds. These were titled 
‘The European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer 
(EUROPAC) Study of Secondary Screening for Early Pancreatic Cancer in Familial 
Pancreatic Cancer Kindreds’ granted by Warwickshire Research Ethics Committee 
(REC Reference 07/H1211/96) and 'The European Registry of Hereditary 
Pancreatitis and Familial Pancreatic Cancer (EUROPAC) Study of Secondary 
Screening for Early Pancreatic Cancer in Hereditary Pancreatitis’ granted by Central 
Manchester Research Ethics Committee (REC Reference 07/H 1008/153) 
respectively.
All participants in the EUROPAC secondary screening trial were recruited from the 
main registry. Participants joining the registry from the time I took up the post as the 
EUROPAC research fellow were made aware of the secondary screening trial on 
registration. Those that had joined the registry between 1997 and 2006 were 
approached by post, providing that they had consented to being contacted about 
further research opportunities at the time of their recruitment. In practice many of 
kindreds recruited to the FPC arm of the registry during my time in post contacted 
the EUROPAC office having searched online for information about pancreatic cancer 
screening after the diagnosis of a pancreatic cancer in a close family member.
110
Modelling of risk in individuals with a possible genetic predisposition for pancreatic cancer
Initial information and the trial documentation were made available either by post or 
email. If high risk individuals were interested in joining the study, they obtained a 
referral from their GP to one of the consultant pancreatologists working on the 
project. In practice, this was almost always Professor Neoptolemos. The individuals 
were seen in the outpatient clinic, where the limitations and risks of the available 
modalities were explained. Participants were recruited if: they wanted to go ahead; 
they met the inclusion and did not meet the exclusion criteria for the respective arm 
of the trial (see table 2); and they provided written informed consent following a 
suitable ‘cooling off’ period.
Table 2: Inclusion and Exclusion Criteria for EUROPAC Studies of Secondary 
Screening
Table summarising the inclusion and exclusion criteria for the secondary screening study for 
high risk individuals from both FPC and HP kindreds. In the FPC group, the criteria for FPC 
had to be fully met i.e. there had to be at least two confirmed pancreatic cancer deaths in at 
least two generations. The only exception to this was for individuals from kindreds with single 
cancer cases, if a pancreatic cancer associated mutation had been identified in both the 
affected individual and the individual wishing to be screened. The usual starting age for 
screening was 40 years, as the risk was minimal before that point, although this could be 
adjusted depending on the outcome of primary screening and the ages of other cancer deaths. 
Exclusions in the FPC group were on the basis of age, females that were either pregnant or 
had not taken contraceptive measures, those unable to provide informed consent and 
members of kindreds with a testable pancreatic cancer associated mutation (e.g. BRCA2) that 
had been tested and shown to be wild type. In the HP group, these criteria were identical, but 
in practice, genetic testing results carried far greater significance.
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Inclusion Criteria Exclusion Criteria
Familial 
Pancreatic 
Cancer (FPC)
Any patient from a confirmed familial 
pancreatic cancer kindred over the age of 
40 years. There is no maximum age limit to 
the screening process.
The diagnostic criteria for Familial 
Pancreatic Cancer are:
• Two first degree relatives with pancreatic 
ductal adenocarcinoma;
and/or
• three or more relatives with pancreatic 
adenocarcinoma;
and/or
• Individuals from families with a causative 
gene linked to pancreatic cancer (eg. 
BRCA2), where the individual has tested 
positive for the mutation and has a first or 
second degree relative that has been 
diagnosed with pancreatic cancer.
2. Individuals aged under the age of 40 years 
can be included on an individual basis if 
their phenotype suggests a particularly high 
risk. This flexibility in individual cases is to 
account for ‘anticipation’ and the recruitment 
decision takes place after multi-disciplinary 
discussion.
Hereditary
Pancreatitis
(HP)
1. Any patient with hereditary pancreatitis over 
the age of 40 years. There is no maximum 
age limit to the screening process.
The diagnostic criteria for Hereditary 
Pancreatitis are:
• At least two relatives with chronic 
pancreatitis in at least two generations in 
the absence of gallstones or a definite 
correlation with alcohol excess;
and/or
• Individuals of any family who carry a 
predisposing mutation for hereditary 
pancreatitis.
1. Individuals under the age of 40
years with the exception of a 
small proportion of individuals 
from pancreatic cancer families 
with particularly young onset
disease.
2. Any patient unable to give
informed consent.
3. Any woman able to bear a child
but who has not taken
appropriate contraceptive
measures.
4. Those testing negative for a 
pancreatic cancer associated 
mutation, where a genetic test is 
available.
1. Individuals under the age of 40 
years with the exception of a 
very small proportion of patients 
younger than the age of 40 
years with hereditary 
pancreatitis who will undergo an 
ERCP as part of their routine 
clinical management.
2. Any patient unable to give 
informed consent.
3. Any woman able to bear a child 
but who has not taken 
appropriate contraceptive 
measures.
4. Those testing negative for a 
detectable pancreatitis causative 
mutation, where a genetic test is 
available.
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2.3.2 The Secondary Screening Protocol
For those individuals that met the inclusion criteria, wanted to enter the secondary 
screening study and provided written consent, the next step was the baseline 
investigations. These included serum blood investigations (fasting glucose and 
CA19-9) and imaging (EUS and CT). The step following these baseline 
investigations depended on initial results and the individual’s attitude towards which 
screening investigations they chose to take up. The algorithm for the FPC arm of the 
study is set out below in figure 4 and it will be this which will be outlined below. The 
only real difference between the algorithms for FPC and HP was that the imaging 
modality of choice in HP individuals was normally CT rather than EUS.
Any detected abnormality was discussed in the meetings of the EUROPAC study 
group and those considered potentially significant were taken to the regional 
pancreatic cancer multi-disciplinary team (MDT) meeting. If the MDT considered a 
detected abnormality to represent a potential malignancy, the individual would have 
been staged in the normal way and the tumour resected if possible, with the 
individual treated non-operatively in the presence of locally invasive or metastatic 
disease. The MDT might have decided that further investigations were indicated. 
This could either have been additional imaging or molecular analysis of pancreatic 
juice. Once the case had been fully assessed, if no definite diagnosis of cancer had 
been made, the participant would have remained on the close surveillance pathway 
with annual investigations.
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Figure 4: The EUROPAC Secondary Screening Protocol
d
Potentialty resectable " 
lesion, patient fil find 
consenting
Lesion irresectfihle. 
patient not fit or v 
declines surgery
Suitable and consenting to ERCP for Pancreatic Juice
(PJ) Analysis for Kras, p16 and p53abnonnalities?
Any evidence of malignancy?
Corroborative
Imaging
Close
Surveillance 
(annual EUS)
Surgery
Non-Operative
Treatment
MDT
for case 
discussion
Baseline Investigations:
Imaging (EUS and CT) with blood tests (CA19-9 and fasting glucose)
Standard Surveillance 
(three yearly EUS)
Primary screening & risk stratification:
High risk consenting individual meeting the inclusion critena enters at
Is a PJ abnormality (other than a single Kras mutation) 
identified in the PJ?
The EUROPAC protocol for secondary screening in high risk individuals from FPC kindreds as 
it was at the end of my period in post as the EUROPAC. The first step is thorough primary 
screening. Individuals who meet the entry criteria and consent to join the study go forward for 
baseline investigations. If a relevant abnormality is detected, the results are discussed at the 
regional pancreatic cancer multi-disciplinary team (MDT) meeting. Their decision options are 
shown by the arrows with dotted shafts. If there is a definite malignancy present, the 
participant will be considered for surgery where possible; if the tumour is inoperable or there 
is already metastatic disease present, the participant will be treated non-operatively. The MDT 
may decide that further investigations are indicated. This may include additional imaging or 
molecular analysis of pancreatic juice (PJ). Once the case has been fully assessed, if no 
definite diagnosis of cancer has been made, the participant will remain on the close 
surveillance pathway with annual investigations. If baseline investigations are normal and 
MDT discussion is not indicated, an ERCP for pancreatic juice analysis is offered. Those that 
have an ERCP and are shown to have either no genetic abnormalities or a single Kras 
mutation in their PJ enter the standard surveillance pathway, where imaging and PJ analysis 
are staggered within a three year cycle. Those with multiple mutations or declining ERCP enter 
the close surveillance cycle of annual imaging.
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If the high risk individual had their baseline investigations and did not require referral 
to the MDT, there was the option to perform an ERCP for juice collection. If informed 
consent was given and the analysis showed any abnormality other than a single 
Kras mutation, the case would be discussed at the MDT and the participant would 
enter the close surveillance pathway of annual imaging. If juice analysis revealed 
either no genetic abnormalities or a single Kras mutation, the participant entered a 
standard surveillance pathway with further investigations staggered within a three 
year cycle, for example, an EUS 18 months later and a further ERCP three years 
after the first one. The standard surveillance pathway therefore meant that one 
ERCP and one imaging investigation would be performed within a three year cycle. 
The close surveillance pathway meant that one imaging investigation would be 
performed per year which might or might not be supplemented by one or more 
ERCPs and/or corroborative imaging, depending on other results.
If baseline imaging revealed normal pancreatic parenchyma, the imaging 
investigation of choice was EUS. if baseline imaging showed chronic pancreatitis to 
be present, the imaging investigation of choice became CT. In practice, this meant 
that the primary method of imaging in the HP group was almost always CT, with EUS 
almost always being the main imaging modality in the FPC kindreds. Other imaging 
modalities were used for corroborative imaging as recommended by the MDT.
The clinician and the participant decided what elements of the screening programme 
were appropriate and acceptable. Participants could opt in or out of each aspect (i.e. 
bloods, imaging and pancreatic juice analysis). The baseline results and the
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participant’s attitude to ERCP effectively determined whether the participant entered 
the standard or close surveillance pathway as set out in figure 4.
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2.3.3 Secondary Screening Investigations
I usually took the blood for the serum sampling but this was processed by NHS staff 
in the relevant department of the Royal Liverpool University Hospital (RLUH) or at a 
collaborating site. The imaging was performed in the relevant part of the radiology or 
gastroenterology department either at the RLUH or at a collaborating site. The BUS 
and ERCPs were performed by either consultant radiologists or gastroenterologists 
at either the RLUH or other collaborating centres. The methods outlined below relate 
to those applied at the RLUH at the time I was co-ordinating the secondary 
screening study.
2.3.3.1 The Blood Investigations
Technical Aspects of Testing for CA19-9 at RLUH
Blood was collected by venepuncture, packaged in a standard lithium heparin tube 
and transported to the biochemistry laboratory. The sample was then centrifuged to 
obtain the 10f.il of plasma required for the assay. Plasma samples were stored and 
processed as a batch twice weekly.
The technique employed, which has been standardised against the Enzymum-Test 
CA19-9 method, was an automated version of a Sandwich Enzyme Linked 
Immunosorbent Assay (ELISA) performed using a Roche Modular E170 analyser. 
There were three phases to the process, the first two were incubations and the final 
phase was the measurement phase. At the first incubation, 10f.il of sample, 
biotinylated monoclonal CA19-9 specific antibody and a monoclonal CA19-9 specific
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antibody labelled with ruthenium complex formed a sandwich. Following the addition 
of streptavidin coated microparticles, during the second incubation the complex 
became bound to the solid phase via interaction of streptavidin and biotin. In the 
measurement phase, the reaction mixture was aspirated into the measuring cell 
where microparticles were magnetically captured onto the surface of the electrode. 
Unbound substances were then removed with Procell. Application of a voltage to the 
electrode then induced chemiluminescent emission which was measured by a 
photomultiplier. Results were determined by the analyser via an instrument specific 
calibration curve. This was generated by a 2-point calibration performed on the 
instrument and a master curve encoded on the reagent bottle barcode. The three 
phases of the assay took a total of 18 minutes.
The result was expressed as units per litre, or more usually thousands of units per 
litre (kU/L). The normal range was <35 kU/L. A result could be determined with the 
standard method described for levels ranging from 0.600-1000 kU/L, with values 
below the detection limits reported as <1.0 kU/L. Values >1000 kU/L prompted 
dilution of the sample with Elecsys Universal Diluent at a 1:10 to permit the process 
to be repeated and a value to be obtained.
Once the result had been calculated, biomedical scientists within the department 
either released the results onto the Telepath computer system, which authorised the 
result or on occasion the endocrine duty biochemist authorised results manually after 
clinical validation. The final stage was the reporting of results electronically to other 
Royal Liverpool and Broadgreen University Hospital Trust (RLBUHT) computer
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systems and external systems where appropriate. A printed report was forwarded to 
the requesting clinician. Results were available within 7 days and, after testing, 
samples were frozen in a -20°c freezer and stored for three months.
Technical Aspects of Testing for Serum Blood Glucose at RLUH
The biochemistry department processed samples taken at the Royal Liverpool 
University Hospital. A fasting blood sample was collected by venepuncture and 
packaged in a fluoride EDTA plasma tube. The tube was transported to the 
laboratory and plasma samples were centrifuged within an hour of receipt. Analysis 
was performed using a ‘Roche P’ automated analyser and was achieved by 
oxidisation of glucose by glucose-oxidase (GOD) in the presence of atmospheric 
oxygen to form gluconolactone. Hydrogen peroxide was formed which oxidised 4- 
aminophenazone and phenol to 4(p-benzoquinone-monoimino)“phenozone in the 
presence of peroxidase (POD). The process resulted in a red dye, with the colour 
intensity being directly proportional to the glucose concentration. The value was 
determined by the analyser using spectrophotometric principles.
The result was expressed as millimols/litre (mmol/l). The detectable range varied 
from 0.11 to 25 mmol/l. Values under 2.5 mmol/l would have prompted a second test 
and levels >25.0 mmol/l would have prompted repeat analysis using a reduced 
sample volume diluted with saline. An error up to 1.8% was included within the 
results obtained.
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Biomedical scientists were responsible for releasing results to the Telepath system. 
This process auto-validated the result or the result could be authorised manually by 
the duty biochemist. After authorisation results were reported electronically to other 
RLUH and external computer systems, with a paper copy being sent to the 
requesting clinician. Glucose was assayed daily and results were available the same 
day. Samples were retained in a cold room for one week after testing.
2.3.S.2 The Primary Imaging Investigations
Technical Aspects of Performing BUS at RLUH
Endoluminal ultrasound examinations were conducted at several collaborating 
centres, but the process at the RLUH will be described. Consenting patients 
attended the department of gastroenterology, normally as an outpatient. The scan 
was performed using analgesic throat spray just prior to intubation. Benzodiazepine 
sedation was given as required but was rarely needed. Participants were intubated 
with an Olympus GF-UE260 scope. Visual images were obtained of the upper 
gastrointestinal tract before ultrasound images were obtained of the pancreas using 
ultrasound frequencies of 5-20 megahertz (MHz). Images could be both stored and 
printed. A report was entered on the Unisoft system and images were uploaded to 
Picture Archiving and Communication System (PACS). The participant then 
underwent a period of observation in the recovery suite before being discharged 
home.
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Technical Aspects of Performing Computed Tomography Scans at RLUH
Computed tomography images were obtained at the Royal Liverpool University 
Hospital using a Siemens Sensation 16 helical multi-slice Computed Tomography 
scanner. Consenting patients attended the RLUH department of radiology, normally 
as an outpatient. The scan was performed following the RLUH enhanced pancreatic 
protocol. The participant was given one pint of water immediately before the scan to 
distend the stomach and duodenum, they were positioned on the scanning table in 
the supine position with their arms outstretched above their head, with nipples and 
the midline being the centring points. The scan was conducted in two parts, the 
arterial and venous phases, lasting 40 and 25 seconds respectively. In the arterial 
phase, 100 mis of intravenous iodinated contrast medium was injected at a rate of 3 
mis per second, with slices taken at 1mm increments. The venous phase was 
essentially a repeat of the arterial phase but the delay between the administration of 
the contrast and conduction of the scan gave an alternative view of the same 
structures.
The data obtained from the scan were simultaneously transmitted to a Siemens 
Leonardo CT workstation in the adjoining room and to the RAGS system. The 
images were available on the RLUH computer system via RAGS immediately and 
these were supplemented by a report once the responsible radiologist with a 
pancreatic sub-speciality interest had reviewed the scan.
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2.3.3.3 Secondary Imaging Investigations
Technical Aspects of Performing USS at RLUH
Trans-abdominal ultrasound scanning of the pancreas was performed at RLUH using 
a GE Logic 9 scanner with a 4-1 MHz curvilinear transducer. The transducer was 
placed against the abdominal wall of an individual who normally lay in the supine 
position. Aquasonic ultrasound gel was used as an interface to maximise image 
quality. The pancreas was assessed in real time, with images of the pancreas taken 
in the axial and sagittal sections. The machine’s TruScan’ technology enabled 
ultrasound data to be both digitally acquired and stored in its raw data format. This 
enabled the study to be subsequently re-accessed and reviewed, after the patient 
had left the department. A report was dictated after each procedure and saved 
images were uploaded to the PACS system.
Technical Aspects of Performing MR and MRCP at RLUH
Magnetic Resonance Imaging (MRI) scans were obtained at the RLUH using a 
Philips Achieva 1.5 Tesla scanner. Consenting patients attended the RLUH 
department of radiology, normally as an outpatient and drank 150ml of pineapple 
juice 10 minutes before the scan. They were positioned on the scanning table in the 
supine position. Coronal and axial sequences were taken first with a balanced fast 
field echo, before a single shot radial coronal T2 weighted turbo spin echo sequence, 
with fat suppression. The repetition rate of the scan was 8000 milliseconds and the
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time to echo was 800 milliseconds. All scans were performed during a resting 
expiratory breath hold. Images were again uploaded to the PACS system.
2.3.3.4 ERCP and Molecular Analysis of Pancreatic Juice
Technical Aspects of Performing ERCP at RLUH
Endoscopic Retrograde Cholangiopancreatography (ERCP) was conducted at RLUH 
in the gastroenterology suite by either a consultant radiologist or gastroenterologist. 
ERCP and endoluminal ultrasound (EUS) were often performed at the same clinical 
session. Analgesic throat spray was administered prior to intubation with 
supplementary intravenous benzodiazepine sedation and opiate analgesia as 
required. The patient was placed in the right posterior oblique position. The patient 
was intubated with an Olympus TJF-260V scope. A visual inspection of the upper 
gastrointestinal tract was undertaken as the scope was passed through the stomach 
into the duodenum with duodenal juice collected by aspiration and placed in a sterile 
universal receiver which was stored on ice at 4°C. The ampulla of Vater was then 
located and cannulated without administration of contrast. The cannula was 
aspirated with a 10ml syringe and bile and pancreatic juice aspirated. These were 
again placed in sterile universal receivers, labelled and stored on ice, normally by the 
EUROPAC fellow, before being taken to the Division of Surgery and Oncology 
primary lab for processing. Images of the biliary tree could be acquired digitally at the 
request of the gastroenterologist or radiologist during the procedure in the antero­
posterior plane. This was performed using a Philips MultiDiagnost Eleva machine
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which pulsed x-rays at a rate of 3 per second, although the use of contrast was 
minimised to reduce the chance of post-procedure pancreatitis. The consultant 
gastroenterologist or radiologist responsible for conducting the ERCP issued a 
written report using Unisoft software. The participant was then observed in the 
department of endoscopy recovery suite.
Technical Aspects of Molecular Analysis of Pancreatic Juice
These methods are those of the School of Cancer Studies as set out in the Van 
paper220. In practice, the methods described were almost always carried out by Dr 
Van in person, although I performed aspects of these methods, particularly Tp53 
analysis alongside Dr Van during the first year of my research period.
Within two hours of collection at ERCP, the chilled pancreatic juice was transferred 
to sterile 1.5ml Eppendorf tubes and spun at room temperature in a micro centrifuge 
(Spectrafuge, Labnet) at 14000rpm for 5 minutes. The supernatant was aspirated 
and then transferred to a sterile 1.5ml Eppendorf. This was immediately stored at 
-80°C along with the pellets, prior to DNA extraction, with details stored on the 
Division of Surgery & Oncology database.
When samples were selected for testing, they were transferred into a freshly 
autoclaved 1500j.il Eppendorf microcentrifuge tube (Eppendorf) in a laminar flow 
hood. Equal volumes (200jal) of sterile water and Phenol: Chloroform: Isoamyl 
Alcohol (25:24:1) were added to 200pl of pancreatic juice and the mixture was 
vortexed for 30 seconds. The aqueous and organic phases were separated by
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centrifugation at 14000 rpm for 10 minutes. DNA was precipitated overnight at 4°c 
using 2.5 volumes of 100% ethanol and 20jul 3M sodium acetate (pH 6.8). The 
following day, the sample was spun at 17,000rpm (Sorval centrifuge) for 30 minutes 
at 16°C. The DNA was then resuspended by the addition of 200j.il of molecular grade 
water and immediately stored at“20°C.
K-RAS Analysis
Amplification Refractory Mutation System (ARMS) Analysis for K-RAS2 Mutations 
was used. This is a mutation specific PCR assay controlled with amplification of an 
overlapping sequence with mutation independent primers. The principle of the ARMS 
system involved the use of primers specific for the different K-RAS2 mutations at 
codon 12 at their 3’ end. The use of a mutation specific primer and a complementary 
primer to a downstream region of the gene resulted in amplification of a K-RAS2 
sequence.
Real-time PCR was performed using a Roche lightcycler. Initially the system used 
relied on air to transfer heat to samples held in glass capillaries, permitting 30-40 
amplification cycles over 20-30 minutes. Subsequently the Lightcycler 480 system 
was used, a 96 well system with a peltier system to allow even heat exchange 
across the plate. In both systems the reaction mixture contained both FastStart Taq 
DNA polymerase and DNA double-strand specific SYBR Green I dye for detection. 
The FastStart Taq DNA polymerase is a modified form of thermostable recombinant
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Taq DNA polymerase and was inactive at room temperature. The enzyme was 
‘activated’ by high temperature (95°C for 10 minutes).
The function of the SYBR Green I dye was to bind to the groove of the DNA double 
helix in the amplified PCR products. This DNA binding enabled SYBR Green I 
molecules to emit light on excitation. The amplicon was detected by its fluorescence. 
Before amplification, the reaction mixture contained denatured DNA, the primers, 
and the dye. The sample for analysis being made up to 20pl using the LightCycIer- 
DNA Amplification Kit SYBR Green I (Roche) in the following proportions: 12|J PCR 
grade water, 2pl Magnesium Chloride (20mM), 2pl SYBR Green I, 2pl 
oligonucleotide primer and 2pl of DNA (or water for negative controls). Undiluted 
samples were quantified by using 1pl of the DNA with 1|_il of each of the control 
primers (concentration 20pmol/(.il).
The six most common K-RAS2 mutations result in changes from the amino acid 
glycine at codon 12 to another amino acid. These are named in this thesis according 
to the substituted amino acid, for example a change from glycine to aspartate will be 
termed Aspartate. Primers specific for the six recognised point mutations (Aspartate, 
Arginine, Valine, Serine, Alanine and Cysteine) were used. Real time PCR was 
performed after the initial activation step of 10 minutes at 95°c. This was followed by 
60 cycles of: 2 seconds at 95°c, 20 seconds at 61°c, 20 seconds at 72°c and 10 
seconds at 81 °c. This was followed by a melting curve ramp from 72 to 95°c over 10 
minutes.
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Melting curve analysis was performed to verify that the PCR products were pure. 
This was done by increasing the temperature from 72 to 95°C at a rate of 
0.04°C/sec. As the PCR products were heated and reached their respective melting 
temperatures, the two DNA strands dissociated. This could be detected by the rapid 
loss of fluorescence. The melting temperature was determined by the product length 
and its G/C content. As PCR product increased in length and the G/C content rose, 
so did the melting temperature. Analysis of melting curves revealed whether pure 
PCR products were present. This was indicated by a single PCR product with a 
single melting curve having a narrow peak. Primer dimers melted at relatively low 
temperatures and had broader peaks.
Quantification analysis was performed using the lightcycler software (Version 5.32) 
for the presence of a PCR product. The quantification value achieved using the 
control primers were compared graphically with the values for each of the relevant 
mutant-specific primers. The assay had been calibrated on both machines using 
varying concentrations of normal blood DNA with at least 100 pairs of PCR reactions 
for each mutation specific primer. This permitted the production of 98% confidence 
intervals on a linear or polynomial (dependent on the mutation specific primer) 
regression curve. Samples were analysed in triplicate for each K-RAS2 mutation and 
threshold cycles plotted. If all three points were below the 98% confidence limit for 
the wild type only regression, the sample was considered to contain mutant 
sequences; otherwise it was classified as wild type.
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pl6 Analysis
Real time PCR measurement of CDKN2A Promotor Methylation in pancreatic juice 
was performed following modification of the DNA from pancreatic juice with sodium 
bisulfite313. Real-time PCR amplification was carried out in 20 pi volumes with 2 pi of 
Light Cycle DNA Mastermix, with a primer concentration of 1pM. PCR reactions were 
carried out on the lightcycler amplification and detection system (as above for K- 
RAS2 analysis).
The mixture was pre-incubated at 95°c for 10 minutes. DNA was then amplified for 
60 cycles of 20 seconds at 950C, 10 seconds at 67°C for methylated primer or 65°C 
for unmethylated primer and then 10 seconds at 72°C. Data were analysed using 
quantification program software. The result was expressed as a methylation index 
(%) which was calculated using the equation below:
Methylation index = [M/(M+U)] x 100%
where ‘M’ was the quantity of methylated CDKN2A sequences measured by 
methylation specific PCR (MSP) following bisulfite conversion and ‘IT was the 
quantity of unmethylated CDKN2A sequences measured by real-time MSP following 
bisulfite conversion314.
p53 Analysis
The Tp53 assay is a yeast functional assay system based on principles developed 
by Flaman et a/315. The process has been modified to use genomic DNA rather than
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ribonucleic acid (RNA). Exons five to eight containing the mutation hotspots316 were 
selected as they coded for the DNA binding domain of the p53 protein and account 
for the majority of recorded Tp53 mutations identified in cancer.
Genomic DNA was amplified by polymerase chain reaction (PCR); the conditions 
were 95°C for 12 minutes, followed by 40 cycles of 94°C for 30 seconds, 60°C for 30 
seconds and 72°C for one minute. The PCR mixture contained 0.25 units of pfu DNA 
polymerase, 1x pfu buffer (Promega) with 2mM Magnesium Sulphate, 20 pmol of 
each primer and 0.2 mm dntps. Primers were designed to allow PCR linkage of 
exons 5-6 and exons 7-8 and then to link 6 to 7. If possible the overlapping primers 
were used to amplify the exons directly from genomic DNA; otherwise an external 
(intronic) primer was used to give product followed by a second nested PCR.
The reporter yeast strain yig-397 was co-transformed with the PCR product of Tp53 
exons 5 to 8 and a circular expression vector carrying the full length coding 
sequence for p53 (pls76). The vector Tp53 sequences were replaced by PCR 
amplified sequences in vivo by homologous recombination.
Wild type p53 allowed expression of ADE2 and therefore, led to production of white 
yeast colonies. Mutant Tp53 sequences resulted in no expression of ADE2 and so 
red colonies became visible. After 48 hours incubation on selective plates (no 
leucine and low adenine), white and red transformants appeared. The uncut circular 
vector was used rather than gap repair. This had the advantage that although it 
decreased the ratio of red to white colonies, it reduced the number of false positives.
129
Modelling of risk in individuals with a possible genetic predisposition for pancreatic cancer
Previous studies showed that the p53 functional assay of tissue containing wild-type 
Tp53 gave 5-10% red colonies with the gap repair vector method315,317. This was 
due to PCR error or the self-ligation of the vector, combined with the presence of 
alternative splice forms of Tp53 in the source material315, 318. Mutations were 
identified by taking plasmids from three red yeast colonies by alkaline lysis and 
transforming these into E coli DH5a and sequencing the product. If two sequences 
from different yeast colonies carried the same Tp53 mutation, the sample was 
classified as mutant.
2.3.3.S Technical Aspects of Processing of Pathological Specimens
Any detected abnormality was discussed at the MDT and resection would be offered 
if it was deemed to be in the patient’s best interest. At the completion of the 
procedure, the fresh pancreatic tissue was collected from theatre and taken to the 
department of pathology where it was given to one the of the consultant pathologists 
with a special interest in pancreatic work. The specimen was then opened and 
sliced, with fresh tissue samples given to the research fellow for snap freezing in 
liquid nitrogen. The remainder of the specimen was then pinned to a cork board and 
submerged in formalin to fix for 24 hours. It was then floated off the cork board and 
fixed back in the formalin for a further 24 hours, before being dissected and sampled 
by a consultant pathologist, with sampled tissue placed into numbered cassettes. 
These cassettes were then returned to formalin until they went into the overnight 
processor, where the tissue was dehydrated through graded alcohol, put into xylene 
and finally wax. The next morning, the tissue was orientated into wax moulds on top
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of the cassettes, hardened (by chilling the blocks on ice) and then the sections cut 
from these blocks. The cut sections were placed onto glass slides and put through 
an automated staining machine for hematoxylin and eosin staining. Alternatively, the 
unstained slides could go for other special stains or for immunohistochemistry.
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2.3.4 Data Storage and Analysis
Results of screening investigations for participants screened at the Royal Liverpool 
University Hospital were obtained from hospital computer systems and from the 
department of gastroenterology. Where screening was performed by another centre, 
results were obtained by requesting hard copies from the collaborating clinician. This 
system was supplemented by visiting satellite sites as necessary. Data were entered 
and stored on the main Progeny database with the same restrictions and safeguards 
described in section 2.1.3.
2.3.5 Prospective Audit
The results of screening investigations were collected and presented quarterly at 
meetings of the EUROPAC study group. Data were presented graphically wherever 
possible. Continually reviewing the results led to the early identification of trends and 
adverse events that will be described in the results section.
2.3.6 Cost Effectiveness
Calculations regarding costs of the secondary screening study were based upon the 
methods used in the paper published on screening in PJS300. Costs will have 
changed slightly in the past four years but using the same values permits simple 
comparison with that paper. The cost of an BUS was taken as $590, the cost of an 
ERCP was taken as $740, with the cost of a CT scan taken as $268. MR scans are 
slightly more expensive than CT scans but for the intents of the cost analysis in the
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results of this thesis, the cost of all cross sectional imaging investigations was taken 
to be $268 per investigation.
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3 Results
3.1 Primary Screening
This thesis will primarily use data obtained on high risk individuals between 1997 and 
July 2008. I had primary responsibility for entering these data in a period between 
October 2006 and July 2008 with the assistance of Mr Matthew Marcus, who was 
appointed as the EUROPAC database manager in November 2006. Data on HP 
families up to January 2009 will also be included in the thesis as they formed part of 
a publication which I completed after the end of my official tenure as the EUROPAC 
research fellow.
Prior to October 2006, a total of 709 files had been opened either on the basis of 
enquiries or actual families recruited. Files were only opened once written consent 
had been obtained from the proband. During my tenure of 22 months as the 
EUROPAC research fellow, 114 new FPC or HP families were recruited and data 
held on existing families were consolidated. The HP kindreds had been recently 
updated by my predecessor as part of his thesis. Letters and follow up 
questionnaires were sent to all consenting members of the FPC kindreds during my 
tenure. Data obtained from primary screening will be displayed in the following 
sections, starting with the FPC arm of the registry and then the HP kindreds.
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3.1.1 FPC Database Summary (July 2008)
By July 2008 a total of 325 families had been recruited to the FPC arm of the 
registry. These families contained over 8000 individuals and over 700 reported cases 
of pancreatic cancer. Blood DNA samples were held locally for over 500 individuals 
including almost 100 affected individuals. Of the 114 families recruited during my 
tenure, 69 were added to the FPC arm of the registry. As recruitment and the initial 
primary screening process was completed for each kindred, a committee which 
invariably included Dr William Greenhalf and myself, supplemented where possible 
by clinical geneticists, other clinicians and scientists (as given in the 
acknowledgements) classified each family. The classification system for first the FPC 
and then HP arms of the registry will be explained over the following pages.
3.1.1.1 FPC Families Classified by Kindred Type
Families that met the criteria for designation as ‘FPC’ had at least two pancreatic 
cancers in at least two generations. A decision was made as to whether a family was 
consistent with autosomal dominant inheritance. This left some families which were 
categorised as ‘FPC query’ (FPC?) where the precise criteria were not met, e.g. 
either the cancers were not in multiple generations or only one cancer case could be 
confirmed. A number of families had been recruited where at least two pancreatic 
cancers coincided with at least one gastric cancer case. These may, in time, be 
shown to belong to an as yet undefined syndrome, which we have given the working 
definition of ‘With Gastric’, but at present there are too few data for a publication. 
Prior to my participation with the EUROPAC registry, the group had discovered the
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BRCA2 mutation in some families consistent with FPC. During my tenure, I was 
involved in organising BRCA2 testing of further families. BRCA2 testing was only 
performed if patients had given explicit consent for any genetic analysis to be 
reported back to them. Preliminary sequencing for purely research purposes was 
carried out by Drs Earl, Niemczyk, or Yan, but any reported result had to be carried 
out in an accredited clinical genetics laboratory. Where the BRCA2 test showed a 
mutation in one of the pancreatic cancer cases and the criteria for designation as a 
FPC kindred were fully met, the family was given the designation ‘BRCA2 FPC’. 
There were other families, which were not consistent with FPC, but contained single 
cases of pancreatic cancer with one or more cases of breast or ovarian cancer. 
Some of these were tested for BRCA2 mutations either by ourselves or collaborating 
groups. Where BRCA2 mutations were identified, these were classified as BRCA2 
Breast Ovarian (BRCA2 BOvJ. Where no mutation was identified, these families 
were classified simply as Breast Ovarian (BOv). The EUROPAC registry took a 
deliberate policy decision not to recruit families with any cancer syndrome other than 
FPC onto the registry. However, because the process of recruitment was 
progressive, some families were recruited to the study and the nature of the genetic 
risk within the kindred only became clear during the process of primary screening. 
This included a number of Breast Ovarian families that had already been recruited 
before my tenure. The association of pancreatic cancer with multiple cases of 
melanoma has been well described319. Initially I intended to study families that we 
believed carried CDKN2A (p16) mutations but had a phenotype consistent with FPC 
rather than FAMMM. However, early in my research a collaborating group (FaPaCa)
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published a paper94 indicating that CDKN2A (p16) mutations in pancreatic cancer 
families were exclusively seen in families with a predisposition to melanoma. I 
subsequently confirmed this observation in our families, but a number of FAMMM 
families are still held on the registry. The association of HNPCC and pancreatic 
cancer was one of the earliest defined inherited predispositions to pancreatic 
cancer107. EUROPAC has also encountered many HNPCC families during our 
recruitment. These include a number with proven genetic mutations (MLH1, MSH2 or 
MSH6). We have also identified other families with suspected FPC which the 
classification committee decided were suspicious for HNPCC but where genetic 
testing was not possible. These were classified as ‘HNPCC?’. As described in the 
introduction, neurofibromatosis (NF) is not typically associated with cancers of the 
exocrine pancreas. EUROPAC has identified two NF families which have confirmed 
cases of pancreatic cancer and this interesting finding will be further investigated by 
my successors. We have also included a single family with Peutz-Jeghers syndrome 
(PJS) on the registry. PJS is normally associated with single cases of pancreatic 
cancer (because of the very high risk of other forms of cancer in these families). The 
final group is called ‘Other’. This includes the families, which for any reason, do not 
fulfil the criteria for classification into any of the above groups. The full breakdown of 
pancreatic cancer families is shown overleaf in table 3.
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Table 3: Breakdown of EUROPAC FPC families by type, August 2008
Table showing the exact numbers of each type of family that had been added to the FPC arm 
of the EUROPAC database by July 2008. ‘FPC’ is the group of families that fully meet the 
criteria for autosomal dominance (multiple cases in multiple generations), ‘FPC?’ is where 
there are multiple cases but the specific criteria for autosomal dominance are not met. ‘With 
Gastric’ is where there at least two cases of pancreatic and at least one case of gastric cancer 
in a family in the absence of another causative syndrome. ‘BRCA2 FPC’ is FPC with a BRCA2 
mutation. tBRCA2 BOv’ is Breast Ovarian cancer syndrome with a BRCA2 mutation and at 
least one case of pancreatic cancer. ‘BOv’ is Breast Ovarian cancer syndrome with a 
pancreatic cancer. Affected individuals may or may not carry BRCA1 mutations but do not 
carry a BRCA2 mutation. ‘FAMMM’ is at least one case of pancreatic cancer in the presence of 
either multiple cases of malignant melanoma or proven CDKN2A (p16) mutations. ‘HNPCC’ 
includes families with a phenotype consistent with the diagnosis with one of the established 
HNPCC genetic mutations {MLH1, MSH2 or MSH6). ‘HNPCC?’ is families where there is a 
suspicion of HNPCC based on a phenotype of multiple cases of colorectal cancer, but the 
testable genetic mutations could either not be proven or are not present. The two ‘NF’ families 
are proven neurofibromatosis with at least two cases of pancreatic cancer and there is a single 
confirmed Peutz-Jeghers family. There are 45 other additional registered families. These 
include the full range of families that for one reason or another were recruited but were never 
classified as belonging to one of the other groups. Total numbers registered by July 2008 are 
given along with the number (in parenthesis) recruited during my period of research.
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Table 3: Breakdown of EUROPAC FPC families by type, August 2008
Family diagnosis Families Percentage (%)
FPC 153 (35) 47 (51)
FPC? 70 (15) 21 :2)
‘With Gastric’ 13(1) 4(1)
BRCA2FPC 5(1) 2 1)
BRCA2 BOv 3(1) 1(1)
BOv 21 (4) 6(6)
FAMMM 3(0) 1 (0)
HNPCC 3(1) 1 (1)
HNPCC? 6(3) 2(4)
NF 2(0) 1 (0)
Peutz-Jeghers 1 (0) 0(0)
Other 45 (8) 14 (13)
Total 325 9) 100
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3.1.1.2 FPC Families Classified by Number of Cancer Cases
One of the most important ways of classifying FPC kindreds is by the number of 
cancer cases they contain. The number of cancers in EUROPAC FPC kindreds is 
displayed in figure 5. Clearly this is a dynamic measure. The FPC families were 
followed up and prospective cancers added to the database during Spring 2008, but 
the results will have changed again since August 2008 as further prospective cancer 
cases have occurred and more information on previously unidentified cancer cases 
within families has become available. The data shown were correct at the end of July 
2008.
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Figure 5: The Number of Pancreatic Cancers in EUROPAC’s FPC, ?FPC, With 
Gastric & BRCA2 FPC Families (July 2008)
■ Two
■ > Five 
=3
Figure showing a breakdown of the total number of FPC, ?FPC, ‘With Gastric’ and BRCA2 FPC 
kindreds that contain the number of pancreatic cancers shown in the legend. There are 162 
families with 2 cancer cases(67%), 60 (25%) with 3 cancers, 11 with 4 (5%), 5 with 5 cases (2%) 
and single families with 6, 8 and 10 cancer cases.
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3.1.1.3 FPC Families Classified by Nationality
As EUROPAC has developed an increasingly international and collaborative 
approach to research, the numbers of families recruited outside the UK has 
increased. Whilst most of the recruited FPC families still originate from the UK, there 
are now significant numbers of families that have been recruited by collaborating 
clinicians, particularly the Clichy and FaPaCa groups in France and Germany. 
Others have been recruited on a piecemeal basis through individual collaborators 
primarily within Europe, but also further afield. As previously stated US families are 
redirected to the US registries. A breakdown of the FPC database by nation of origin 
is shown below. Families recruited from overseas tend to contain higher numbers of 
cancers. This is probably due to recruitment bias, with only the most severely 
affected families being referred and consenting to join an overseas registry. All the 
families with more than five pancreatic cancers were recruited by non-UK 
collaborators.
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Figure 6: A Breakdown of EUROPAC FPC, ?FPC, ‘With Gastric’ & BRCA2 FPC 
Families by Nationality, July 2008
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Figure showing the country of origin of families registered with EUROPAC and meeting the 
criteria for designation as a FPC, ?FPC, With Gastric or BRCA2 FPC kindred in July 2008. The 
vast majority obviously come from the UK. The French and German families were contributed 
by the Clichy and FaPaCa groups respectively, with the remainder coming in small numbers 
from other international, predominantly European, collaborators.
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3.1.2 HP Database Summary (July 2008)
By July 2008 over 450 families had been recruited to the pancreatitis arm of the 
EUROPAC database. These families included almost 7000 individuals of which over 
1100 either reported, or were reported to have had symptoms of pancreatitis; there 
were 76 confirmed cases of pancreatic cancer. Participants were consented for 
genetic testing and DNA was sent to the Mersey Regional Genetics Service at the 
Liverpool Women’s Hospital. Testing was specifically aimed at identification of the 
p.R122H, p.N29l and p.A16V mutations of the PRSS1 gene and so sequencing was 
initially limited to exons one, two and three of that gene. If none of these mutations 
were identified, the remainder of the gene was then sequenced.
3.1.2.1 HP Families Classified by Mutation and Kindred Type
Table four (see below) summarises the families registered in July 2008 that were 
consistent with an autosomal dominant inheritance of a predisposition to pancreatitis 
(at least two cases in at least two generations) as well as families with a defined 
mutation even where autosomal dominance had yet to be proven. Classification was 
normally by mutation. Where no PRSS1 mutation was identified, but families had a 
phenotype consistent with HP, they were classified as ‘Neg All HP’. There are some 
families with proven PRSS1 mutations (or polymorphisms) other than p.R122H, 
p.N29l or p.A16V, which are too rare to have been clinically characterised; these fall 
within the group 'Other Mutations’. Finally there are some families included in this 
table, where genetic testing was not performed during my period of research. Seven
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of these were families in whom testing should be possible in future (HP families) and 
two were families where the proband has refused genetic testing but was willing for 
the family to remain on the registry (HP problem).
Table 4: A Summary of Primary Screening Data for HP families (July 2008)
Table showing types of true HP families broken down by number of total individuals (1st, 2nd or 
3rd degree relatives of the index case); individuals affected by pancreatitis; and individuals 
affected by pancreatic cancer. Groups are determined by PRSS1 mutation, with p.A16V 
kindreds listed in this table irrespective of phenotype. The ‘Neg All HP’ group includes families 
where the phenotype is consistent with HP but a mutation has not been identified despite 
sequencing of PRSS1. The group ‘Other mutations’ includes very rare PRSS1 mutations or 
polymorphisms, which are too rare to have been clinically characterised. ‘HP families’ are 
kindreds where the phenotype is consistent with HP and genetic testing should be possible 
but has yet to be initiated or is in process. ‘HP problem’ is where the proband wishes to be on 
the registry, but has declined genetic testing. Numbers in black are the totals in July 2008, 
numbers in parentheses are those recruited during my time as the EUROPAC research fellow.
Group Families Total
individuals
Affected
individuals
Cancer
Cases
P.R122H 98 (i 2447(12! 449 (10 25 (0)
p.N29l 41 (1) 1159(16) 177(1) 11 (1)
p.A16V 10(5) 272 (76) 24(10) 3(2)
Neg All HP 41 (5) 787 (94) 145 (23) 14 (2)
Other mutations 13(0) 94 (0) 22 (0) 1 (0)
HP families 7(2) 169 (49) 18(6) 0 (0)
HP problem 2(0) 14(0) 12(0) 1 (0)
HP TOTAL 212 4942 847 55
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3.1.2.2 HP Families Classified by Nationality
EUROPAC was intended to be a collaborative venture from the start, but in practice 
was initially dominated by UK families recruited by UK collaborators. This situation 
changed during my tenure, initially as the result of the collaboration with the group 
from Nijmegen, Holland and later, the decision to collaborate with the registry at 
Clichy, France. The collaboration with the French also led to a further family being 
recruited to the study to improve characterisation of the p.A16V mutation.
The HP side of the registry remains UK dominated but figure 7 shows a much more 
equal balance of countries of origin of ‘true HP’ families than is the case in the ‘true 
FPC’ kindreds. The main area of recruitment from outside the UK is France, then 
Germany, with a total of 55 kindreds recruited by other collaborators from other 
countries. There are two families from outside Europe. One was recruited by a 
collaborator in New Zealand, where there is no national registry, with data for the 
second family having been provided by Professor David Whitcomb of Pittsburgh, 
USA as part of the p.A16V study. As with FPC, US families are routinely redirected 
to the US registries.
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Figure 7: A Breakdown of EUROPAC HP families by Nationality, July 2008
SS UK n=79
II France n=53
Germany n=25
Other
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Non
European
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n=2
Figure showing the country of origin of families registered with EUROPAC and meeting the 
criteria for designation as a HP kindred by the end of July 2008. All p.A16V kindreds have been 
designated as HP kindreds irrespective of phenotype. The greatest number of families 
obviously comes from the UK, with significant contributions from both the French and German 
groups based at Clichy and Greifswald respectively. The remainder have been recruited via 
other international, predominantly European collaborators, with one family from New Zealand 
and a p.A16V family from the USA, recruited specifically for the p.A16V study.
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3.1.2.3 Clinical Characteristics of HP
The most obvious parameters to include in quantifying risk of cancer in HP are the 
clinical features of the pancreatitis and the genotype. These obviously may overlap 
as the mutation could impact directly on the severity of the pancreatitis and thus 
(presumably) on cancer risk. Analysis of the clinical phenotype produced by the 
different PRSS1 mutations is therefore fundamental to this thesis. Potential areas of 
study include the age of onset of pancreatitis and the development of endocrine and 
pancreatic failure. Figures for these are shown over the following pages. The 
existence of pancreatic failure is a factor that must be taken into account when 
deciding to screen an individual and will influence the balance of risk and benefit to 
the patient when performing a resection for suspected malignancy. Penetrance and 
cancer risk are also obviously relevant. It is an attractive theory that the risk of 
pancreatic cancer in HP is directly related to the age of onset of pancreatitis. Prior to 
this thesis, this had never been properly examined and the results are shown at the 
end of this section as figure 13. To avoid repetition a survival curve comparing risk in 
HP kindreds to the general population has not been included in this section, but is 
included below at the start of the section on risk stratification in HP as figure 22.
It should be noted that the data used in the rest of this section were prepared using 
the data guillotine used for the p.A16V study (January 2009) so these differ slightly 
from the July 2008 figures used in table 4.
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Age of Onset of Pancreatitis
Much of the data in this section relate to the analysis performed investigating 
possible differences between the phenotype produced by the p.A16V mutation of 
PRSS1 as compared to the more common mutations. A visual comparison of 
pedigrees indicates that there are differences between the phenotype of p.A16V and 
the phenotype associated with other PRSS1 mutations, but the low prevalence of the 
p.A16V mutation and the even smaller numbers of affected individuals with 
pancreatitis, diabetes mellitus, malabsorption or pancreatic cancer mean that there is 
insufficient power for a definitive statistical analysis.
The data for onset of pancreatitis, diabetes and malabsorption for all mutation 
groups are shown in three separate figures over the next three pages. These data 
were all correct as of January 2009, when the final analysis for the p.A16V study was 
performed.
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Figure 8: Age of Onset of Pancreatitis in EUROPAC HP Kindreds (Jan 2009)
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Figure showing the cumulative incidence of pancreatitis in the different mutation groups 
p.R122H, p.N29l, p.A16V, and Neg All HP, where the phenotype is consistent with HP but no 
mutation has been identified after PRSS1 gene sequencing. This figure was prepared to see if 
there was any statistical difference between onset of pancreatitis in p.A16V kindreds 
compared to the other mutation groups, but the low numbers of affected individuals in the 
p.A16V group mean that there is insufficient power for a definitive statistical analysis.
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Age of Onset of Diabetes
Figure 9: Age of Onset of Diabetes in EUROPAC HP Kindreds (Jan 2009)
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Figure showing the number of affected individuals from HP kindreds that have endocrine 
pancreatic failure. This is diagnosed by raised fasting glucose or the requirement for regular 
prescription of either oral anti-hyperglycaemics or injected porcine insulin. Of the numbers 
shown, 120 affected individuals have both endocrine and exocrine pancreatic failure. 
Diagnosis of exocrine failure is on the basis of either a faecal elastase result below the normal 
range or the requirement for regular prescription of supplementary pancreatic enzymes.
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Age of Onset of Malabsorption
Figure 10: Age of Onset of Malabsorption in EUROPAC HP Kindreds (Jan 2009)
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Figure showing the number of affected individuals from HP kindreds that have exocrine 
pancreatic failure. A diagnosis of exocrine failure is accepted on the basis of either a faecal 
elastase result below the normal range or the requirement for regular prescription of 
supplementary pancreatic enzymes. Of the numbers shown, 120 affected individuals have both 
endocrine and exocrine pancreatic failure. Diagnosis of endocrine failure is by raised fasting 
serum glucose or the requirement for regular prescription of either oral anti-hyperglycaemics 
or injected porcine insulin.
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For all end points ‘Neg All HP’ is significantly different from the two groups with 
known HP mutations (p.R122H and p.N29l). These differences have already been 
described and discussed elsewhere in previous publications92,93. There are too few 
data to prove differences between p.A16V and the other groups, but the survival 
curves illustrate possible trends. To simplify analysis and increase power, the two 
mutation groups (p.R122H and p.N29l) were combined and will be described as the 
‘mutation group’ in contrast to the ‘Neg All HP’ group.
The age of diagnosis of diabetes appears similar in p.A16V and the ‘Neg All HP’ 
group (Logrank P value for p.A16V compared to the combined mutation group was 
0.076, with a P value for p.A16V compared to the ‘Neg All HP’ group of 0.83). In 
contrast, when looking at age of diagnosis of exocrine pancreatic failure, the p.A16V 
group is more like the mutation group than the ‘Neg All HP group’ (Logrank P value 
for p.A16V compared to the ‘Neg All HP’ group is 0.087 with a P value for p.A16V 
compared to the combined mutation group of 0.88). There is the suggestion that the 
age of onset of pancreatitis in p.A16V appears later than with the mutation group and 
is more like the ‘Neg All HP’ group than either p.R122H or p.N29l (Logrank P value
for p.A16V compared to the combined mutation group is 0.080, X2i = 3.06, 
contrasting with a P value for p.A16V compared to the ‘Neg All HP’ group of 0.18).
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Penetrance of the PRSS1 Mutations
Estimates of penetrance so far have focussed on kindreds where the responsible 
PRSS1 mutation is generally one of high penetrance. Families have samples taken 
from as many individuals as possible within the kindreds, with the total of affected 
individuals expressed as a percentage of the total number of mutation carriers 
identified. As the penetrance of a mutation reduces, an exact calculation of 
penetrance becomes more difficult as individuals that are not affected are often 
reluctant to agree to genetic testing. As part of the p,A16V study and this thesis an 
alternative mathematical approach was developed. The index case in each family 
was identified. The proportion of this index case’s first degree relatives affected by 
pancreatitis was calculated by dividing the number of first degree relatives affected 
by pancreatitis by the total number of first degree relatives. Assuming an autosomal 
dominant pattern of inheritance, each first degree relative of an affected individual 
has a 50% chance of being a mutation carrier, so the derived figure was doubled to 
give an estimate of penetrance. This was performed blind to any mutation analysis 
using all families on the EUROPAC registry with the results shown in Table 5. Not all 
the families used in this analysis had a phenotype consistent with autosomal 
dominant inheritance. Where all the pancreatitis cases in the family were within a 
single generation (suggesting a multigene or environmental cause), these families 
were termed Single Generation (FIP). All p,A16V families were grouped together 
irrespective of phenotype.
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Table 5: Estimate of Penetrance in Pancreatitis Families
A summary of the total number of first degree relatives of the index case in each mutation or 
phenotype group and the number that are affected by pancreatitis. Assuming that 50% of all 
first degree relatives are mutation carriers, the result can be doubled to give an estimate of 
penetrance in each group. Families are grouped by PRSS1 mutation. There are some families 
(Neg All HP) with a phenotype consistent with HP but no identifiable PRSS1 mutation despite 
sequencing of the gene. The group ‘Single Generation (FIP)’ contains families where all the 
pancreatitis cases occur within a single generation. All p.A16V families were grouped together 
irrespective of phenotype, the breakdown of this group being shown in table 11 of this thesis.
Mutation First degree 
relatives of the
index case
First degree 
relatives affected 
by pancreatitis
Estimated
Penetrance 
(if 50% of first degree 
relatives are carriers)
P.R122H 448 157 (35.0%) 70%
p.N29l 189 57 (30.2%) 60.4%
Neg All HP 210 66 (31.4%) 62.8%
Single Generation (FIP), 
excluding p.A16V
218 43(19.7%) 39.4%
p.A16V 
(All groups)
62 14(21.9%) 43.8%
This analysis is subject to ascertainment bias. Families with greater numbers of 
cases are more likely to be recruited. Furthermore, in families with variable 
penetrance, an index case is more likely to be in a section of the family with the 
greatest number of affected individuals. On the other hand, this approach also 
means that one affected carrier is always omitted from the calculation (the index 
case). In Figure 11 (see below), the penetrance for individual families is represented 
in a box plot. Kruskal-Wallis testing of the medians showed a significant difference 
across the five groups with a P value of 0.02, although p.A16V was not significantly
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different from any of the other 4 groups if tested with the Mann Whitney U-Test 
{P=0.06 to 0.8, going from right to left in Figure 11).
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Figure 11: An Estimate of Penetrance in Different Mutation Groups
Neg AllA16V R122H
HP families
PRSS1 Mutation Groups
Penetrance for individual families is estimated by doubling the proportion of affected first 
degree relatives of index cases. This assumes that 50% of first degree relatives of the index 
case are mutation carriers. Results of actual mutation analysis and knowledge of off kindred 
relationships were ignored in this calculation. The box plot shows the inter-quartile range 
(box) and the range (whiskers). The indented region indicates the 95% confidence interval for 
the median (marked with a horizontal line). Kruskal-Wallis testing of the medians showed a 
significant difference across the five groups with a P value of 0.02. The medians in this figure 
differ from the mean (across all individuals for each group) displayed in table 5 because the 
data are skewed. The FIP group has some families that will have no first degree relatives with 
pancreatitis, once the proband has been discounted (i.e. the penetrance will be zero).
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3.1.2.4 Non-Hereditary Pancreatitis Families
In 241 families shown in table 6, the EUROPAC classification committee decided 
that there was no convincing evidence of autosomal dominant inheritance of a 
predisposition to pancreatitis. The majority were simple sporadic cases of idiopathic 
disease but in other families, although there were multiple cases of pancreatitis, 
these were restricted to a single generation. EUROPAC has termed such families 
‘Familial Idiopathic Pancreatitis’ (FIP). In nine kindreds, cases of apparent sporadic 
pancreatitis or FIP were associated with at least one case of pancreatic cancer. A 
separate classification group was established during my tenure for this, termed 
‘Idiopathic Pancreatitis with Cancer’ (IPCA).
Prior to my time in post, EUROPAC had specifically aimed to only recruit HP 
kindreds, whether this was based on genotype or phenotype analysis. Any non-HP 
kindreds recruited prior to my tenure had been recruited unintentionally, as 
recruitment took place prior to the primary screening process or genetic testing. On 
classification, there was insufficient evidence to classify the families as true HP 
kindreds, but the data were retained. During my tenure, there was a deliberate 
change in recruitment strategy, where single cases of pancreatitis were recruited if 
there was evidence of a pancreatitis associated genetic mutation. These mutations 
might be in the CFTR gene, (these families were classified as CFPANC) or towards 
the end of my time in post, affected individuals with mutations of the SPINK1 gene 
were also recruited. I also registered individuals affected by pancreatitis, where there 
was a related case of pancreatic cancer as described above. Changing EUROPAC’s
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recruitment policy has obvious implications for introducing or at least exacerbating 
ascertainment bias in the recruitment process, but should, in time, permit research in 
kindreds with CFTR and SPINK1 gene mutations and permit further characterisation 
of their clinical phenotype, using the same methods used in the figures shown in the 
previous section.
Table 6: A Summary of Primary Screening Data for Families or Individuals with 
Idiopathic or Sporadic Pancreatitis (July 2008)
Table showing a breakdown of the number of each type of family with pancreatitis not 
consistent with HP. Data have been broken down by number of total individuals within the 
kindreds, individuals affected by pancreatitis and individuals affected by pancreatic cancer. 
Numbers in black are the totals in July 2008, numbers in red (in parentheses) are those 
recruited during my period as the EUROPAC research fellow. The kindred types include: 
Familial Idiopathic Pancreatitis (FIP), where there are multiple cases of pancreatitis within a 
single generation; Sporadic, which contains single affected individuals, including the small 
number of affected individuals with a proven SPINK1 mutation recruited in the last months of 
my research period; IPCA, where there was one case of pancreatitis and one of pancreatic 
cancer; and CFPANC where there was a case of pancreatitis with a proven CFTR mutation.
Group Families
Total
individuals
Affected
individuals
Cancer
Cases
FIP 44 (11) 941 (100) 95 (21) 6 3)
Sporadic 172 (11) 743 (125) 172 (11) 0
IPCA 9(3) 155 (50) 9(3) 15
CFPANC 16(3) 172 (42) 18 (3) 0
Idiopathic Totals 241 2011 nr} 294 21
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Onset of Pancreatitis and Cancer Risk
As stated above, age of onset of pancreatitis in affected individuals is interesting in 
its own right and it is logical to theorise that the number of years an individual has 
been exposed to chronic pancreatic inflammation could be related to their cancer 
risk. Figure 12 shows that there is a poor correlation between age of onset of 
pancreatitis and cancer in EUROPAC HP kindreds.
Figure 12: Onset of pancreatitis and cancer in EUROPAC HP kindreds
■ Cancer v Pancreatitis 
— Linear (Cancer v Pancreatitis)
R2 = 0.1092
o 30
Age of onset of pancreatitis
Figure illustrates the minimal relationship between age of onset of pancreatitis and age of 
onset of pancreatic cancer. The relationship was assessed using R2 testing, which showed the 
proportion of the variability in this dataset that is accounted for by linear regression to be less 
than 11%.
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3.2 Risk Stratification
As stated in section 1.8, improving risk stratification was the first aim of this thesis. 
Figure 12 shows that contrary to expectation, age of onset of pancreatitis correlates 
poorly with cancer risk. In contrast, other factors were identified that did impact on 
cancer risk and these factors have been used to develop a preliminary system of risk 
stratification, for both FPC and FIR kindreds. These will be introduced in this section 
along with a description of a novel mathematical model to stratify risk in FPC 
kindreds, which permitted this to be performed on an individual, rather than familial 
basis, for the first time.
3.2.1 Risk Stratification in FPC Kindreds
Before the progress made in risk stratification in FPC kindreds is shown, it is 
important to see what the risk of pancreatic cancer is in these kindreds.
3.2.1.1 What is the Pancreatic Cancer Risk in FPC?
The risk from pancreatic cancer in FPC kindreds has been incompletely 
characterised, prompting the work set out in the remainder of section 3.2.1. As 
stated previously, the best available published work at the start of this thesis was 
that of Klein et al185, where the relative risk of cancer within kindreds was expressed 
depending on the number of cancer cases they contained. The risk in EUROPAC’s 
FPC kindreds has only recently been published96, with their pancreatic cancer risk
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compared against that of the general population of the United States using the SEER 
data.
The SEER data are cross-sectional, while familial data, such as that held by familial 
pancreatic cancer registries are, by definition, longitudinal. To compare the two sets 
of data it is either necessary to model longitudinal data using the SEER figures or to 
take a date for a cross-sectional study of the registry data.
This work suggested a constant increased risk for all age groups, which 
approximates to a 120 fold increase in risk. Even with this 120-fold increase, risk 
below the age of 40 is negligible, which supports that being the age of entry to the 
secondary screening study.
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Figure 13: Age Specific Risk of Pancreatic Cancer in Families with FPC
At risk 
(Europac) 2011 1772 1311 689 133
Cumulative events 
(Europac) 0 14 158 359
Figure 13a: The Surveillance Epidemiology and End Results (SEER) survey in the USA has 
provided cross sectional data on cancer risk in five year ranges. This can be used to model 
longitudinal cumulative survival, allowing comparison with a Kaplan-Meier survival curve. 
Approximately 50% of the FPC family members are predicted to be mutation carriers, meaning 
baseline survival from pancreatic cancer of all potential carriers should be approximately 50%.
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Figure 13b: Probability of Developing Common Cancers in the US General 
Population Compared to the Pancreatic Cancer Risk in EUROPAC FPC Kindreds
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Figure 13b shows the approximate pancreatic cancer risk in EUROPAC FPC kindreds (derived 
by increasing the SEER pancreatic cancer risk 120-fold) compared with the risk of pancreatic 
and other common cancers in the US general population, which were all derived from the 
SEER data.
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3.2.2 Methods of Risk Stratification in FPC
As described previously in this thesis, there are traditional methods of risk 
stratification in FPC, which analyse that data gleaned from traditional primary 
screening. There are also novel methodologies. The following section will show what 
can be gleaned from analysis of primary screening data before the novel methods 
are examined.
3.2.2.1 Analysis of Primary Screening Data
Demographics
Further analysis of the Surveillance Epidemiology and End Results (SEER) data120 
gives an insight into how risk compares between the genders showing a slightly 
greater incidence of pancreatic cancer in men than women. A comparison has been 
carried out in Figure 14a with data from the EUROPAC registry, taking individuals 
alive in the year 2000 and using a five year window for occurrence of pancreatic 
cancer. The SEER data clearly show a higher incidence of pancreatic cancer in men 
in all age groups. The EUROPAC data are far less clear cut, although this could be 
due to the small numbers of at risk individuals in each age group. Overall, in the 
EUROPAC families, death from pancreatic cancer does occur slightly earlier in 
males, (see Figure 14b) but the final lifetime risk for men and women is roughly 
equivalent in this population (approximately 50%), which is, again, consistent with 
autosomal dominant inheritance of a predisposition to pancreatic cancer and is in 
stark contrast to the situation in sporadic disease.
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Figure 14: Gender and Risk of Pancreatic Cancer in FPC Families and Sporadic 
Disease
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In Figure 14a the incidence of pancreatic cancer for each gender is plotted for 5 year age 
groups using the SEER data. More men develop pancreatic cancer than women in each age 
group. This is compared to data from the EUROPAC database using a separate scale, taking 
the age of individuals alive in 2000 and following for pancreatic cancer until 2005. The number 
of individuals taken for the analysis are given below the graph (E=EUROPAC). There is a trend 
for a higher percentage of men to develop pancreatic cancer in the earlier age groups, but the 
small number in each group makes comparisons difficult.
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Figure 14b: Survival of Males and Females in EUROPAC FPC Kindreds
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Figure 14b shows a survival curve for both males and females from EUROPAC FPC kindreds. 
Women develop pancreatic cancer later than men, but overall lifetime risk is equivalent.
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Lifestyle Risk Factors: Smoking
The risk factor where there is the clearest link to sporadic pancreatic cancer is 
tobacco smoking125. Figures vary between the studies but the risk of pancreatic 
cancer has been calculated to be two-fold higher in smokers126, with some evidence 
of a dose-response relationship127. This raises the question as to the significance of 
the relationship between smoking and the cancer deaths in FPC kindreds. Taking 
the end of July 2008 as a guillotine date (the data displayed in table 3), EUROPAC 
held smoking data on several hundred individuals. A Kaplan-Meier analysis was 
performed, with the numbers ‘at risk’ displayed beneath, which is shown on the 
following page. The results show that present smokers had the worst survival, 
followed by ‘never smokers’, with ‘ex-smokers’ having the best survival. The reason 
for this is likely to be reporting bias. Many of the data collected by EUROPAC are 
collected retrospectively. Family members will remember if a relative was a smoker 
or non-smoker at the time of their diagnosis or death, but relatives are unlikely to be 
able to give accurate data on whether an individual smoked at some point in the 
past, so an unknown proportion of the deceased reported ‘never smokers’ will have 
been ‘ex-smokers’. Although it is difficult to quantify the degree of bias involved, 
clearly it will be in the direction of fewer ‘ex-smokers’ being reported within those 
affected by pancreatic cancer (because these individuals will almost invariably be 
dead).
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Figure 15: Pancreatic Cancer and Smoking in EUROPAC FPC Kindreds
— Present Smoker
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1420
56
52
73
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25
26 
28
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8
5
260
Figure to show the relationship between smoking and death from pancreatic cancer in 
EUROPAC FPC kindreds. The data show that ‘never-smokers’ have poorer survival than ‘ex- 
smokers’, which is likely to be the result of data bias.
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3.2.2.2 Mathematical Modelling
Despite the information that can be gleaned from the statistical analysis of the 
primary screening data shown in the preceding section, none of the data were 
directly relevant to determining risk on an individual, rather than on a familial, basis. 
As part of this thesis, it was decided to use the data held on the EUROPAC FPC 
database to produce a mathematical model capable of predicting individual cancer 
risk within a set time period. This model would have potential utility as an accurate 
method of risk stratification, in counselling high risk individuals and (after completion 
of prospective testing and validation) for assisting in recruitment to the screening 
study.
A collaborative venture was initiated with individuals from the Department of Medical 
Physics and Clinical Engineering at the Royal Liverpool and Broadgreen University 
Hospital which used the methods set out in section 2.2.2.2. For the model to be 
mathematically proven it had to be able to withstand tests of both discrimination and 
calibration. As stated in section 22.2.2, ‘discrimination’ is the ability of the model to 
separate the subjects into two groups, (those that developed cancer and those that 
did not) and was tested using Harrell’s C-Index which is an extension of the Area 
Under the Receiver Operating Characteristic (AUROC) Curve. ‘Discrimination’ is the 
primary test and values >0.7 are acceptable, ideally being as close to 1 as 
possible310'311.
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The second method used to test the model was ‘calibration’. This is the degree of 
correspondence between the probability of an event being predicted by the model 
and the probability of that event having actually occurred. It is tested using Hosmer- 
Lemeshow analysis with the results quantified as a chi-square (x2). Calibration is 
acceptable if the p value is >0.05 and it should ideally be as close to 1 as possible312, 
320. The model was shown to have satisfactory discrimination and calibration for 
individuals aged from 45-69 years. Discrimination was lost (i.e. was <0.7) outside of 
this age range due to the low number of pancreatic cancers in those age groups. A 
sample of model output from the WinBUGS software is shown in figure 16 for 
individuals aged 45-49 years, with all discrimination and calibration outputs 
summarised in the subsequent table, table 7.
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Figure 16: Model Output for the Age Range 45-49 Years
Figure showing the model output for high risk individuals from FPC kindreds aged 45-49 
years. Discrimination is shown to be 0.77, with the x2 value used to measure model calibration 
being 0.38, with a p value of 0.984. Discrimination is the primary test and values >0.7 are 
acceptable, ideally being as close to 1 as possible. Calibration is acceptable if the p value is 
£0.05 and should ideally be as close to 1 as possible.
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Table 7: Summary of Discrimination and Calibration of the Mathematical Model
Table summarising the values determined for discrimination and calibration for each group 
assessed. Discrimination is the primary test and values >0.7 are acceptable, ideally being as 
close to 1 as possible. Calibration is acceptable if the p value is >0.05 and should ideally be as 
close to 1 as possible. Discriminatory power was lost in the young and old due to the low 
number of cancers in these groups. Calibration was adequate until the age of 79 years, but in 
the absence of acceptable discrimination, the model is only valid for those aged 45-69 years.
Age in 
Years
Total Cancer
Cases
Discrimination
(Standard Deviation)
Calibration
X2 P value
40-44 21 0.66 (0.120) 0.02 1.0
45-49 33 0.77 (0.061) 0.38 0.984
50-54 56 0.75 (0.041) 0.05 1.0
55-59 77 0.72 (0.036) 0.83 0.935
60-64 120 0.72 (0.035) 1.72 0.787
65-69 88 0.72 (0.033) 5.78 0.216
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The Online Interface
The computer interface that was developed permitted both data entry and the 
production of a survival curve online by registered users. The inputted data 
permitted a decision on which side of the family carried the presumed FPC gene and 
data were gathered as fully but efficiently from that side of the family as possible. At 
the end of the online data collection process, entered data were used to produce a 
summary sentence. If this summary sentence was accepted as correct, a survival 
curve was produced using these data which were then stored on the secure server 
as an excel spreadsheet. During the testing phase, it took approximately ten minutes 
to enter the data for a family and produce a survival curve, although a new user 
would likely require slightly longer than this until they were familiar with the system. 
An example screen from the interface is shown on the following page as figure 17.
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Figure 17: Sample Screen from the Online Interface
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An example of the online interface. Data entry is organised using either a drop-down or radio 
button format to make it as user friendly as possible and to ensure that inputted data are in a 
format that can be used as inputs to the mathematical model.
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Pseudo-prospective Testing
The pseudo-prospective testing described in the Materials and Methods investigated 
whether there was a potential clinical application. The data for 138 individuals were 
entered, of which 27 subsequently developed pancreatic cancer. The model was 
able to discriminate between the cancer and the non-cancer cases (C-Index 0.77). 
Using cut-offs determined by ROC analysis, (a cancer risk in the next five year 
period of >2.84% combined with a Family Index of 0.3), the model indicated that 
115/138 should be screened. All 27 cancer cases fell within the screened group with 
none missed. Put another way, if the model had been used in this group to decide 
whether to screen them or not, it would have spared one in six individuals the risks of 
screening for no disadvantage. The results of the calculations performed in Medcalc 
are shown in Table 8. Fisher’s Exact test gave a P value of 0.0075, but as the aim 
was to further sub-stratify risk on an individual level, the numbers that would not 
have to undergo screening are more significant than the statistical result.
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Table 8: MedCalc Output Showing Results of Pseudo-prospective Testing
The results of the pseudo-prospective testing. Pedigrees were backdated in 2007 to the year 
2000 to see if the model could differentiate between individuals that developed pancreatic 
cancer and those that did not (between 2000 and 2007). Once the data had been inputted for 
138 high risk individuals, cut off points of cancer risk over the next five years of >2.84%, 
combined with a Family Index of 0.3 were adopted to determine who should be screened. The 
model indicated that screening should be initiated in 88 out of 111 of the ultimately unaffected 
(no cancer) individuals and in all 27 of the ultimately affected (cancer) individuals. The figures 
in parentheses are the expected values if the same proportion of individuals had been 
screened at random, which would have resulted in approximately 5 missed cancers.
Not Screened Screened Totals
No Cancer 23(18.5) 88 (92.5) 111
Cancer 0 (4.5) 27 (22.5) 27
23 115 138
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3.2.2.3 Serum Glucose
As described in the Introduction diabetes mellitus and failure of glucose regulation in 
general are closely related to development of pancreatic cancer and possibly risk of 
pancreatic cancer. In this thesis I will outline the first set of data relating to glucose 
level measurements as part of a screening program. I will also describe further 
confirmatory work on glucose levels in newly diagnosed pancreatic cancer patients. 
The serum fasting glucose data gathered from high risk individuals were from 
members of both FPC and HP kindreds. Some of these were participants in the 
secondary screening study, others replied to a written approach. I also collected 
random glucose data for 282 individuals that had had resections at the RLUH for 
sporadic peri-pancreatic cancer. It is obviously difficult to compare random glucose 
samples from one cohort with fasting samples from another. An exact relationship 
between random and fasting glucose has not been proven, although for the purpose 
of diagnosis of diabetes, fasting values of >7 mmol/L and random (or post-prandial) 
values of >11.1 mmol/L were laid down by the World Health Organisation (WHO) in 
1999321.
The glucose data from EUROPAC’s screening studies require further maturation 
before they can be properly analysed. In the absence of detected abnormalities 
leading to surgery in the FPC group, there is no way of looking at fasting glucose 
levels in either those with PanINs or early cancer. Analysis is also hindered in the HP 
group by the high incidence of endocrine pancreatic failure, the high number of 
abnormalities on imaging and the minimal number of proven pre-malignant or
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malignant lesions detected. Data collection is continuing and productive analysis 
should become possible in the future, nevertheless, there are some suggestive data 
which can be reported here as an initiating point for discussion.
Data for 282 cases of peri-pancreatic cancer were gathered prospectively by 
members of the research group pre and post surgery over a number of years, but 
unfortunately glucose data were not included in this before my time with the group. 
The glucose data for these patients were therefore obtained retrospectively from 
clinical notes and other records. The pre-operative values were obtained as close to 
the date of surgery as possible, if possible on day of surgery when it was assumed 
that these would be fasting samples. The post-operative values were taken as close 
to four weeks post-surgery as possible. This was an arbitrarily selected time point 
which was assumed to give the individual time to recover from their surgery. The 
nature of the data collection and previous hospital computer systems meant that I 
had to largely rely upon random glucose measurements with little or no contextual 
details attached to the values. For example, many of the clinical notes had since 
been destroyed making it impossible to determine in some cases who was known to 
be diabetic and taking anti-glycaemic medication at the time the blood was taken.
Figure 18 shows the distribution of random glucose levels, clearly demonstrating a 
population with very low levels (below 5 mM, note the steep gradient) a large 
population with moderate glucose levels (between 5 and 10mM, note the almost flat 
curve) and a population with very high glucose (above 10mM glucose, note the steep 
gradient). The steep increase in gradient started between 10 and 11 mmol/L so the
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WHO value of 11.1 mmol/L321 was accepted as indicative of diabetes for the 
purposes of the analysis in the rest of this section,
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Figure 18: Distribution of Random Glucose Values in Sporadic Peri-pancreatic 
Cancer
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A graphical representation of the number and distribution of 430 ranked pre-operative random 
glucose measurements (shown in blue) taken from 282 individuals that had resections at the 
Royal Liverpool University Hospital for sporadic peri-pancreatic cancer. The ranked number is 
shown on the x axis (lowest rank =1, highest ranked =430), with the glucose level shown on 
the y axis. The differential is shown in red, with the trend line for the differential shown in 
black. Given a normal distribution (i.e. random variation around a mean), the ranked values 
should increase gradually and evenly. That would mean that the differential of the curve 
(change in value per ranked sample) should be constant and the line should be horizontal. The 
trendline for the differential in this figure shows that we get abnormal values before sample 20 
and after sample 380.
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The glucose data were grouped by diagnosis (PDAC, ampullary and 
cholangiocarcinoma) and have been displayed below in table 9. There were no 
significant differences in age and gender between the diagnostic groups. Chi- 
squared testing showed no statistically significant differences in terms of gender 
(p=0.791) and Mann-Whitney-U testing showed no significant difference between 
median ages in the respective groups (p=0.417).
Table 9: The Demographics of Peri-pancreatic Cancer Patients with Glucose Data.
Table to show the gender and age of peri-pancreatic cancer patients that had random glucose 
levels available both pre and post surgery. They were analysed together and by cancer type. 
There were no statistically significant differences between the cancer groups, when analysed 
for either gender or age.
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Number of 282 155 77 50
patients
Gender 155:127 88:67 41:36 26:24 0.791a
(M:F)
Median Age 66.4 66.5 67.3 65.1 0.417b
in years with (66.5-72.4) (56.0-73.3) (58.4-70.3)
(IQR) (n=282) (n=155) (n=77) (n=50)
a= Chi-squared test using 3x2 contingency table 
b= Mann-Whitney-U test
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One significant finding from examining the retrospective glucose results from those 
with peri-pancreatic cancer was that hyperglycaemia (serum glucose £11.1 mmoi/L) 
was not only more common in the PDAC group compared to those with either 
ampullary or cholangiocarcinoma, but it also appeared to resolve after surgery in this 
group. There were 27 patients with PDAC, who had pre-operative hyperglycaemia, a 
resection for PDAC and a post-operative glucose result. Post operative results were 
missing for a further two individuals and they were excluded. Of the 27 with all data, 
25 individuals had resolution of their pre-operative hyperglycaemia following surgery. 
Conclusions are weakened by the lack of data on hypoglycaemic agents and 
diabetic status but it is noteworthy that there was no significant change in pre­
operative hyperglycaemia following resection for either ampullary or 
cholangiocarcinoma. These data are summarised on the following page in table 10.
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Table 10: Pre- and Post-operative Glucose According to Tumour Group
Table showing the pre- and post-operative random glucose levels dichotomised as either <11.0 
or >11.1 mmol/L by tumour type. The pre-operative values were obtained as close to the date 
of surgery as possible, if possible on day of surgery (when it was assumed that samples 
would be fasting). The post-operative values were taken as close to four weeks post-surgery 
as possible (an arbitrarily selected time point assumed to give individuals time to recover from 
surgery). Pre-operative diabetes (definition as described in the text based on WHO 
classifications321) was more common in PDAC patients (24%) than in those with either 
ampullary (9%) or cholangiocarcinomas (14%), with \2 testing giving p=0.035. Post-operative 
glucose results were available for 27/29 individuals that had a resection for PDAC and had pre­
operative hyperglycaemia. Of these 27 individuals, 25 had a glucose result <11.0 mmol/L 
following resection of their tumour, with hyperglycaemia remaining in just 3%. There was no 
significant difference in glycaemic control between tumour groups following surgery, with \2 
testing giving p=0.507.
Ampullary
Cholangiocarcinoma 
PDAC
p=0.035 p=0.507
Preoperative Postoperative
glucose glucose
<11.0 >11.1 <11.0 >11.1
53 5 51 3
37 6 39 3
93 29 115 4
The clinical relevance of the strong relationship between pre- and post-operative 
hyperglycaemia and tumour type is uncertain. When the PDAC group was analysed 
with respect to the change in random blood glucose after surgery (see figure 19), no 
difference in survival was shown between the groups irrespective of whether 
glycaemic control improved, remained unchanged or worsened following resection of 
the pancreatic ductal adenocarcinoma. There was also no relationship between 
glucose levels and survival in the other tumour groups (data not shown).
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Figure 19: Survival in Those With a Resected Pancreatic Ductal Adenocarcinoma 
Analysed by Change in Random Glucose Levels
-*-Caused
—Cured
—Diabetic
—Improved
—Unchanged
Time (Years)
Caused 3 0 0 0 0 0 0
Cured 29 13 6 3 2 1 1
Diabetic 3 1 0 0 0 0 0
Improved 1 1 0 0 0 0 0
Unchanged 83 42 18 10 5 4 3
A Kaplan-Meier survival curve to show the potential differences in survival between those that 
had a pancreatic resection at the Royal Liverpool University Hospital for PDAC, analysed by 
the difference between pre-operative and post-operative glucose levels. A cut off of >11.1 
mmol/L was used as indicative of diabetes. The ‘caused’ group had a glucose <11.1 mmol/L 
pre-operatively and a level >11.1 mmol/L post-operatively. The cured group had a level >11.1 
mmol/L pre-operatively and a glucose <11.1 mmol/L post-operatively. The diabetic group had a 
glucose level £11.1 mmol/L both pre- and post-operatively, with no marked (>10%) change. In 
the improved group, the glucose level was >11.1 mmol/L both pre- and post-operatively, but 
there was a marked (>10%) improvement after surgery. The largest group ‘unchanged’ had a 
glucose level <11.1 mmol/L both pre- and post-operatively. The most striking feature of this 
figure is the lack of difference in survival between those patients that had apparent diabetes 
before surgery (but not after) and the group where there was good glycaemic control pre- and 
post-surgery.
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As described above, the conclusions that can be drawn from analysis of the fasting 
glucose in high risk individuals are limited as there has only been a single participant 
with proven PanIN lesions. The distribution of fasting samples for members of 
EUROPAC FPC kindreds is displayed below in figure 20. The axes have been 
matched to figure 18, which showed the random glucose results in those having 
resections for peri-pancreatic cancer, to permit comparison.
Figure 20: Distribution of Fasting Glucose Values in Asymptomatic Members of FPC 
Kindreds
Number of Fasting Glucose Samples
This figure shows the number and distribution for the fasting glucose samples obtained from 
members of FPC kindreds. The ranked number of the glucose results is shown on the x axis 
with the glucose level shown on the y axis. Glucose levels are shown in blue, with the 
differential shown in red and the differential trendline in black. None of these individuals are 
known to have developed pancreatic cancer. Given a normal distribution, the differential of the 
curve (change in value per ranked sample) should be constant and the line should be 
horizontal. The trendline for the differential in this figure shows that we get abnormal values 
before sample 5 and after sample 100.
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Although there are no gross abnormalities in the high risk individuals, it is of note that 
there are some values that are outside of the normal range. These findings, by 
themselves, do not show that high glucose is a sufficiently early marker to be used in 
screening, but the results (the lack of any survival difference) in the sporadic cancers 
suggest that high glucose is not a marker of late disease.
Since the completion of this aspect of my thesis, a number of groups have published 
regarding the relationship between pre and post operative diabetes on survival from 
pancreatic cancer. Although results have varied, overall, the data do not support a 
relationship between survival and diabetes. This is consistent with my own findings 
and is contrary to my expectations at the outset of my period of research322,323.
187
Modelling of risk in individuals with a possible genetic predisposition for pancreatic cancer
3.2.3 Risk Stratification in HP
As stated previously, prior to the work that has gone into thesis, the two most 
common HP mutations had been well characterised, but almost nothing was known 
about the phenotypes produced by (and the cancer risk caused by) the rarer PRSS1 
mutations, including the third most common PRSS1 mutation, p.A16V. Before 
discussing the characterisation achieved in p.A16V kindreds, the cancer risk in all 
HP kindreds will be described.
3.2.3.1 What is the Cancer Risk in HP Kindreds?
The existence of an increased cancer risk in HP was first identified by Lowenfels et 
al in 199791 but was far more accurately characterised by Howes et al92 and then 
Rebours et al93 using EUROPAC and French data in 2004 and 2008 respectively. 
These works inevitably concentrated on the most common HP mutations, p.R122H 
and p.N29l, where statistical analysis was made easier by their higher prevalence.
The lifetime cancer risk in all affected individuals from EUROPAC HP kindreds 
(irrespective of the causative mutation) has been compared to that of the general US 
population using the SEER data. This is shown below in figure 21 and the relative 
risk in affected individuals has been shown to be 28-fold that of the general 
population.
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Figure 21: Comparison of Cancer risk in EUROPAC HP Kindreds and the United 
States General Population.
100 <?■
EUROPAC HP
SEER
28 fold increase on SEER 
risk
At Risk 0 10 20 30 40 50 60 70 80
SEER 21.8 18.9 15.8 12.9 9.8 6.4 3.7 2.1 0.8
(millions) 
EUROPAC HP 497 121 27 3
Figure to illustrate the relative risk of pancreatic cancer in affected individuals from HP 
kindreds compared to that of the United States general population. The cancer risk in 
individuals affected by HP approximates to a 28-fold increased risk over members of the 
general population of the United States (SEER). The x axis shows age of individuals in years. 
The y axis shows calculated cumulative survival shown as a percentage. This is derived from 
calculations of risk at each specific age point. This calculation is required permit comparison 
between the cross-sectional SEER data and the longitudinal EUROPAC data.
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3.2.3.2 Characterising the Phenotype of the p.A16V Mutation of 
PRSS1
Pancreatic cancer is therefore a significant problem in HP kindreds. Characterisation 
of the phenotype in p.A16V kindreds (not just the cancer risk described here, but 
also onset of pancreatitis and pancreatic failure described earlier in this chapter) had 
always been limited by rarity of the mutation and the associated low numbers. The 
first challenge was therefore to identify and recruit as many p.A16V kindreds as 
possible.
Identification of p.A16V in EUROPAC Families
EUROPAC’s p.A16V families were recruited because their phenotype suggested an 
autosomal dominant predisposition; p.A16V was originally reported in idiopathic 
pancreatitics. Preliminary analysis of existing EUROPAC families suggested that 
there were differences between p.A16V and the true HP mutations. Collaborators 
around the world were contacted to gather as many p.A16V families as possible to 
enable the mutation to be more accurately characterised. A total of 10 kindreds were 
identified. Six had a phenotype consistent with HP, three with idiopathic disease and 
one with FIP. Altogether 37 mutation carriers were identified although only 22 of 
these were clinically affected by pancreatitis. There were a total of three pancreatic 
cancer cases although only one had definitely been affected by pancreatitis. Data 
were also collected for age of onset of pancreatitis and numbers affected by 
endocrine and exocrine pancreatic failure. The data relating to pancreatitis and its
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non-cancer outcomes have been shown above as survival curves but are also 
summarised in table 11 to put them in the context of cancer risk.
Table 11: Summary of EUROPAC p.A16V Families, January 2009
Each p.A16V family is described including the number of individuals with symptomatic 
pancreatitis. The median age of onset of pancreatitis is derived using the method of Kapian- 
Meier. Median age of onset is given for all patients with pancreatitis or for all patients with 
p.A16V mutations (censoring at age of last contact for unaffected individuals). IQR is the age 
of 25% incidence to the age of 75% incidence. The numbers of individuals diagnosed with 
diabetes, malabsorption or pancreatic cancer are shown in the final three columns. Absolute 
totals are in plain text, with totals in those affected by pancreatitis in parentheses.
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Modelling of risk in individuals with a possible genetic predisposition for pancreatic cancer
The Variable Phenotype in p.A16V Families
As shown in the previous table, the p.A16V mutation of PRSS1 is not exclusively a 
HP mutation. Sample families from each group are shown on the next page in Figure 
22.
Figure 23: Sample Pedigrees Indicating the Variable Phenotype of p.A16V
Ages and unique personal identification numbers are shown below each family member 
followed by a description of the type of p.A16V test carried out. Arrows indicate index cases. A 
shaded left upper quadrant indicates that the individual is affected by pancreatitis, shading of 
the left lower quadrant indicates diabetes mellitus, with a shaded right lower quadrant 
indicating exocrine pancreatic failure. The presence of a dot in the right upper quadrant 
signifies the presence of a p.A16V mutation, individuals assumed not to have a p.A16V 
mutation are described as off kindred and are marked with a cross. The central black circle 
indicates the presence of a confirmed pancreatic adenocarcinoma. A) Displays autosomal 
dominant inheritance. B) Includes an idiopathic case of pancreatitis. C) Defined as having 
familial idiopathic pancreatitis; as cases of pancreatitis, diabetes and pancreatic cancer are 
restricted to a single generation.
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Modelling of risk in individuals with a possible genetic predisposition for pancreatic cancer
Family A is an example of a kindred described as having HP (Figure 22A); as with all 
such families the definition of HP was based on multiple cases and preceded genetic 
testing. All families in this group would be defined as HP regardless of whether 
mutations were detected. In this case the family was identified after the proband’s 
children (individuals 3 and 5) were affected by pancreatitis. Both p.R122H and 
p.N29l were excluded and a p.A16V mutation in one copy of PRSS1 was detected in 
the proband (individual 1).
It remains possible that p.A16V is an associative rather than a causative mutation, 
but testing has yet to identify an affected individual that does not carry p.A16V in any 
of the p.A16V HP kindreds and mutations in other candidate modifier genes (CFTR 
and PSTI) have not been detected. ‘Affected’ means that individuals have reported 
symptoms of pancreatitis and the possibility of sub-clinical disease cannot be 
excluded in other family members.
In Family A one of the proband’s siblings has diabetes (individual 8). This could be a 
manifestation of pancreatic inflammation in the absence of pain, but this individual 
does not carry p.A16V. It is possible that, at least in this kindred, p.A16V is modifying 
the symptoms of an underlying inherited pancreatic disease, with the mutation 
increasing the chance of pain. Diabetes mellitus is, however, not uncommon, and the 
cases in such families may well be coincidental.
The p.A16V mutation could explain the pancreatitis in all the p.A16V HP kindreds, 
but even in these families, not all carriers had explicit symptoms. Unavoidably, most 
unaffected individuals in the families were not tested. Of the 23 individuals who were
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confirmed to have the p.A16V mutation only 15 had reported symptoms of 
pancreatitis. All of the proband’s siblings in Family A were tested for p.A16V, three 
(individuals 9 to 11) carried the mutation but none reported symptoms. The 
proband’s mother was tested and no mutation was detected, indicating that the 
mutation was inherited from the father (individual 7). There were no cases of 
pancreatitis present within any of his eight siblings, although three were affected by 
diabetes mellitus. No testing was conducted within this generation. Two of these 
diabetics were identical twins, consistent with a genetic predisposition to diabetes in 
this part of the kindred. It is, however, important to note that if the risk of diabetes is 
independent of the p.A16V mutation and the inherited risk accounts for the diabetes 
seen in individual 8; then the father of the proband (individual 7) must have carried 
both the p.A16V mutation and the predisposition to diabetes without developing 
symptoms.
At the time of guillotine for the p.A16V paper (January 2009) the EUROPAC 
database contained 142 families with a phenotype consistent with idiopathic disease 
that had undergone genetic testing. Three of these have a proven p.A16V mutation 
(2.1%). The families are named G (Figure 22B), H and I (family trees not shown). In 
all cases referral was atypical for EUROPAC, in that there was no family history. 
Unlike any of the HP families, genetic testing was performed before recruitment to 
the study. For example, Family G (Figure 22B), was referred after an 11 year old boy 
(individual 1) was admitted to hospital with recurrent abdominal pain which had first 
started at the age of 5. An appendicectomy was performed, histology showed no 
evidence of inflammation. He subsequently developed a pancreato-pleural fistula
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requiring a chest drain. Due to his personal history, his clinicians requested testing 
for a PRSS1 mutation. Subsequent to discovery of a p.A16V mutation, his mother 
and brother (individuals 3 and 4) underwent testing and have been confirmed as 
unaffected p.A16V carriers. Neither of the proband’s maternal grandparents 
(individuals 8 and 9) are affected and testing has not been performed in either case. 
Similarly in families H and I there was childhood onset disease, consistent with the 
original identification of p.A16V in sporadic cases identified in paediatric units191. 
This may represent referral bias rather than a feature of p.A16V perse.
At the time of guillotine for the p.A16V paper there were 40 pancreatitis families on 
the registry, where despite thorough investigation, the disease appears to be limited 
to a single generation with no evidence for spontaneous mutation. This phenotype is 
consistent with a multigene or recessive syndrome. One of these 40 families, Family 
J (Figure 22C), carries a p.A16V mutation (2.5%). It was referred after pancreatitis 
was diagnosed in four of eight siblings, one of whom had already died from a 
histologically proven adenocarcinoma of the pancreas at the age of 44. The other 
affected siblings all tested positive for the p.A16V mutation. The remaining four 
siblings were unaffected and declined genetic testing. The pancreatic cancer case 
was not tested for p.A16V although she had been affected by pancreatitis, prior to 
developing malignancy. Both the parents and offspring were asymptomatic and 
testing was not performed in either the preceding or subsequent generation.
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Phenotype of p.A16V Compared to Other PRSS1 Mutations
A visual comparison of pedigrees indicates that there are differences between the 
phenotype of p.A16V and the phenotype associated with other PRSS1 mutations. 
However, the low incidence of p.A16V and the even smaller numbers of carriers 
affected by diabetes mellitus, malabsorption or pancreatic cancer means that there is 
insufficient power for a meaningful statistical analysis. Nevertheless, the data 
summarised in table 11 confirm that cancer and both endocrine and exocrine failure 
are features that occur within p.A16V families.
Figures 8-10 in section 3.1.2.3. do not provide adequate evidence to suggest a 
difference in disease progression between p.A16V and the other PRSS1 mutations, 
but as described above, there is a clear difference in penetrance. With just three 
cancer cases there is no possibility of proving a difference between age of onset of 
cancer in p.A16V and any other group (as Kaplan-Meier analysis of only affected 
individuals would lack adequate power) but the unavoidable impression is that 
p.A16V carriers have a lower cancer risk than carriers from the other mutation 
groups, if for no other reason than penetrance being lower. Cancer risk in p.A16V 
may equate to that seen in individuals with non-genetic chronic pancreatitis, but 
again, the low numbers prohibit meaningful statistical analysis.
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3.3 Secondary Screening
As stated previously, secondary screening of high risk individuals for early pancreatic 
cancer had been happening on a piecemeal basis under local ethical approvals for 
several years. The second aim of this thesis was to pilot a trial of secondary 
screening in high risk individuals. Having planned the study, the next step was to 
obtain the necessary ethical approvals.
3.3.1 Ethics
As stated in section 2.3.2, I made two separate National Research Ethics Service 
(NRES) applications for the EUROPAC Study of Secondary Screening for Early 
Pancreatic Cancer \r\ the FPC and HP groups respectively. The FPC application was 
granted by Warwickshire Research Ethics Committee (REC Reference 07/H1211/96) 
with the HP application being approved by the Central Manchester Research Ethics 
Committee (REC Reference 07/H1008/153). Samples of the patient information 
sheet and consent form from the FPC application have been included in chapter 6 of 
this thesis as an appendix. The main concern of the ethics committee was the issue 
of gender discrimination. This contrasted with the concerns of the research group 
which will be discussed in Chapter 4.
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3.3.2 Secondary Screening in High Risk Kindreds (June 2008)
The results in this section were prepared for a presentation given to the EUROPAC 
study group in late June 2008 and had been collated over the previous 2 months. 
Many of the data had been collated prospectively but they were checked and any 
gaps in the data were closed. The data for secondary screening in FPC kindreds will 
be presented first followed by those for the HP kindreds.
3.3.2.7 Secondary Screening in FPC (June 2008)
Taking 30th June 2008 as the date of guillotine for these data, a total of 70 individuals 
from FPC kindreds had entered the EUROPAC study of secondary screening for 
early pancreatic cancer in high risk groups. Of those, 65 remained within the study 
and wished to continue with further investigations. The reasons for the loss of the 
five individuals that had entered the screening study and then left it were mixed. One 
decided to leave the registry entirely, whilst a second stayed on the registry but 
declined any further investigations. The third patient remained on the registry but 
emigrated to a country with no collaborating clinicians, whilst a fourth was lost to 
follow up despite efforts to relocate him. The final individual was withdrawn from the 
study after additional primary screening and the recruitment of other family members 
indicated that at least one of the cancer cases in the family was highly unlikely to be 
pancreatic.
Screening was carried out at seven screening centres within the UK, but the vast 
majority of investigations were performed at either Liverpool, or the second largest
200
Modelling of risk in individuals with a possible genetic predisposition for pancreatic cancer
centre, University College London. Of the 65 individuals that remained within the 
screening study, 60 were compliant with the protocol, meaning they had had either 
their baseline investigations within the last three years (if juice analysis then 
indicated they should follow the standard surveillance pathway) or the most relevant 
investigation (normally BUS) within the last twelve months if they were following the 
close surveillance pathway. One of the major challenges was to standardise the 
management of those that had previously had investigations under local ethical 
agreements at various centres. The first step was informed consent followed by 
serum blood samples. These had often not been collected outside Liverpool prior to 
the national ethics application, but existing results were chased and additional blood 
forms sent out to individuals not compliant with the protocol. This meant that at time 
of guillotine for the data displayed in tables 12 and 13, just 15 of the 65 being 
screened had signed and returned the new consent form; although written consent 
was in place for everybody under local agreements.
Variation between screening centres also meant that there was no set protocol for 
blood tests being gathered under local consents. There were just 16 fasting glucose 
samples available (all collected since the national ethics approval), but a total of 81 
CA19-9 results recorded, most of which had been collected using local research 
ethics committee approvals. Of these 81 CA19-9 samples, five individuals had serum 
CA19-9 levels greater than the normal range of <35 kU/L. Four of these individuals 
had levels between 36-44 kU/L. These levels did not correspond to identifiable 
lesions of concern on imaging. One individual subsequently developed a pancreatic 
cyst in 2010 which is being managed conservatively. One individual screened at a
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satellite centre (under local ethical consent) had a CA19-9 result of 1726 kll/L in 
November 2006 and 6704 kU/L in June 2007. However, these grossly abnormal 
CA19-9 results did not correspond to identifiable changes on imaging. Two EDS 
examinations had been performed (in 2005 and 2007), which were unremarkable. 
Two CT scans were performed, one in 2005 and a second in November 2006. There 
was also a MRCP in January 2006, which was also reported normal. She was seen 
in the clinic in June 2007 when her main problem was a change in bowel habit to 
towards constipation and a colonoscopy was requested. She was subsequently 
diagnosed with carcinomatosis with an unknown primary and died in 2008. A biopsy 
confirmed adenocarcinoma and it is certainly possible, but not definitively proven, 
that the primary site of the malignancy was in the pancreas.
A total of 64 CT scans had been performed. Eight abnormalities had been detected 
but these were essentially all incidental findings with none indicating a pancreatic 
tumour. A total of 73 EUS scans were performed. These detected a total of seven 
abnormalities. Five were definite benign disease. There were four diagnoses of 
incidental gallstones and one of chronic pancreatitis. There were two potentially 
significant abnormalities detected. One was for a pancreatic cyst and the second 
was pancreatic duct dilatation. Both were discussed at MDT and monitored by 
interval imaging, with no indication to proceed to a resection. A total of 12 MRI or 
MRCP scans had been performed. These showed three abnormalities, two were 
IPMNs which were being managed with interval surveillance and there was an 
incidental diagnosis of gallstones in an individual screened in London.
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Finally, a total of 16 ERCPs had been performed in 16 different participants in the 
FPC group. These were all carried out at Liverpool. Juice was collected successfully 
in 11 individuals. Six individuals (of the 16) had their procedure complicated by acute 
pancreatitis (three cases were where juice was successfully collected and three were 
in individuals where it was not), giving a rate of 37.5% for all procedures. Of these, 
as described in the section on adverse events, all settled with conservative 
management although one individual had sterile pancreatic necrosis and 
subsequently developed exocrine pancreatic failure requiring supplementation with 
porcine pancreatic enzymes.
The analysis of the 11 pancreatic juice samples successfully collected showed that 
seven of the samples had no K-RAS2 mutations. One individual had a total of four 
mutations out of the six tested for, with the other three individuals having a single 
Kras mutation each. CDKN2A methylation and Tp53 results were available for a total 
of eight individuals. Two individuals had a CDKN2A promoter methylation >12% 
(including the individual with multiple K-RAS2 mutations), but there were no Tp53 
mutations detected.
In terms of overall clinical impact, negative results meant that two patients entered 
the ‘standard’ surveillance pathway and were imaged on a three yearly basis. 
Conversely, two of the individuals with mutations entered the ‘close’, rather than the 
‘standard’ pathway.
On the next two pages the secondary screening data for the FPC kindreds will be 
summarised. Table 12 will show the numbers of individuals screened, the site,
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compliance and number of ‘screening years’. Table 13 will summarise the numbers 
of each investigation performed and the number of abnormalities detected.
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Table 12: Summary of FPC Screening (June 2008)
Table summarising the numbers of high risk individuals from FPC kindreds that have been 
screened by EUROPAC collaborators up to June 2008. Numbers (and percentages where 
applicable) are given for the total that have ever been screened and who are still being 
screened, these are divided by the relevant screening centre. The number of individuals 
compliant with the protocol are also given, taken as the most relevant investigation performed 
in the past 12 months if on the close surveillance pathway, or within the past three years if on 
standard surveillance. Finally there is a figure given for the total number of ‘screening years’ 
in these 65 individuals.
Number Percentage
Total Ever Screened 70 N/A
Total Still screened 65 93%
Centre (n=65)
Liverpool 35 54%
London
23 35%
Other
7 11%
Compliant with protocol 60/65 92%
Screening Years 133 N/A
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Table 13: Summary of Investigations performed in FPC cohort (June 2008)
Table summarising the numbers of investigations performed in high risk individuals from FPC 
kindreds by EUROPAC collaborators up to June 2008. Investigations are grouped into blood 
investigations, imaging and ERCPs for collection of pancreatic juice. Abnormal blood results 
were those outside of the normal reference range. The total number of abnormal imaging 
results (benign and suspicious) are listed for each modality with numbers of suspicious 
lesions detected shown in the final column. EUS detected a cyst in one individual and 
pancreatic duct dilatation in another. MR detected IPMN lesions in two separate individuals. 
The abnormal result recorded for ERCP relates to the imaging appearances. As stated 
elsewhere, ERCP was predominantly performed for juice analysis. This detected Kras 
mutations in four individuals (out of 11 samples), one of whom had multiple K-RAS2 
mutations. Juice analysis results were termed suspicious if £2 K-RAS2 mutations; CDKN2A 
hypermethylation; or Tp53 mutations were present. The total number of abnormal and 
suspicious lesions from juice analysis is one less than the sum of the values in that column. 
This is explained by the individual with the multiple K-RAS2 mutations also having CDKN2A 
hypermethylation >12%.
Total
Number
Total
Abnormal
Suspicious
lesions
Blood
Fasting Glucose 16 0 N/A
CA19-9 81 5 N/A
Imaging
EUS 73 7 2
CT 64 8 0
MR 12 3 2
ERCP 16 5 2
K-RAS2 11 4 1
CDKN2A 8 2 2
Tp53 8 0 0
206
Modelling of risk in individuals with a possible genetic predisposition for pancreatic cancer
3.3.2.2 Secondary Screening in HP (June 2008)
By 30th June 2008, the numbers that had entered the screening study from HP 
kindreds was lower than in the FPC kindreds. A total of 24 high risk individuals from 
HP kindreds had had screening investigations, under either local or national ethical 
agreements at some point. Of those, again, five were no longer being screened. 
Three of these had been withdrawn from screening as they had been operated on. 
Two of these were the cases A and B described in detail in section 3.3.3 of this 
thesis. The third had a total pancreatectomy performed at another centre by a 
collaborating clinician for intractable pain, rather than on the basis of screening 
investigations. Of the remaining two HP individuals, one had their investigations 
suspended by the research team (as screening had been started before the age of 
40 by a collaborator under local ethical authority at another centre). The intention is 
to restart the screening cycle when the individual reaches the age of forty years. The 
final participant was, unfortunately, lost to follow up.
Screening was located at seven screening centres across the UK, but as with the 
FPC cohort, the vast majority of individuals were being screened either in Liverpool 
(n=9), or the second largest centre, University College London (n=4). The remaining 
six individuals were screened across five other sites, as close to their home address 
as possible. Of the 19 individuals that remained within the screening study, 18 were 
compliant with the protocol, meaning as in the FPC cohort, that they had either had 
their baseline investigations within the last three years (if juice analysis indicated 
they should follow the standard surveillance pathway) or the most relevant
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investigation (normally CT) within the last twelve months if they were under ‘close 
surveillance’. The same problems regarding variation in practice, due to local ethical 
agreements were encountered as in the FPC cohort. This led to comparatively few 
blood samples having been collected outside Liverpool before the national ethics 
application.
At time of guillotine in the HP cohort, just three fasting glucose samples were 
available and there were 26 CA19-9 results. The fasting glucose results were all 
within the normal range. The CA19-9 results were more interesting, with two results 
(in the same individual) outside the normal range of <35 kll/L. There was a result of 
137 kU/L and 89 kU/L from 2005 and 2008 respectively. CT imaging throughout this 
period showed severe chronic pancreatitis with no formed tumour. An ERCP was 
performed in April 2006. Juice analysis detected no abnormality. At time of writing 
the individual remains well. She has minimal pain but both endocrine and exocrine 
pancreatic failure.
A total of 28 CT scans, 31 BUS scans and two MR scans had been performed. One 
of the problems with imaging in the HP group was that by definition, very few of the 
scans were normal (see table 15), making detecting early changes of possible 
emerging malignancy problematic.
A total of 16 ERCPs were performed in the HP group in 11 individuals. There were 
again some problems obtaining pancreatic juice with samples ultimately being 
successfully collected at 13 procedures performed in nine individuals (with a total of 
three failed juice collections in two different individuals). Juice analysis in the HP
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subgroup detected ‘later’ changes than were seen with FPC individuals. Of the 13 
samples collected from nine individuals, all were tested for mutations of K-RAS2. 
Five separate individuals had no detectable mutation. There were 7 K-RAS2 
abnormalities detected in four separate individuals. Only one of these was a single 
mutation and this was in a retest for an individual that had previously had multiple K- 
RAS2 mutations. Arginine was the most common mutation detected (present in six 
samples taken from four separate individuals), with no Aspartate or Alanine 
mutations detected. There were CDKN2A promoter methylation results from 12 
samples in eight separate individuals, with four samples in three separate individuals 
showing CDKN2A hypermethylation >12%. Tp53 mutation testing had been 
performed eight times in seven separate individuals. There had been a D245G 
mutation detected, although the retest showed no detectable Tp53 abnormality. This 
individual is described in this thesis as Case A.
There were no confirmed cases of post-ERCP pancreatitis. One individual had post- 
ERCP abdominal pain and was observed overnight, but her serum amylase 
remained within the normal range and she did not require any further medical 
treatment.
The clinical impact of ERCP and juice analysis was again limited. Of the 19 
individuals that remain within the screening study (those operated are excluded from 
this analysis), two were placed on the close surveillance pathway on the basis of 
their pancreatic juice analysis results, with one remaining on the standard
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surveillance pathway, as their pancreatic juice analysis showed no detectable 
abnormality.
On the next two pages the above data will be summarised in two tables, which are 
similar to those displaying the secondary screening data for the FPC cohort in the 
previous section. Table 14 will show the numbers of individuals screened, the site, 
compliance and number of ‘screening years’. Table 15 will summarise the numbers 
of each investigation performed and the number of abnormalities detected.
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Table 14: Summary of HP Screening: (June 2008)
Table summarising the numbers of high risk individuals from HP kindreds that have been 
screened by EUROPAC collaborators up to June 2008. Numbers (and percentages where 
applicable) are given for the total that have ever been screened, are still being screened and 
sub-divided by screening centre. The number compliant with the protocol (taken as the most 
relevant investigation performed in the past 12 months if on the close surveillance pathway, or 
within the past three years if on standard surveillance) is also shown followed by the total 
number of screening years in these 21 individuals.
Number Percentage
Total Ever Screened 24 N/A
Total Still screened 19 79%
Centre (n=19)
Liverpool 9 47%
London 4 21%
Other 6 32%
Compliant with protocol 18/19 95%
Screening Years 57 N/A
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Table 15: Summary of Investigations Performed in the HP Cohort (June 2008)
A summary of the investigations performed in high risk individuals from HP kindreds by 
EUROPAC collaborators up to June 2008. Investigations are grouped into blood 
investigations, imaging and ERCPs for collection of pancreatic juice. Blood investigations 
were termed as abnormal if they were out of the normal reference range. Imaging 
investigations were termed abnormal if they showed changes consistent with chronic 
pancreatitis or other benign disease (including small cysts and pancreatic duct dilatation), 
with one CT scan showing changes indicative of possible malignancy. In the ERCP section (in 
contrast to the FPC kindreds), some individuals from the HP kindreds had more than one 
ERCP. The figures shown are the totals for each group, with data in parentheses being the 
number of separate individuals. A total of 16 procedures were performed in 11 separate 
individuals. Juice was collected successfully from 13 procedures in 9 separate individuals, all 
of which were tested for K-RAS2 mutations. Twelve samples (from eight individuals) were 
tested for CDKN2A hypermethylation, with eight samples (from seven separate individuals) 
tested for mutations of the Tp53 gene. Single mutations of K-RAS2 were defines as abnormal 
but not suspicious. Multiple K-RAS2 mutations, CDKN2A hypermethylation (>12%) or those 
with a Tp53 mutation were termed suspicious. Any disparity between the total with an 
abnormality or a suspicious lesion and the total of the numbers in that column is explained by 
the presence of more than one of the abnormalities being present in the same sample.
Total
Number
Total
Abnormal
Suspicious
lesions
Blood
Fasting Glucose 3 0 N/A
CA19-9
Imaging
26 2 N/A
EUS 31 16 0
CT 28 24 1
MR 2 2 0
ERCP 16(11) 11 (6) 7(5)
K-RAS2 13(9) 7(4) 6(4)
CDKN2A 12(8) 4(3) 4(3)
Tp53 8(7) 1 (D 1 (1)
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3.3.3 Management of Detected Abnormalities
In this section the management of abnormalities detected by screening will be 
discussed. The process for all abnormalities will be described, followed by the 
specifics on the two members of HP kindreds that had resections under the auspices 
of the secondary screening study.
3.3.3. f All Abnormalities
Any significant abnormality identified by the screening process was discussed at the 
next weekly EUROPAC meeting. If changes were considered significant by the 
EUROPAC study group, cases were presented for discussion at the next Regional 
Pancreatic MDT meeting, where any clinical decisions were taken. The process has 
been described in section 2.3 and summarised in figure 4. At the commencement of 
my research period when all screening was being performed under local consents, 
the return of results to the EUROPAC was dependent on local screening clinicians. 
Real time tracking of results markedly improved following the introduction of the 
national MREC ethical agreement, although retrospective audits remained necessary 
to ensure all results had been collated. During the course of my research, two 
patients came to resection on the basis of screening results and other symptoms. 
The third resection performed on a HP individual at another centre for intractable 
pain will not be described as the screening study had no bearing on the clinical 
decision making. Both resections performed as a result of the screening study were
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undertaken in members of HP kindreds. They will be referred to as cases A and B 
and are described below.
3.3.3.2 Case A
Case A was a female, born in 1958 and proven to be a p.R122H mutation carrier 
from a HP kindred. Her mother had died from pancreatic cancer at the age of 61 
years. She was initially referred in late 2005 and was seen in January 2006 in the 
outpatient clinic in Liverpool by the then EUROPAC research fellow, Mr Vitone, and 
Professor Neoptolemos. The reason for the referral was her interest in the secondary 
screening study. She gave informed consent, bloods were drawn and a CT and 
ERCP for juice analysis were requested. The CT showed no pancreatic abnormality 
but the juice analysis showed her to have multiple Kras (Arginine, Serine and 
Cysteine) mutations; a p53 (G245D) mutation and raised CDKN2A promoter 
methylation at 18% (the upper limit of normal being 12%). According to the Bayesian 
analysis performed as part of Van et a/220, these three changes gave an estimated 
risk of developing pancreatic cancer of about 90%220. An EDS was requested and 
was performed in July 2006. Despite being a proven p.R122H mutation carrier the 
EDS showed normal pancreatic tissue with no evidence of chronic pancreatitis. The 
case was discussed at MDT and it was decided to repeat the ERCP and juice 
analysis. This was performed in August 2006 without complication. The subsequent 
juice analysis detected Kras mutations (Arginine and Valine); raised CDKN2A 
promoter methylation, which increased to 50-100%, but there was no Tp53 mutation
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detected. A further EDS was performed in November 2006 which detected changes 
consistent with mild chronic pancreatitis.
Case A came back to the outpatient clinic in March 2007 and was seen by myself 
and Professor Neoptolemos. Over the winter she had had three attacks of pain with 
one admission to her local district general hospital with acute pancreatitis with 
documented hyperamylasaemia. It was decided to repeat her EUS and ERCP in 
May 2007, which would have been six months since her last EUS and ten months 
since her last ERCP for juice analysis. A few days after the clinic, she was 
readmitted locally with acute pancreatitis and again had raised serum amylase. She 
contacted Professor Neoptolemos and was eventually listed for a spleen and 
duodenum preserving total pancreatectomy. This was performed in May 2007 and 
she recovered without complication. Her histology showed normal pancreatic 
parenchyma with neither malignancy nor PanIN lesions in the blocks examined. I 
reviewed her post-operatively in the outpatient clinic. She recovered well, though 
required significant doses of both endocrine and exocrine pancreatic supplements. 
She had an element of exocrine pancreatic failure before surgery but the insulin 
dependent diabetes was a result of the operation itself.
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3.3.3.3 Case B
Case B was a proven p.N29l mutation carrier born in 1959 from a large HP kindred. 
She was referred just after case A and was first seen in the outpatient clinic by 
Professor Neoptolemos in February 2006. She was recruited to the secondary 
screening study and a CT and ERCP were requested. A clinical diagnosis of 
malabsorption was made and she was commenced on Creon. The baseline CT 
showed no abnormality. The ERCP was successful in collecting pancreatic juice. 
The analysis detected mutations in Kras Arginine, Serine, Cysteine and Valine; 
CDKN2A promoter methylation was also raised at 17.6% (<12% being the normal 
range). Following these results, an EDS was requested. This was performed in 
November 2006 and showed no significant abnormality.
As the significance of the molecular analysis was unproven on a prospective basis, it 
was decided to repeat the EUS six months later. This was done in May 2007, when a 
cystic lesion was detected. A CT of the pancreas was requested, confirming the 
presence of the lesion, along with widespread calcium deposition, although there 
was no evidence of metastatic disease. The case was discussed at MDT and the 
decision was to bring the patient back to clinic to discuss either ongoing close 
surveillance or resection. She chose to go ahead with resection and was listed for a 
spleen and duodenum preserving total pancreatectomy. This was performed without 
complication and the histology showed PanIN 1a and 1b with focal areas of PanlN2, 
but no malignancy. Post-operatively, she developed endocrine failure, in addition to 
her pre-existing exocrine pancreatic failure.
216
Modelling of risk in individuals with a possible genetic predisposition for pancreatic cancer
3.3.4 Cost Analysis
The secondary screening study has led to the use of significant numbers of 
investigations and has yet to discover its first cancer. An audit of the secondary 
screening study was completed in June 2008. The numbers of investigations have 
been multiplied by the cost per investigation used in the last paper on cost analysis 
published in the literature300, with comparisons discussed in section 4.3.6. It should 
be stressed that these costings are only for the imaging investigations. No attempt 
has been made to estimate expenditure on other costs such as serum blood 
investigations, staff and labour costs of either the EUROPAC research fellow or the 
scientists analysing the pancreatic juice. Furthermore, there is also no allowance 
made for clinical costs, including the two resections performed as part of this study.
Table 16: Estimate of EUROPAC Expenditure on Secondary Screening Imaging
Table giving estimated costs per imaging investigation (costs taken from Latchford et a?00 to 
permit comparison); the number of each test performed in both FPC and HP kindreds; with 
total estimated cost of each investigation in the right hand column. Total expenditure on 
imaging alone was >$113 000 to July 2008.
Test Estimated Cost
per Test ($)
Total number of
each test (FPC)
Total number of
each test (HP)
Total Cost per
test to June
2008.
CT $268 64 28 $24 656
MR $268 12 2 $3 752
BUS $590 73 31 $61360
ERCP $740 16 16 $23 680
Total $113 448
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3.3.5 Adverse Events
The only adverse events that I am aware of or were reported during my period of 
research were a run of cases of acute pancreatitis triggered by collection of 
pancreatic juice at ERCP in individuals from the FPC kindreds. There were a cluster 
of three cases in the Spring and Summer of 2006 that prompted an audit that was 
one of my first tasks when I started my research.
All ERCPs that had been performed where pancreatic juice had been collected were 
included. All screening ERCPs were included, whether juice had been successfully 
collected or not. Many of the ERCPs had been performed in symptomatic individuals 
who required the procedure as part of their treatment. Juice was collected to test and 
validate the collection and analysis of pancreatic juice for cancer associated 
mutations that led to the Van paper220 prior to the commencement of the screening 
studies. Those with benign disease acted as controls. Of a total of 312 ERCPs, 108 
were performed for biliary stone disease, 46 were performed in chronic pancreatitics, 
44 had pancreatic or biliary tract cancer, with 114 performed for other benign 
disease (including strictures and research). Of the 312 individuals, thirteen had a 
serum amylase >450 U/l records on the hospital computer system following the 
procedure, giving an overall rate of 4.2% (13/312). However, of the thirteen cases, 
six had taken place within the twelve asymptomatic members of FPC kindreds that 
had had an ERCP for collection of pancreatic juice for screening purposes at the 
time the audit was initiated. The pancreatic duct had been cannulated in three cases, 
but not in the other three. The other seven cases took place in patients with both
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gallstones (n=3) and chronic pancreatitis (n=4), the pancreatic duct having been 
cannulated in one patient from each of these two groups. The overall rate of 4.2% 
compares well with rates quoted in the literature but the rate of 50% in FPC 
screening participants at time of guillotine for this audit is obviously a marked 
anomaly. All cases of pancreatitis audited were mild324, except for the final case 
where the individual developed approximately 50% pancreatic necrosis. This did not 
become infected and he was discharged home without intervention but subsequently 
required exocrine pancreatic enzyme supplements. All other patients were 
discharged without further complication. The above audit showed that there was not 
a single case of post-ERCP pancreatitis in members of the HP kindreds. The issues 
surrounding this will be discussed in the following chapter.
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4 Discussion
4.1 Primary Screening
Primary screening is hugely time consuming and of variable utility. It is possible to 
fully characterise a family from the data provided by family members and prove the 
diagnoses using available public records. In other kindreds, even where knowledge 
of other relatives is equally good, one can hit a problem relatively early in the 
process that cannot be overcome, with the result that the family remains poorly 
characterised. When performed effectively, primary screening is often the most 
important tool available in family characterisation and risk stratification. A 
shortcoming is that in the FPC kindreds, in the absence of a genetic test, risk is 
generally determined on a familial rather than individual level. It is the inability to 
differentiate between the varying risks of family members that has driven attempts to 
improve characterisation of risk on an individual basis described in this thesis.
4.1.1 How Effective Are We At Identifying High Risk Families?
As stated above, the process of traditional primary screening can prove informative 
for both study participants and their clinicians. In other cases, it is of minimal benefit 
and even when thoroughly performed, can cause its own problems with the potential 
for both false positives and missed families.
The single simplest test for the effectiveness of EUROPAC’s primary screening 
programme is the number of prospective cancers detected in these families either by 
regular follow up or within the secondary screening study. The pseudo-prospective
220
Modelling of risk in individuals with a possible genetic predisposition for pancreatic cancer
testing of the risk stratification model identified 27 prospective cancers in 
EUROPAC’s FPC families between 2000 and 2008, in line with expectation. Given 
this, it is surprising that we have identified so few cancers in our screening cohort. 
Part of this could be explained by the fact that the screening period has not been 
sufficiently long, but one must also consider the quality of families recruited in the 
past and the entry criteria to the screening study. EUROPAC has withdrawn one 
individual from both the FPC and HP arms of the screening study (recruited under 
local ethical approvals) due to them not meeting the inclusion criteria drawn up for 
the secondary screening study. This illustrates the problem of local centres 
submitting patients to screening, due to either individual or centre demand, in 
contradiction of the protocols laid down by the research group.
In contrast, despite best efforts, traditional primary screening will be inadequate to 
fully characterise some genuine families. For example, it may be impossible to prove 
one or more genuine pancreatic cancers, meaning that a family would be classified 
as ‘FPC query’ and would therefore, not be considered for the screening study. Also 
some obviously high risk individuals may be unwilling to enrol in screening or may 
wish to avoid some aspects of screening such as the ERCP element. In support of 
this, the one individual on the EUROPAC registry who may have developed 
pancreatic cancer within a screening window despite investigations did not have 
pancreatic juice analysis.
Thorough primary screening and risk stratification is difficult in its own right, but is 
only the first step. As stated previously, despite considerable efforts over many years
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at several screening centres, prospective cancers have been missed but not 
detected (at a curable stage) by the early screening studies.
It is these difficulties with both primary and secondary screening that made the risk 
stratification model attractive. Before the risk stratification project was started, the 
classification committee would make a subjective estimation of risk based on the 
number of affected individuals within a family, the total number at risk and the 
proximity of the nearest affected individuals to the key family members. Now that the 
risk stratification model has been completed, the simplest method of making this 
estimate of risk is via the online template. As prospective cancers are detected and 
the risk stratification model is proven with prospective data, the decision to include 
participants on the screening programme will become less subjective and based on 
quantitative estimation of risk. At present, it is possible for a member of a FPC 
kindred to enter the secondary screening study even though their nearest effective 
relative may be, for example, an uncle and the age of their parents makes it highly 
unlikely that they are a gene carrier. Screening such individuals exposes them to the 
risks of screening and increases the costs of detecting what will be a very low 
proportion of pancreatic cancers.
One simple step to increase the cancer risk amongst the screened cohort in the 
secondary screening study is to limit entry to the study to families with three or more 
pancreatic cancers until the methods and protocols have been optimised. This 
would, however, exclude more than 2/3 of EUROPAC’s FPC kindreds from 
screening and obviously raises the prospect of a prospective cancer occurring in a
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family not considered at sufficient risk for the secondary screening study. The entire 
process raises serious ethical considerations. Those related to primary screening will 
be discussed in the following section, with those related to secondary screening 
discussed later in the relevant part of this chapter.
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4.1.2 The Ethics Surrounding Primary Screening
The identification of high risk groups is not straightforward. Individuals normally 
contact EUROPAC as they are conscious that their family history may heighten their 
own risk of pancreatic cancer. At the end of the primary screening process, the 
research team often confirms an elevated risk, but until the generation of the 
computer model, was unable to quantify this on an individual basis. With a genetic 
test only available to a minority, one was left using estimates of risk derived from the 
work of Klein et a/185 and this imprecision often increased rather than alleviated 
anxieties.
There are some advantages to undergoing the primary screening process. Primary 
screening makes no difference to an individual’s inherited cancer risk, just their own 
awareness of it. Access to information may help individuals rationalise their fears 
and adopt risk minimisation strategies such as smoking cessation. High risk 
individuals identified by primary screening may enter the secondary screening study 
which gives a rational focus and potential solution.
If EUROPAC only made people aware of their heightened risk, without offering 
access to any form of screening, the ethics of the whole process of primary 
screening would be called into question. Until the secondary screening protocol has 
been proven as capable of detecting early pancreatic cancers at a curable stage, 
increasing anxiety without a proven solution means that the justification for primary 
screening is inadequate.
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High risk individuals have, by definition, personal experience of pancreatic cancer. 
They are often highly motivated to participate in research and it is a challenge to 
make sure that the decisions they take are objective. If screening for pancreatic 
cancer is to be developed, it must be done in the group most likely to benefit. This 
makes it inevitable that the high risk group be identified.
EUROPAC can act as a source of information about pancreatic cancer but is unable 
to offer either proven screening or prophylactic surgery. Individuals react in different 
ways to this situation. Some decline to register and refuse any future contact. 
Optimistically we can say these patients return to their original state of anxiety. Most 
kindreds register with some entering and others declining to enter the secondary 
screening study. In either case there is a presumed benefit from discussion of their 
anxieties. A small group of individuals may or may not register, but find it difficult to 
cope with the conflicting evidence and advice regarding screening. They often have 
a high level of anxiety, which may have been exacerbated by their contact with 
EUROPAC. They may require considerable input from the research team with 
questionable advantage to either the researchers or the individuals concerned.
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4.1.3 The Differences Between FPC and HP
In those that meet the criteria for definition as a FPC kindred (and the cancer cases 
in the family have been confirmed), lifetime risk approaches 100% in carriers 
equating to approximately 120 fold that of the general population (see figure 13). A 
genetic test is only possible in a handful of FPC families where a BRCA2 mutation 
has been identified.
This contrasts with HP kindred where the vast majority can have their diagnosis 
proven by a relatively simple genetic test and due to previous work by this group and 
others, the attached risks are well characterised for most individuals.
The level of anxiety about cancer risk is family (and individual) dependent and no 
differentiation can be made between FPC and HP kindreds. There are other 
differences that are particularly relevant to secondary screening and these will be 
discussed in section 4.3.
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4.2 Risk Stratification
The low number of prospective cancers and the absence of curable pancreatic 
cancers detected within the early screening studies has prompted a renewed focus 
on risk stratification. The work done as part of this thesis will be discussed with 
reference to both FPC and HP kindreds.
4.2.1 The Role of the Mathematical Model
The mathematical model has the potential to be a significant step forward in risk 
stratification between kindreds and selection of individuals from within these families 
for screening. However, before it can be used for this, it needs to be proven using 
prospective cancers, rather than the retrospective dataset used for its construction. 
Despite this limitation, it is already a useful tool for patient counselling, being a 
definite step forward from the Klein’s familial risk calculations185.
The creation of a new tool for risk stratification and counselling raises the question 
about how best to use it. As already described, traditional primary screening and risk 
stratification has been limited to a few research centres. The model and online 
interface offer the possibility of broadening access and raise questions as to how this 
is best done. The options are: to limit access to the interface to the large research 
centres and effectively continue with the present system; or we could give access to 
hospital based pancreatologists, all hospital consultants, all medically qualified 
personnel including GPs, or make the interface accessible to the general population. 
There are advantages and disadvantages to each scenario but I favour restricting
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access to consultant pancreatologists, at least until the model has been proven using 
prospective data and the protocol for secondary screening for high risk individuals 
has been validated. These pancreatologists would preferably all be EUROPAC 
collaborators who would complete the assessment during an outpatient consultation. 
This should ensure quality control and mean that newly identified high risk 
individuals have specialised counselling available as their heightened risk is 
confirmed.
Once the model and screening have been prospectively proven, online access to the 
risk stratification model could be opened up to primary care physicians as a tool to 
help them counsel patients. It could also help GPs decide which individuals to refer 
on for potential recruitment to the screening study. It is likely that a GP would require 
an initial double appointment supported by further consultations when completing the 
template and providing counselling to a high risk individual. It may be that they would 
prefer this to be undertaken by EUROPAC as it will not be simple to accommodate 
this given the time constraints operating in most UK primary care facilities.
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4.2.2 The Role of Serum Glucose
The role of glucose as a potential modality for either diagnosing or stratifying risk of 
pancreatic cancer remains unproven in both the general population as well as high 
risk groups. It has been established that hyperglycaemia can be a symptom of 
serious, often malignant disease237. The data and provisional results included in this 
thesis have not disproven it as an early marker of pancreatic cancer, but it remains 
unclear whether it is of any more utility than other markers (such as CA19-9), which 
can only reliably detect pancreatic cancer when it has reached an incurable stage.
The data collection that has been performed as part of this thesis offers the 
opportunity to analyse whether a raised serum fasting glucose level is associated 
with either PanIN lesions or early cancer. However, in the absence of either detected 
cancers or pre-cancerous lesions in the FPC arm of the secondary screening study, 
the data need time to mature and any analysis will have to wait until at least some 
have been detected.
The work displayed on glucose in the results section of this thesis is weakened not 
only by the lack of detected lesions, but is confounded in the HP arm by the 
incidence of pancreatitis associated endocrine pancreatic failure.
The data from sporadic pancreatic cancer cases presented in this thesis suggest that 
hyperglycaemia is a result of the presence of a pancreatic ductal adenocarcinoma, 
but not cholangio- or ampullary carcinoma and that it resolves after surgery in the 
PDAC group but not in the other groups. This is in keeping with the findings of other
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centres132, 234 and although the reasons for this cannot be proven, the theory of 
diabetogenic peptides being released from PDAC is attractive, with S100A8 
remaining a possibility131. In any event, pre- and post-operative glucose levels do not 
affect survival irrespective of the tumour type resected.
The data on sporadic cases in this thesis are biased by the lack of information on 
diabetic status, length of diagnosis and medication taken (both pre and post- 
operatively). Despite these biases (which affect all three groups equally), the degree 
of resolution of hyperglycaemia after surgery in the PDAC group is so overwhelming 
and obviously different to the other two tumour types that the findings are almost 
certainly not an artefact.
In the future serum glucose may be shown to have utility as a tumour marker, with 
new onset diabetics being a potential high risk group for screening. At present, 
however, with screening protocols remaining at an early stage and no cancers yet 
detected and cured in existing higher risk groups, extending screening to lower risk 
groups must remain something for the future.
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4.2.3 Improved Characterisation of the Phenotype of p.A16V
Prior to this thesis analysis of the p.A16V mutation of PRSS1 had been avoided, 
probably due to the low number of available data. This challenge was overcome by 
recruiting as many mutation carriers as possible worldwide. This approach led to 
new challenges which will be discussed in the following sections.
4.2.3.1 Recruitment
EUROPAC has traditionally recruited individuals with a family history indicating a 
genetic predisposition to pancreatitis, prior to any genetic testing. This approach did 
not prove adequate to characterise p.A16V and active recruitment was required from 
Europe and elsewhere, to identify any individual with a p.A16V mutation. This is an 
obvious departure from EUROPAC’s traditional recruitment policy and could have 
introduced bias to the data.
Individuals with p.A16V mutations have been recruited to EUROPAC since the early 
days of the registry, but it has been difficult to define cancer risk and rationally 
include carriers in cancer screening due to the low number of individuals affected by 
pancreatitis and the even lower number of cancers in these kindreds. HP clearly has 
an elevated risk of cancer that far exceeds the risk associated with idiopathic chronic 
pancreatitis and in this thesis I have argued that HP patients represent a suitable 
group for research based screening but sporadic pancreatitics do not. The question 
that must be addressed is whether the pancreatic cancer risk in p.A16V kindreds is 
closest to that of HP kindreds (justifying screening); affected individuals with
231
Modelling of risk in individuals with a possible genetic predisposition for pancreatic cancer
sporadic pancreatitis (who are currently not screened); or a completely new category 
with a new definition. The p.A16V mutation has mainly been described in idiopathic 
pancreatitis188, 191, 216 but in this thesis I have shown that it can also have a 
phenotype consistent with both HP and compound recessive disease.
4.2.S.2 Comparison of p.A16V with Other Mutation Groups
The low number of p.A16V families, combined with the different referral pattern for 
this mutation, made comparison of disease severity between p.A16V and the other 
mutations difficult. Hierarchical analysis has been used in other studies to allow for 
family structure92 but low numbers prevented this in p.A16V. Relatively simplistic 
statistical approaches were adopted for analysis of the p.A16V data and this must be 
taken into account when considering the results, but the great variability in 
penetrance for this mutation is self evident.
The most likely cause for the variability in phenotype is that the p.A16V mutation 
contributes to a multi-gene effect, whereas simple autosomal dominant aetiology is 
accepted for both p.R122H and p.N29l related pancreatitis. Multigene dependence 
may explain the trends seen for both later onset of pancreatitis and diabetes in 
p.A16V but the low numbers make definitive conclusions difficult. There is the 
possibility that rather than being a purely genetic phenomenon, there is an 
interaction between genetic and behavioural factors, such as smoking, but this 
remains unproven with the data being too few to come to a conclusion.
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4.2.3.3 Mechanism of Action of p.A16V
As stated previously, p.R122H and p.N29l have both been linked to either increased 
auto-activation (or reduced deactivation) of cationic trypsinogen217, 218. 
Phenotypically, p.R122H and p.N29l are very similar, although p.R122H results in a 
slightly earlier age of onset as shown in figure 8 of this thesis and in previous reports 
using EUROPAC data92. The p.A16V mutation lies at the edge of the signal peptide 
of trypsinogen and has previously been considered to influence secretion191. It is 
tempting to assume that a secretion defect is inadequate to cause pancreatitis 
without some other genetic or environmental factor being involved, hence the 
difference in phenotype. The mis-folded protein response associated with secretion 
failure is considered to explain the link between the p.R116C mutation of PRSS1 and 
pancreatitis but so far this mutation has only been linked to autosomal dominant 
disease325. In addition, the latest available data indicate that the p.A16V mutant is 
actually secreted normally325. Other work has established that p.A16V increases the 
rate of chymotrypsinogen C (caldecrin) activation of trypsinogen by approximately 
four-fold. This results in accelerated trypsinogen activation in vitro, possibly 
explaining the link with pancreatitis326. How this mechanism could result in the 
variable penetrance seen in p.A16V remains unclear.
Some families do appear to have a phenotype consistent with HP. This suggests 
relatively common polymorphisms in modifier genes within the populations that 
contribute to these families, although it remains possible that this is explained by a 
shared environment. One family has highly aggressive disease restricted to a single
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generation, suggesting a ‘jackpot’ combination of the p.A16V mutation from one side 
of the family and polymorphisms in modifier genes from the other. Relatively few 
families were identified with single cases of pancreatitis but it is likely that a higher 
proportion of such families go unreported and most will never undergo genetic 
testing. Penetrance in such families may require specific environmental exposures 
and the low number of individuals recruited with a phenotype consistent with 
sporadic disease may be the result of EUROPAC’s traditional recruitment criteria.
4.2.3.4 Cancer Risk and p.A16V
Prior to this thesis, almost nothing was known about the pancreatic cancer risk 
associated with the p.A16V mutation. The presence of three cancers in ten p.A16V 
kindreds are fewer than would be expected if the risk in p.A16V kindreds were the 
same as in p.R122H and p.N29l families and it is noteworthy that there were no 
cancers in the families with a phenotype consistent with sporadic disease. The data 
are, however, too few to issue specific guidance on whether individuals from p.A16V 
kindreds should be screened. In terms of current clinical management, it would seem 
sensible to manage p.A16V kindreds by phenotype, offering access to the screening 
study to those with a phenotype consistent with HP, but to not offer it to those whose 
phenotype is consistent with sporadic disease. This can obviously be reviewed as 
more conclusive data become available.
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4.3 Secondary Screening
Setting up the secondary screening studies raised a large number of ethical and 
management issues that will be discussed in the following sections.
4.3.1 Ethics
Obtaining the national ethical approvals for the studies of secondary screening had 
been discussed within EUROPAC for several years and as such, was a significant 
step forward. Going through the process required to obtain national ethical approval 
meant that the foreseeable ethical issues were considered and solved in advance 
but any large trial will inevitably lead to ethical dilemmas that arise on a prospective 
basis. Both anticipated and prospective ethical dilemmas will be discussed in this 
section.
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4.3.2 Prospects for Success
It is of interest that there are now five studies of screening for early pancreatic 
cancer in high risk groups. If the data were pooled, there would be several hundred 
years of patient follow up, but the first curable cancer has yet to be detected. This 
raises the possibility that the level of risk within the study populations does not justify 
either the monetary cost or health risks associated with secondary screening.
The most likely reason for this is inadequate primary screening. When any research 
group is launching a study, both potential participants and the research teams would 
have been keen to start the screening process. It is possible that some individuals 
were entered into the studies where the diagnoses of pancreatic cancers in families 
were thought likely but could not be completely proven, meaning that some 
individuals from kindreds with a normal risk of pancreatic cancer may be participating 
in the screening studies, albeit quite happily. I have already described that 
EUROPAC withdrew one individual from the FPC screening study for exactly this 
reason and that a second individual from a HP kindred was screened before the age 
of 40 years. This increases the number of investigations required to detect a cancer, 
increases costs per cancer detected and has implications in terms of complications 
and side effects caused by unnecessary screening.
A second important method by which to judge the screening protocol is whether it 
fails to detect a cancer that is emerging within one of the patients that is being 
screened. It is important to maintain the screening intervals and minimise patients 
lost to follow up to try to prevent this eventuality. As has been described, no
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prospective cancers have been missed in the EUROPAC cohort undergoing the full 
screening process, although a possible pancreatic cancer did develop in an 
individual at the periphery of the screening programme. Both the University of 
Washington and John Hopkins studies have described interval cancers and there is 
no place for complacency.
A screening program should be judged on the basis of how many investigations and 
years of screening will have to be undertaken to detect each cancer, the costs 
incurred, both financial and in terms of adverse events, and whether the resultant 
surgical treatment can prove curative. Even using 2006 figures300 EUROPAC has 
already spent more than $110 000 on imaging alone and has yet to detect a cancer. 
Determining the success of treatment will require at least five years follow up after 
surgery and therefore falls beyond the scope of this MD project, particularly given the 
rate at which abnormalities are being detected.
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4.3.3 The EUROPAC Secondary Screening Protocol
There is minimal evidence to justify screening for pancreatic cancer by blood testing 
in isolation. However, minimally invasive methods of screening are attractive, and in 
time, the data gathered as part of the secondary screening studies may make it 
possible to show a correlation between changes in blood results and abnormalities 
detectable on imaging. However, the detection of several prospective cancers will be 
needed before the significance of blood tests performed as part of a screening 
program can be quantified.
I would argue that EDS is the best way of imaging normal pancreatic tissue. It is 
minimally invasive and generally well tolerated. The results section of this thesis 
show compliance in the FPC group to be 93% compared to 79% in the HP group. It 
is the primary imaging modality in the FPC group (where the pancreatic tissue is 
normal) and delivers excellent, if user dependent, images. The main drawback with 
EDS is its inability to differentiate cancer from acute or chronic lesions in individuals 
with severe chronic pancreatitis or post-surgical change. This severely limits its use 
in the HP sub-group and EUROPAC does not use EUS as the primary imaging 
modality in these individuals, reserving it for corroborative imaging of lesions shown 
by other modalities and for guiding FNA if recommended by the pancreatic MDT.
The use of CT scanning in preference to MRI deserves an explanation. CT has been 
proven to be able to detect early pancreatic cancers and this has yet to be done in 
the case of magnetic resonance imaging. MRI has definite attractions, principally that 
it does not involve the delivery of a dose of ionising radiation to the study
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participants, a proportion of which are known to have DNA repair mutations. 
However, the aim of this study is to detect early pancreatic cancers. Even if there are 
risks attached and the screening interval needs to be carefully considered, it is 
important to use the modality which is most likely to detect an emerging cancer, 
particularly in view of the prognosis if diagnosis is delayed. When screening BRCA2 
mutation carriers, where the mutation prevents the repair of genetic abnormalities, 
there is a stronger case for using MRI as the primary imaging modality. One must at 
least attempt to avoid or minimise the generation of new potentially non-repairable 
DNA abnormalities by the ionising radiation involved with CT. As the technologies 
continue to improve and research continues, MRI may be shown to be equally as 
effective as CT in detecting early pancreatic cancers. The lack of ionising radiation 
would then make it the non-invasive imaging modality of choice.
The use of ERCP has both advantages and disadvantages. Potentially, molecular 
analysis offers the best chance of detecting lesions that are progressing towards 
PDAC whilst they are still at a pre-malignant stage. It informs the screening interval 
in the EUROPAC screening protocol indicating which at risk individuals merit 
particular attention. If molecular analysis is proven in a prospective trial to indicate 
emerging pancreatic cancer it would become ethically justifiable to remove a 
pancreas on the basis of molecular results alone. It is important, however, to 
differentiate between the resection of an indeterminate lesion in the presence of 
molecular abnormalities and a second scenario of operating where genetic 
abnormalities are present in pancreatic juice, but imaging indicates a normal 
pancreas. The role of molecular analysis could yet take on particular significance in
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the HP group where the role of imaging is limited by the chronic inflammation and 
the risk of post-procedure pancreatitis appears low. However, the two operations 
performed so far were both in HP patients with multiple pancreatic juice 
abnormalities. Histology results indicated that one had PanIN 2 lesions and the other 
had a normal pancreas, showing that it is possible to detect multiple genetic 
abnormalities, including a Tp53 mutation, in the pancreatic juice harvested from a 
histologically normal pancreas. Inevitably it is impossible to know in such patients 
whether the molecular markers were genuinely indicative of a nascent cancer and if 
this were the case, how long it would have taken for this tumour to develop. The only 
way to be sure of this would be to follow patients with mutations detected in juice 
without any surgical intervention. There are obvious ethical difficulties associated 
with such an approach.
Any endoscopic procedure brings a risk of perforation but the real drawback of 
ERCP is the potential for post-procedure acute pancreatitis279. The numbers 
performed remain too small to make meaningful statistical analysis possible, but 
whilst the risk in the HP sub-group, (where inflammation takes place on a chronic 
basis) appears small, the risk in FPC patients is very real. There were no cases of 
pancreatitis amongst the 16 ERCPs performed to August 2008 in the HP group. In 
contrast post-procedure pancreatitis affected 6/16 individuals in the FPC group, with 
just 11 of those procedures successfully obtaining a sample of pancreatic juice.
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4.3.3.1 How the Screening Protocol has Evolved
Prior to the national research ethics application, screening in high risk groups had 
already been initiated using existing local ethical approvals. This took place on an 
evolving basis at several centres. The national application brought several issues 
into focus. Primary screening was improved to increase the probability that 
individuals were at genuine risk before investigations were initiated and the 
secondary screening protocol was first adjusted and then followed. This was both to 
minimise the chance of missing an evolving cancer and to avoid unnecessary 
screening. The protocol will continue to need adjustment as prospective cancers 
develop.
The collection of fasting glucose was added in light of the increasing interest in 
glucose prompted by the results of other groups, particularly those based at the 
Mayo Clinic236,327,328. Screening intervals became more formalised with the definite 
adoption of BUS, followed by CT, as the imaging modalities of choice in the FPC 
group. Initially, any genetic abnormality in the pancreatic juice prompted further 
ERCP for a repeat sample. As the number of results increased, single Kras 
mutations were accepted within the standard surveillance pathway, although an 
abnormality in CDKN2A or Tp53 still triggered the individual being identified for entry 
to the close surveillance pathway.
After the national ethics application was approved, the only change to the protocol 
shown in figure 4 during my period of research was that rectal diclofenac was
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adopted as prophylaxis against post-ERCP pancreatitis in the FPC group. There are 
a range of factors that have been implicated as being associated with post-ERCP 
pancreatitis245, 278. These can be grouped as patient factors and technical factors 
related to the procedure. The evidence linking diclofenac to prophylaxis of 
pancreatitis is mixed280, 281 and the screening cohort offers an opportunity to 
investigate this further. Following the introduction of diclofenac prophylaxis, there 
were no further cases of pancreatitis during my time in post.
An application for an amendment has since been granted to collect duodenal juice 
after administration of secretin to compare molecular results with and without 
cannulation of the pancreatic duct. This should eradicate the risk of pancreatitis but 
is beyond the scope of this MD project and is very likely to form part of my 
successor’s thesis.
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4.3.4 Problematic Screening Scenarios
As mentioned above, the screening study led to both the identification of obvious but 
also some unanticipated ethical and management problems and these will be 
examined in turn.
4.3.4.1 Differences Between FPC and HP Kindreds
Individuals from FPC kindreds generally have normal pancreatic parenchyma. The 
results section of this thesis shows that of the 70 EUROPAC individuals from FPC 
kindreds screened to date, just two suspicious abnormalities have been detected. 
Imaging normal tissue maximises the sensitivity and specificity of imaging and 
molecular analysis should allow more accurate stratification of risk, but there are two 
major disadvantages.
Firstly, individuals from FPC kindreds have an increased risk of post-ERCP 
pancreatitis. There were six cases of pancreatitis out of the 16 ERCPs performed in 
the high risk individuals from FPC kindreds and pancreatic juice was only obtained 
from 11 of the procedures. Whilst diclofenac may reduce the risk and sampling 
duodenal juice after administration of secretin may remove it, this is a potentially 
serious problem that requires careful thought. The causes for this apparent trend 
towards more post-ERCP pancreatitis in this group are unclear, although it could be 
due to cannulation of a normal pancreatic duct.
The second issue is that the generally normal pancreatic parenchyma in the FPC 
group means that any false positive result from multimodality screening would
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potentially prompt the resection of normal pancreatic tissue, with the potential for 
post-surgical endocrine and exocrine pancreatic failure, depending on the procedure 
performed.
In contrast screening of high risk individuals with HP brings its own specific 
problems. The available imaging is far less specific due to the presence of chronic 
pancreatitis, with the low specificity of BUS in the HP group, prompting the adoption 
of CT as the primary imaging modality, despite the associated dose of ionising 
radiation. The stratification offered by molecular analysis is also less marked as at 
least some of the genetic changes used to stratify the risk of an existing or evolving 
cancer can be found in the pancreatic juice of chronic pancreatitics220. ERCP 
appears safe in this group. Of the 16 ERCPs performed, there was one patient that 
experienced post-procedure pain, but there were no cases of pancreatitis. It is 
possible that, as more data are collected, the molecular analysis of pancreatic juice 
could take on a greater relative significance in this group compared to FPC due to 
the problems with imaging, although this statement cannot be supported from the 
limited evidence currently available. Case A has shown that molecular changes as 
advanced as a Tp53 mutation can be detected in pancreatic juice from what is 
subsequently shown to be a histologically normal pancreas. Case B has shown that 
it is not easy to differentiate between inflammatory and malignant cystic lesions. This 
makes it likely that the histology from a higher proportion of operations performed in 
the HP group will subsequently show benign disease, although in Case B’s case, 
PanIN lesions were present.
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The disadvantages of screening HP individuals are offset by the high incidence of 
exocrine and/or exocrine pancreatic failure in this group. It is common for pancreatic 
failure to result from pancreatic resectional surgery329. The Howes paper92 showed 
the cumulative risk (95% Cl) at 50 years of age for exocrine failure to be 37.2% 
(28.5%, 45.8%) and 47.6% (37.1%, 58.1%) for endocrine failure. The two resections 
performed during the period of this MD project have both been on HP patients with 
pre-existing exocrine pancreatic failure.
Pancreatic resections carry a significant risk of both mortality and morbidity, but at 
least when resections are performed, the excised tissue would generally be 
expected to be of chronically diseased, rather than normal tissue - although as case 
A shows, this will not always be the case.
4.3.4.2 Screening Commencement and Cessation
Figures 13 and 21 show that although the risk of pancreatic cancer increases with 
age, it is very low below the age of 40 years even in high risk patients, but then rises 
steadily thereafter. EUROPAC’s decision to start screening from the age of 40 years 
results from this analysis. There are arguments for and against taking 40 years as 
the starting age for screening. If one starts screening earlier than the age of 40 
years, one exposes individuals to unnecessary ionising radiation. Delay raises the 
possibility of a missed cancer.
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Any start point is potentially controversial as it is by definition arbitrary. Cancer risk 
will gradually increase. It will neither be zero at the age of 39 years nor maximal at 
the age of 40.
It is important to try and stratify risk within high risk kindreds on an individual basis. 
Individual risk is obviously the most important factor in determining the point at which 
screening should commence. It can often only be estimated, even after thorough 
primary screening, although the risk stratification model should aid in this.
There must also be sufficient flexibility to allow for special circumstances. Some FPC 
kindreds contain proven cancers that have occurred before the age of 40, with the 
youngest diagnosis known to EUROPAC being at the age of 29 years. Commencing 
screening from 40 in this kindred would cause both a great deal of anxiety to the 
individuals concerned and risk missing a cancer. Similarly, the existence of 
anticipation amongst EUROPAC FPC families has also been identified101 and must 
be taken into account in the multi-disciplinary discussion that takes place at the end 
of the primary screening process.
In HP kindreds 40 years is also the starting age for entry to the screening study. 
EUROPAC data, which were initially presented by Howes et a/92 and also included in 
a review of HP by Vitone et al244, show that the cumulative risk of pancreatic cancer 
in HP kindreds rises from 0.5 to 3.4% between the ages of 40 and 50 years. Cancer 
risk rises exponentially thereafter reaching 33.3% at the age of eighty years. The 
cancer risk at each age must be balanced against the risks involved with an 
experimental screening protocol involving the use of ionising radiation.
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The EUROPAC secondary screening programme is at an early stage, but has not 
missed a cancer so far. On the basis of this (albeit limited) experience, the screening 
programme should continue to start from the age of 40, unless the family history 
indicates a particularly high risk. Flexibility will be required as prospective cancers 
occur both inside and outside the screening population.
The age at which screening should commence is therefore supported by the 
available statistical data, for both FPC and FIP kindreds. The age at which screening 
should cease is, however, more difficult. The published data92, 244 and figure 21 of 
this thesis show that cancer risk increases with age. The year on year risk of an 
individual from an FPC kindred developing cancer begins to decline after the age of 
67, with those unaffected by pancreatic cancer having an increasing chance of not 
being mutation carriers for each subsequent year that they remain unaffected. 
Sporadic cases of pancreatic cancer will also occur in high risk families with an 
incidence that increases with age. In the HP kindreds no link has been shown 
between cancer risk and the number of years of pancreatitis, but there is no specific 
age when the risk of cancer starts to reduce.
Choosing the time at which to stop screening is ethically complex. All screening 
programmes have a date at which screening stops. This may be due to risk-benefit 
or financial factors. It is clinically and ethically difficult to screen somebody for early 
pancreatic cancer for many years and to stop this, for example when an individual 
reaches the age of 70. At present the decision on when to stop screening in both 
FPC and HP kindreds is being made by an individual’s consultant clinician and is
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largely determined by the individual’s ability to withstand major pancreatic surgery 
were a tumour to be discovered. However, this is one area that needs to be 
subjected to ongoing re-assessment as the screening studies continue. On the 
basis of experience with secondary screening to date, there is no indication to 
change the current policy and decisions should continue to be made by responsible 
clinicians in conjunction with the screening participant.
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4.3.4.3 Screening Individuals with Post-surgical Changes
A further dilemma that should be considered is whether to attempt to screen 
individuals, predominantly from HP kindreds that have had a previous partial 
pancreatectomy. In time, this scenario may also become relevant to individuals from 
the FPC group that have already had a Pylorus Preserving Kausch-Whipple 
procedure (PPKW) for a pancreatic tumour. At present there are insufficient data to 
make an evidence based decision, but if one accepts the PanIN theory and PanINs 
have been shown to develop throughout the pancreas, it is logical that tumours could 
arise within the pancreatic remnant. In terms of screening this raises several 
problems that will be discussed in the following paragraphs.
Firstly it would be difficult to detect an emerging lesion in the presence of post- 
surgical change. If a new lesion were to emerge, imaging would probably detect it 
later and struggle to differentiate between possible aetiologies. In cases where there 
are problems with imaging, the molecular analysis could take on a greater 
significance, but as figure 23 shows, the surgical reconstruction performed as part of 
a pylorus preserving Kausch-Whipple (PPKW) procedure means that the duct is not 
readily accessible with an endoscope. Whether juice could be collected from these 
participants after secretin and whether its analysis would mean anything remains to 
be proven.
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Figure 23: Reconstruction of Gastro-intestinal Tract after Whipples Procedure
Hepaticoj ujenostomy 
(re-establishes
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Figure illustrating the reconstruction of the gastrointestinal tract performed following the 
resection of the pancreatic head performed during a pylorus preserving Kausch-Whipple 
procedure (PPKW). Copyrighted and used with permission of Mayo Foundation for Medical 
Education and Research, all rights reserved.
The secondary screening programme has, as yet, gathered too few data to give a 
firm recommendation on screening pancreatic remnants for early cancers but I feel 
that collaborating clinicians should continue to make screening decisions on an 
individual basis and data collection should continue in these challenging participants.
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4.3.4.4 HP Screening Dilemmas
This section contains a discussion on screening in three different but related groups 
of individuals either with pancreatitis or from HP kindreds. They will be considered in 
turn, but my attitude to screening all three groups is similar.
Should Those with Chronic Pancreatitis be Screened?
Those with chronic pancreatitis have long been known to have an elevated risk of 
pancreatic cancer134, 330,331. As outlined in the introduction, there are also mutations 
of the SPINK1 and CFTR genes that are associated with the development of 
pancreatitis, rather than being causative mutations in the true sense. The cancer risk 
in chronic pancreatitis from a non-HP aetiology62 has been estimated at 15%, 
obviously far lower than in true HP (see figure 21) or FPC (see figure 13). Screening 
is proving challenging enough in the groups at highest risk and my opinion is that 
those at lower risk should not be put through the rigours of a screening study until 
the protocol has been optimised. Once the specificity of multi-modality testing has 
been optimised, screening may become justifiable if the potential number of lives 
saved outweighs the morbidity and mortality of intervention on the inevitable false 
positives.
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Should Unaffected Carriers of HP Mutations be Screened?
The calculation of lifetime risk of pancreatic cancer in individuals affected by HP has 
been calculated at 35-53%91"93. Cancer in HP mutation carriers unaffected by 
pancreatitis is very rare but the diagnosis of two cancers in separate individuals in 
exactly this position described earlier in this thesis has raised the question as to 
whether such individuals should be screened.
The exact cause of pancreatic cancer in HP individuals is unproven. Chronic 
inflammatory change is an attractive theory, but as stated above there is no proven 
link between cancer risk and number of years of pancreatitis in the EUROPAC 
population. The diagnosis of cancer in the two asymptomatic carriers also raises the 
possibility that the aetiology of cancer risk is not exclusively related to pancreatitis.
At present the decision whether to offer screening is being taken by the responsible 
clinician, who makes an assessment of risk and benefit and the individual’s wishes. I 
am only aware of these two cases of pancreatic cancer in unaffected HP mutation 
carriers worldwide. The adverse events section of this thesis shows that the 
screening process is not risk free and my opinion on screening unaffected mutation 
carriers is similar to that relating to those with non-hereditary chronic pancreatitis. I 
believe the screening protocols should be optimised in populations with better 
defined risk before potentially being extended to groups where the risk is lower or 
less well defined.
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Should Affected Individuals with very rare PRSS1 Mutations be Screened?
There are other kindreds with at least one and often several cases of pancreatitis 
with a proven PRSS1 mutation which is presumed to be the cause of the disease 
within the kindred. Although the cancer risk in p.R122H and p.N29l kindreds can be 
proven, quantifying a cancer risk (or even proving that the pancreatitis is genetic) in 
kindreds with very rare PRSS1 mutations is statistically impossible. In kindreds with 
a p.N29T mutation and a phenotype consistent with HP, it is sensible to manage 
them in the same was as HP kindreds with a p.N29l mutations. The cancer risk in 
pancreatitics risk with other very rare PRSS1 mutations such as p.R116C or p.E79K 
cannot be quantified. My own opinion is that screening decisions in these kindreds 
should be similar to those in the p.A16V kindreds, where decisions are made on the 
basis of phenotype. If the phenotype is consistent with HP or IPCA, then access to 
screening should be offered. Where the phenotype is consistent with idiopathic 
disease, then those individuals should be treated in a similar fashion to those with 
idiopathic or non-HP chronic pancreatitis, with access to the screening study 
considered only after the protocol has been optimised.
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4.3.4.S What Should be the Indications for Surgery?
Whenever a potentially significant abnormality is detected in a study participant, the 
case is discussed at the supra-regional pancreatic MDT. Pre-operative decision 
making is subjected to local peer review in that venue. As long as there is a general 
consensus from MDT members that surgery is indicated, participants are offered 
resection. Those from the screening study are treated exactly the same as all other 
individuals discussed at the MDT, with the main indication for surgery being the 
presence of a potentially resectable mass on imaging in the absence of metastatic 
disease. It must be borne in mind that an unknown percentage of the detected 
lesions in the HP group will be inflammatory, as was the case in the second of the 
two resections performed to date.
Can Prophylactic Surgery be Justified?
Given the current limitations of screening, one definite way of removing the risk of 
pancreatic cancer in high risk individuals is prophylactic total pancreatectomy. Those 
undergoing such surgery would not only face the ~5% mortality risk of major 
pancreatic surgery332 but would by definition require both exocrine pancreatic 
supplements and insulin for life333,334 . The resultant diabetes would often be difficult 
to control335. Prophylactic surgery is a radical step but, given the personal 
experiences of pancreatic cancer in EUROPAC kindreds, is not an unusual request 
from individuals contacting the study office.
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When discussing prophylactic total pancreatectomy, it is important to differentiate 
between the FPC group, with their normal pancreatic parenchyma and the HP group 
with what is normally chronically diseased tissue, with the individual often diagnosed 
with either exocrine and/or endocrine pancreatic failure. I am unaware of any 
individual from a FPC kindred that has ever had prophylactic pancreatectomy, but a 
total pancreatectomy in a HP individual that has already been diagnosed with 
exocrine and pancreatic failure is less controversial. If there is a proven HP mutation, 
lifetime pancreatic cancer risk exceeds 40% and individuals may see the 5% 
mortality risk of surgery as acceptable in an attempt to remove this. In addition it may 
bring the added benefit of relief from the symptoms of chronic pancreatitis.
Can Surgery be Justified on the Basis of the Results of Molecular Analysis?
The ideal time for surgical intervention would be when development of malignancy 
becomes inevitable within a pre-malignant lesion but before any emerging tumour 
either becomes locally invasive or undergoes metastasis. At present this window 
cannot be accurately defined. In time, the molecular analysis of pancreatic juice may 
permit identification of a ‘pre-malignant window’, but the initial results from the 
screening study have raised more questions than they have answered, with one of 
the resected pancreata being histologically normal, despite the presence of multiple 
genetic abnormalities including a Tp53 mutation in the pancreatic juice. Data 
collection should continue, but it is unclear how long it will take to show whether the 
molecular analysis has any clinical role other than the phasing of screening 
investigations, or indeed, whether this is even justified.
255
Modelling of risk in individuals with a possible genetic predisposition for pancreatic cancer
Which Operation Should be Offered?
If participants in the screening study come to surgery, the options are either a 
Whipple procedure or a total pancreatectomy. In Whipple’s procedure, the tail of the 
pancreas is retained (see figure 23). The morbidity of post-operative pancreatic 
failure would be reduced but this must be offset against the risk of a further lesion in 
the pancreatic remnant, which as stated above, would be both difficult to detect and 
may not be easy to remove. Although it is more common for pancreatic cancers to 
arise in the head rather than the body or tail336, it has already been shown that 
PanIN lesions occur throughout the entire pancreas337, as was true with Case B 
described in this thesis. The principal aim of screening and the associated surgery is 
related to cancer detection and cure. Despite the increased morbidity of post-surgical 
pancreatic failure induced by a total pancreatectomy rather than Whipple’s 
procedure, resection of the entire pancreas (albeit duodenum and spleen preserving 
where appropriate), appears the best choice for the majority of patients that come to 
surgery with early lesions as a result of screening.
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4.3.5 Operations so far
To date two study participants from EUROPAC secondary screening study have 
undergone pancreatic resection as a result of investigation results. The first resection 
(Case A), described in section 3.3.3.2 is interesting for a number of reasons.
Baseline imaging showed normal pancreatic parenchyma on CT, later confirmed on 
EUS, but molecular analysis showed all three genetic abnormalities associated with 
pancreatic cancer to be either present or outside of the normal range. Repeating the 
juice analysis showed ongoing abnormalities in Kras and CDKN2A but the second 
Tp53 result was Wild Type (normal). Following resection, her pancreatic histology 
was found to be normal, with no evidence of either PanIN lesions or malignancy.
This obviously raises a few questions. The genetic testing is performed on free DNA 
that is shed into pancreatic juice following necrosis or abortive apoptosis. It has 
already been theorised that the presence of Kras mutations would be predicted to 
cause senescence in any cell harbouring the mutation338, but it is interesting that two 
of the three Kras mutations were not detected and a new mutation was observed in 
the second test. The main mutation in both cases was p.G12R suggesting a possible 
clonal population but with a mosaic of the of the K-Ras mutant cells around it, 
perhaps dying due to lack of protective tumour suppressive mutations. In addition, 
the p53 test showed a mutation (p.D245G) which was no longer present in a second 
sample of pancreatic juice. It could be that the cells that had shed the mutated Kras 
and Tp53 sequences had undergone apoptosis and were no longer present at the
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time the second sample of juice was obtained. The data are too few to come to a 
definite conclusion.
Histological results following Case A’s resection showed the presence of normal 
pancreatic tissue in all the examined blocks, despite a thorough search for PanIN 
lesions. This undermines the attractive theory that Kras mutations, CDKN2A 
hypermethylation and Tp53 mutations could be used as markers of increasingly 
abnormal changes along the metaplasia-dysplasia pathway as outlined in figure 1. 
Case B, described in section 3.3.3.3, also had both a Kras mutation and CDKN2A 
hypermethylation in her pancreatic juice. Her subsequent histology sectioned the 
entire pancreas. There were numerous foci of PanIN 1a and 1b with possible foci of 
PanlN2, but no neoplasia. These histological findings are in keeping with the 
theories summarised in figure 1.
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4.3.6 Cost Analysis and Cost Effectiveness
Screening for early pancreatic cancer is not cheap. In an environment where 
demand for healthcare outstrips the supply, then pancreatic screening requires the 
diversion of resources from other treatment priorities and it is important that any 
expenditure delivers an overall health benefit.
The cost of screening for pancreatic cancer in Peutz-Jeghers kindreds has 
previously been calculated to be $350 000 per life saved300, although it may be 
possible to reduce this cost significantly by use of molecular analysis of pancreatic 
juice. To date EUROPAC has spent at least $113 000 on imaging and pancreatic 
juice collection, without detecting a cancer. It is likely that the number of 
investigations required per cancer detected will be reduced as the protocol is 
optimised, but the true cost of screening for pancreatic cancer will only become 
apparent after several cases have been identified.
If we consider that there are at least five centres screening high risk individuals for 
pancreatic cancer and one has yet to be discovered at a curable stage, this supports 
the FaPaCa conclusion297 that screening should not be extended beyond the study 
setting.
Whether screening for early pancreatic cancer ever becomes an NHS service will 
depend on total cost per life saved once the protocol has been optimised. A national 
programme would require National Institute of Clinical excellence (NICE) approval 
and would have to compare with other screening programmes. The UK breast
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cancer screening programme has previously been calculated to cost in the region of 
£25 000 per life saved339.
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4.3.7 Adverse Events
There were two areas where there were significant adverse events related to 
screening process. These related to the death of one individual from carcinomatosis 
with an unknown primary and to a number of cases of acute pancreatitis triggered by 
ERCPs performed for the collection of pancreatic juice.
The death from carcinomatosis was in an individual registered by the Liverpool office 
prior to my research period. They were referred to a screening clinician nearer to the 
individual’s home address in November 2004 for screening investigations. Her 
screening results were first seen by the Liverpool team in the late Spring of 2008 
when all screening results that had not been copied to the Liverpool EUROPAC 
office at the time they were performed were being checked and collated (with local 
site visits where necessary) as part of work performed for this thesis.
The individual had both a baseline EUS and CT in July and August 2005 
respectively. The EUS was normal. The CT showed mild heterogeneity of the lateral 
aspect of the pancreatic head, which was commented on and an MR was suggested. 
An MRCP performed in January 2006 was reported normal. The individual next had 
a CA19-9 result of 1726 kU/L in November 2006. A CT was performed that month 
that showed no interval change from the baseline scan in 2005 and an EUS was 
repeated in January 2007, which was again normal. The patient was reviewed in the 
clinic in June 2007. Their major symptom at that point was a change in bowel habit 
to constipation. A colonoscopy was requested along with repeat tumour markers. 
The CA19-9 result came back at 6704 kU/L. The individual was subsequently
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diagnosed with carcinomatosis with an unknown primary. A biopsy showed 
adenocarcinoma. She died in 2008 and despite the normal imaging performed in the 
preceding years, it remains possible that the primary malignancy was a pancreatic 
adenocarcinoma.
This case was managed by a satellite centre prior to the introduction of the screening 
protocol summarised in figure 4. If this was indeed a case of pancreatic cancer, my 
interpretation is that it developed despite ‘close surveillance’. It is difficult to make 
any definite decisions from a single case of possible pancreatic cancer, but along 
with pancreatic cancers that have developed within the US screening programmes, it 
raises the possibility that changes on imaging can occur late in the process of cancer 
development.
The second area that must be regarded as an adverse event is the rate of post- 
ERCP pancreatitis following pancreatic juice collection. Nationally, the expected rate 
of acute pancreatitis after ERCP is about 5%277 and the vast majority of attacks were 
expected to be mild. Although numbers were too small for definitive conclusions, at 
one point the rate of post-ERCP pancreatitis in the FPC group reached 50%, with 
one case of non-infected pancreatic necrosis and subsequent exocrine pancreatic 
failure. To exacerbate this, it was not always easy to collect the pancreatic juice. 
Even at the end of my research period, of the 16 ERCPs performed, just 11 led to 
successful juice collection. The post-ERCP acute pancreatitis in the FPC secondary 
screening population prompted the research team to contact the responsible 
research ethics committee to ask for permission to use diclofenac per rectum as
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prophylaxis against pancreatitis. This was adopted on an interim basis after the 12th 
ERCP and there were no further episodes of pancreatitis in the subsequent four 
cases to the time of guillotine.
The majority of screening patients are intelligent and articulate and sought out 
EUROPAC to gain access to secondary screening. The risks and benefits of each 
test were outlined in the patient information sheets and whilst I did not collect data 
for this, my own experience was that most individuals wanted to discuss these risks 
in detail before consenting to undergo them. They were particularly interested in 
discussing the balance of risk and benefit with regard to ERCP, where the patient 
information sheet outlined the potential risk of pancreatitis, but the immediate and 
direct benefit to the individual was less tangible than with imaging investigations.
My opinion is that data collection should continue in consenting members of both the 
FPC and HP kindreds, but if the molecular analysis of post-secretin duodenal juice 
can be validated, the post-ERCP pancreatitis problem will have been permanently 
resolved.
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4.3.8 The Balance of Risk and Benefit
Most members of FPC and HP kindreds are enthusiastic about accessing the 
screening study but the benefits remain unproven. To date, no pancreatic cancer has 
ever been detected in an organised screening study at a curable stage. It remains to 
be shown whether screening will lead to earlier treatment and whether this can prove 
curative.
The risks of the screening programme need to be considered carefully. These are 
physical and psychological. The psychological risks involve the heightening of 
anxiety and confirmation of a diagnosis with a genetic syndrome may lead to a 
reduction in self esteem or even depression. The diagnosis could lead to 
discrimination from insurers and employers, but there are also physical risks that are 
potentially even more serious. Blood testing risks are minimal but the imaging needs 
more consideration. EDS is the single test that is most likely to discover an early 
pancreatic cancer but it carries the risk of perforation of a hollow viscus. The risk of 
perforation from an endoscopic procedure is low279 but if it did occur it could be life 
threatening and surgical intervention would probably be necessary. The use of 
repeated CT scans exposes the participant to the risk of ionising radiation, which has 
been estimated by the US Federal Drug Agency as 10 Milli-Sieverts (mSv) per 
abdominal CT scan268. To put this into perspective, the UK legal dose limit for adult 
whole-body exposure is currently 20 mSv/year, but in 1997 the average annual dose 
in the UK nuclear industry was around 0.6 mSv340,341.
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The collection of pancreatic juice at ERCP contains an element of risk as discussed 
previously. The risk of pancreatitis after ERCP is thought to be in the region of 5%, 
although it was much higher than this in the FPC sub-group until diclofenac was 
introduced. The most severe case of pancreatitis induced through screening 
developed sterile necrosis and exocrine pancreatic failure. At worst, ERCP could 
lead to infected pancreatic necrosis and even death.
Molecular analysis may permit a reduction in the screening interval and total 
radiation exposure, but it remains possible that the reduction in mortality from 
pancreatic cancer screening would need to be offset against one or more deaths 
from acute pancreatitis. Both the University of Washington and Johns Hopkins 
groups have previously used ERCP for imaging in the search for PanINs. Johns 
Hopkins have discontinued ERCP for imaging as it was felt that the risks outweighed 
the gains295. The above risks and benefits are not simple to analyse and quantify but 
they will need to be considered on an ongoing basis as the project develops. As 
stated previously, the EUROPAC secondary screening study, has yet to detect a 
cancer. The use of ERCP has avoided some radiation load from annual 
investigations, but it could certainly be argued that the six cases of pancreatitis 
induced so far exceeds the benefit derived.
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4.4 A Reassessment of the Aims and Objectives
The aims and objectives are laid out in section 1.8 but in summary the first aim was 
improving risk stratification on an individual basis in both the FPC and HP groups 
and required: further characterisation of the phenotype associated with PRSS1 
mutations; investigation of whether serum fasting glucose levels can differentiate 
between individuals from FPC kindreds with differing risk profiles; the development 
of a computer model capable of stratifying risk in high risk individuals from FPC 
kindreds.
The second aim was piloting a trial of secondary screening in high risk individuals 
and required the achievement of set objectives namely: obtaining the ethical 
approvals; developing a multi-centre collaborative screening network; continuing with 
effective primary screening to identify high risk individuals; and the testing and 
development of the EUROPAC secondary screening protocol.
The first aim (and associated objectives) was achieved. If one is aiming to screen 
individuals for cancer, risk stratification on a familial level alone is unsatisfactory and 
the ideal must be to perform this on an individual basis. As previously stated the 
cancer risk in the more common PRSS1 mutations is well established but clinical 
characterisation of the p.A16V mutation had never previously been attempted. The 
investigation of the relationship between serum fasting glucose and differing risk 
profiles has not shown significant results to date and achieved less than I had hoped 
for at commencement of the project. The main limiting step was the lack of early 
lesions detected in the screening study, but data collection is ongoing and as
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prospective cancers develop, retrospective trends in serum glucose results may 
identify a new modality for early diagnosis of pancreatic cancer. The final aspect of 
improving risk stratification on an individual basis in FPC was the development of the 
mathematical model and its online template. This had been done before in Breast- 
Ovarian cancer but had never been attempted or achieved in FPC. The format 
adopted means that the model can be adjusted and improved as more data become 
available and prospective cancers develop. It has considerable potential in primary 
screening, risk counselling and identification of individuals for secondary screening. I 
believe that this will become a part of routine clinical practice in this specialised field.
The second aim (and associated objectives) was again either fully or partially 
achieved. The trial was piloted, the ethical approvals were granted and both existing 
and new collaborators were utilised to deliver national coverage to permit individuals 
to enter the screening study, with individuals screened as close to their home 
address as possible. Primary screening continued with 114 new families recruited, 
with both new and existing families becoming better characterised. The quality of the 
data collated and stored was improved, cancer deaths were proven more effectively 
and only genuine families that met all the inclusion criteria were permitted access to 
the secondary screening study. Within the screening studies: collection of glucose 
data was added; imaging intervals were strictly defined and delivered; and as greater 
numbers of juice analysis results became available, single Kras mutations were 
accepted within the standard surveillance pathway. The testing and development of
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the EUROPAC secondary screening protocol was somewhat limited by the failure to 
detect the first ever pancreatic cancer as part of an organised screening programme, 
but accepting these limitations, the protocol has developed into a deliverable and 
testable structure that is delivered through a number of regional screening centres. 
Prospective cancers will occur in the screening population. It remains to be proven 
whether these will be detected at a curable stage and whether the financial cost of 
each cancer detected (and/or life saved) will lead to an expansion of screening for 
early pancreatic cancer beyond the research setting.
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5 Conclusion
There has been considerable progress in both FPC and HP and screening over the 
past few years. The HP mutations are better characterised than ever, although there 
is more work to be done on the very rare PRSS1 mutations and the mutations 
associated with, but not causing pancreatitis. The computer model can now put the 
first ever individualised value on cancer risk for individuals from high risk groups. 
Potential future developments include the detection of the first screening cancer and 
in the longer term, the characterisation of the pre-malignant pathway and clarification 
of the optimal time for surgical intervention.
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6 Appendix
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6.1 The Patient Information Sheet for the EUROPAC FPC 
Secondary Screening Study
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The European Registry of Hereditary Pancreatic Diseases
EUROPAC Study Co-ordinator, 5th Floor UCD Block, Royal Liverpool University
Hospital, Daulby Street,
Liverpool, L69 3GA, United Kingdom
Tel: +44 151 706 4168 europac@liv.ac.uk www.europac-
org.euFax: +44 151 706 5826
Patient Information Sheet
SECONDARY SCREENING IN FAMILIAL PANCREATIC CANCER
Part One
We would like to invite you to take part in a research study. Before you decide, you 
need to understand why the research is being done and what it would involve for 
you. Please take time to read the following information carefully. Talk to others about 
the study if you wish.
This information sheet is split into two parts. Part one will tell you the purpose of the 
study and what will happen to you if you take part. If you are interested in the study, 
part two gives more detailed background information. Please contact the EUROPAC 
office using the details above if you have any questions or would like to clarify 
anything. Take time to think everything through before taking a decision.
Key Facts
• This is a research study to see if it is possible to detect early pancreatic 
cancer in individuals from families that have a risk that is greater than the 
general population.
• The best chance of long term cure from pancreatic cancer is through early 
diagnosis.
• There is no single test that can detect early pancreatic cancer.
• The aim is to combine several methods so that the overall screening process 
will be effective.
• You can choose to have any of the available tests performed and choose not 
to have others.
• There is no guarantee that the process will detect early cancers or if a cancer 
were found whether it would be early enough to cure it.
• You can change your mind at any point and deciding not to be screened does 
not effect your ongoing involvement with the registry.
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1.1 What is the purpose of study?
The aim of this study is to detect pancreatic cancer either as it emerges or as soon 
as possible after it emerges. This may increase the chance of a cure. Pancreatic 
screening is difficult. There is no single test that will detect every emerging cancer. 
The hope is to combine a number of tests to increase the overall accuracy of the 
screen.
1.2 Why have I been invited?
You have been invited to participate in this trial as you are already registered with 
the EUROPAC study. It is rare to have a genetic cause for pancreatic cancer but the 
information you provided when you joined the study shows that this is a possibility in 
your family. There are several hundred people in a similar position to you across the 
country.
When you registered with EUROPAC you should have had a discussion about your 
personal circumstances that relate to your risk of pancreatic cancer compared to the 
general population and had the opportunity to discuss related issues and questions 
with a genetic counsellor and/or a consultant pancreatic specialist. Your family 
history indicates that you may have an increased risk.
1.3 Do I have to take part?
It is up to you to decide. We will describe the study, go through the information sheet 
and leave it with you as your copy. We will ask you to sign a consent form to show 
that you have agreed to take part. Secondary screening is a separate study to the 
registry that you already take part in. If you choose not to become involved with the 
screening study, it does not affect your position with the registry in any way. If you 
wish to participate in the screening study, you can take up any or all of the proposed 
screening tools. If you become involved you can change your mind at any time 
without giving a reason. This will not affect the standard of care you receive in any 
way.
1.4 What will happen if I take part?
The first step in taking part in the screening study is to see a specialist in an 
appropriate pancreatic clinic. If you are not under a specialist or your specialist is not 
involved with the screening study, you will need to be referred to a specialist that is. 
This would normally be via your GP. The EUROPAC office will be able to provide 
contact details of the most appropriate clinician for you to be referred to. The clinic 
appointment will be for a discussion about the screening process and to check that 
there are no reasons why you should not take part.
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If you decide to go ahead, a set of baseline investigations will be arranged. Blood 
tests, scans and an analysis of your pancreatic juice are available. You can choose 
to take up any or all of the options. They will be described in detail in the section 1.7. 
Depending on the results, the tests will either be repeated on an annual or three 
yearly basis.
You would normally be followed up in the clinic once a year. This visit would last IQ- 
20 minutes and comprise of a review of your case, a discussion between you and 
your specialist, an examination if appropriate and your next investigations would be 
arranged. This follow up in the clinic is likely to continue at the end of the trial. If you 
chose to take up blood testing this would normally be conducted at the outpatient 
clinic.
The imaging tests and the procedure to gather your pancreatic juice would require 
you to attend a hospital on separate occasions. The imaging is likely to take an hour 
or two and you would be able to go home afterwards. An ERCP may require an 
overnight stay.
This is a long term project and will last for ten years, the blood tests and imaging can 
all be described as best medical management in high risk patients. The collection of 
pancreatic juice for molecular analysis is a research investigation. The findings are 
convincing within a laboratory setting but the molecular analysis has not been proven 
in living subjects in an ongoing trial.
There is no aspect of normal medical treatment that will be withheld as part of this 
trial and at the end of the trial it is expected that the results will be published in the 
scientific literature. You would not be identifiable to others as a result of any 
publications.
1.5 Expenses and Payments
There are no funds available for payments to those participating in this study.
1.6 What will I have to do?
The first step is to come to the clinic. If you decide to go ahead, the next step will be 
the blood and imaging tests. One of the blood tests (CA19-9) will normally be 
performed after the clinic but if the clinic is in the afternoon, the fasting glucose may 
require you to have a second sample taken as it is important not to have consumed 
any solids or any liquids other than water. This could be taken on a separate visit to 
the hospital or by staff at your GP practice.
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The imaging tests Computed Tomography (CT) and Endoluminal Ultrasound (BUS) 
will require a visit to hospital. These will be at your nearest regional pancreatic centre 
and you would not need to stay overnight. The CT takes 10-15 minutes. You would 
need to lie still on a trolley whilst you move in and out of the machine but the scan 
does not hurt and it is rare to feel claustrophobic with modern scanners.
The BUS would not require you to stay overnight at the hospital. Again, it would be 
performed at your nearest pancreatic centre. The procedure will be described in the 
section 1.7.
Endoscopic Retrograde Cholangio-Pancreatography (ERCP) is used for collection of 
pancreatic juice. This is a similar type of test to the BUS and would be performed at 
the same centre. The purpose is to take a sample of your pancreatic juice rather 
than to gain an image of the pancreas. You would need sedation for this and would 
need either a couple of hours afterwards to rest or perhaps to stay in overnight.
If you decide to take up blood tests only, these would be repeated on an annual 
basis. If you opted for blood tests and imaging this would again be annual. If you had 
an ERCP and the DNA in your pancreatic juice was normal, we would repeat your 
investigations within a three year cycle, or if changes were detected the imaging 
would be annual. If you are having annual testing, typically, you would be asked to 
attend one outpatient clinic per year and have one investigation.
1.7 What is being tested?
None of the blood tests or imaging techniques are ideal. The aim is to see what 
combination of tests gives the best chance of picking up an early cancer and the 
least chance of missing one.
The methods that can be taken up include:
Blood Tests Fasting Glucose
CA19-9
Imaging Endoluminal Ultrasound (EUS)
Computed Tomography (CT)
Molecular Methods
Endoscopic Retrograde Cholangio-Pancreatography (ERCP) to 
allow molecular analysis of pancreatic juice
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Fasting glucose is a simple test to check the sugar level in your blood. It increases if 
you become diabetic.
The CA19-9 is a marker that can be detected in your blood. It may increase if a 
pancreatic cancer is present, but also may not. It can become raised when there is 
no cancer present so is an incomplete test.
The EUS is a telescope test where a camera is inserted through your mouth and 
down your gullet into your stomach. Once inside the stomach, ultrasound images of 
your pancreas are obtained. As the organs are so close a very high definition picture 
can be obtained.
The CT is a scan that combines conventional X-ray technology and a computer to 
build up a three dimensional image of your insides.
The ERCP is similar to the EUS but the scope is passed a little further and a small 
plastic tube is used to take juice from the site where your pancreas drains into your 
small intestine. Changes in your pancreatic juice DNA (the genetic material that has 
come from the cells in your pancreas) could signify a possible early tumour that 
cannot be seen on the imaging investigations. These DNA changes (if found) will 
have arisen during your lifetime and will not be the sort of DNA changes that can be 
passed on to your children.
If the investigations suggested a possible problem, then your case would be 
discussed at a special meeting of pancreatic experts to decide on a plan of 
treatment. They may recommend continued surveillance, further tests to clarify the 
findings or even an operation if a growth were present that could be removed.
1.8 What are the alternatives?
You can take up any or all of the screening investigations. An alternative is not to 
participate in the screening study and continue as you have done until today.
1.9 What are the possible disadvantages to taking part?
All the screening methods have advantages and disadvantages.
The blood tests are very low risk and a serious complication would be very rare. All 
the equipment that would be used will be sterile, single use equipment in common 
use within the NHS. A bruise would be a relatively common complication.
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A CT scan builds up an image by passing radiation through the body. It is known 
that moderate and high doses of radiation are damaging and at worst could even 
cause a cancer. The risk of cancer from each CT scan is described as low and 
calculated at somewhere between a one in a thousand and one in ten thousand 
chance. A single CT scan of the abdomen has been calculated to be the equivalent 
of a few years of normal background radiation. Your baseline imaging is likely to 
show that you have a normal pancreas. In this case EUS would be the main method 
of imaging for you. This involves no radiation and your total radiation exposure over 
the course of the study would therefore be limited.
The EUS involves the insertion of a scope through the mouth, down the gullet and 
into the stomach, where images of the pancreas are obtained by a very high 
definition ultrasound. There is a very small chance of the instrument puncturing the 
gullet or stomach, this would be expected to occur somewhere between one in a 
thousand and one in ten thousand times the procedure is performed. If this did 
happen, depending on the site of the damage, this may require an operation and in 
extreme cases could be fatal.
The ERCP carries a similar risk of puncturing an organ as the EUS and involves a 
low dose of radiation. In addition it carries a risk of acute pancreatitis. This is 
inflammation of the pancreas that comes on suddenly. The exact cause is unclear 
but is due to irritating the pancreas when the juice is collected. Overall the rate of 
post-ERCP pancreatitis in the UK is 1.6%. It may be more common in people with a 
normal pancreas, but at present a rate cannot be calculated. Attacks of acute 
pancreatitis are normally mild and would necessitate a short stay in hospital whilst 
the associated pain and nausea settle. About every sixth attack is classed as 
‘severe’ and there can be complications. These complications can be serious and 
even fatal, although the chance of this is about 1 in 5000.
Other disadvantages
You may find that having screening investigations makes you more anxious about 
your health and your cancer risk. This is difficult to predict. Other people find having 
the investigations reassuring as it helps to put their mind at rest.
Any of the blood and imaging methods could detect a problem that is unrelated to 
pancreatic cancer. CT scans are very effective at detecting problems within the body 
and there is always the possibility of finding something unexpected. If this falls within 
the expertise of the clinician that would oversee the screening process for you, he or 
she would deal with this. If appropriate, you would be referred to another specialist.
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It is possible that the screening investigations could detect an apparent growth in the 
pancreas. Growths can be ‘benign’, (for example, inflammation or scarring) or could 
be a cancer. It is difficult to tell the difference between the two before surgery. If a 
growth was found and it is possible to remove it, your consultant would discuss your 
options with you in the clinic. An operation may be offered. There are risks to any 
operation and it is possible that you could have an operation only to be told after the 
specimen has been fully analysed that there is no cancer present.
1.10 What are the side effects of any treatment received?
Treatment for pancreatic cancer is surgery, where possible. Pancreatic surgery is a 
major undertaking. All operations carry a risk; approximately 1-3% of all people that 
present clinically with pancreatic cancer and have the cancer removed, die without 
leaving hospital. Individuals that have growths detected by screening would be 
younger and healthier than the group that present clinically but the risk remains 
significant. A more likely scenario is that after leaving hospital you may require 
enzyme supplements and insulin for life.
1.11 Ionising radiation
The implications of repeated CT scanning and ERCP have been described in section 
1.9.
1.12 Harm to the unborn child
Men
Damage to male sperm as a result of this study should not occur as any radiation 
exposure would affect the upper part of the abdomen, well away from the genital 
organs.
Women
It is possible that the radiation exposure involved with this study could damage an 
unborn child. If there is any doubt about possible pregnancy you may be asked to 
have a pregnancy test. Women who could become pregnant must use an effective 
form of contraception during the course of this study. Any woman that becomes 
pregnant during the course of the study should immediately inform the EUROPAC 
office.
1.13 What are the possible benefits?
Your family history suggests an increased risk of developing pancreatic cancer. If 
you developed one during the period of screening, it is hoped that this would be 
detected and earlier surgical treatment may achieve a cure.
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1.14 What happens when the research stops?
This depends on the outcome of the study. After the end of the term of the study (ten 
years), if an effective screening protocol has been developed, it is likely to continue, 
funded by the NHS. If the proposed investigations are shown to be ineffective at 
accurately diagnosing early pancreatic cancer at a time when it can be cured, 
screening would be unlikely to continue to be offered in its present form through the 
NHS. Individual consultants may continue to offer some ongoing surveillance via the 
NHS within families with an elevated risk, depending on their own personal practice.
1.15 What if there is a problem?
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. More detailed information on this 
will be covered in part two.
1.16 Will my taking part be confidential?
Yes, we will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in part two.
If the information in part one has interested you and you are considering 
participating in the study, please read the additional information in part two 
before making a decision.
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Part Two
2.1 What if new relevant information becomes available?
New information about pancreatic cancer or the screening investigations employed 
may become available during the course of the study. If this happens, your research 
doctor will tell you and discuss whether you should continue in the study. If you 
decide not to carry on, your research doctor will make arrangements for your 
ongoing care to continue. If you decide to continue in the study he/she may ask you 
to sign an updated consent form.
It is possible that new information might become available that would prompt your 
research doctor to advise you to consider withdrawing from the study. He/she will 
explain the reasons and arrange for your care to continue. If the study is stopped for 
any other reason, we will tell you and arrange your ongoing care.
2.2 What will happen if I don’t want to carry on with the study?
If you want to withdraw from the study, please contact the staff in the EUROPAC 
office and tell the consultant who has been overseeing your screening investigations. 
If you would like the EUROPAC office staff to do this for you, they will be happy to do 
this. If you withdraw from the screening study we would be keen for you to remain 
involved with the registry and let us know your progress. Withdrawal from the study 
would not affect your clinical care. Information we have collected before your 
withdrawal will not be destroyed or erased but will not be considered when the 
screening process is analysed.
If you wish to withdraw any stored blood or tissue samples, we will do this wherever 
possible. Sometimes samples will have been combined with others. If all the material 
that you originally donated cannot be destroyed, all reference to you will be removed 
from any database relating to the sample. This means that the sample will be 
anonymised and will not be traceable back to you under any circumstances.
2.3 What if there is a problem?
Complaints
if you have a concern about any aspect of this study, you should ask to speak to the 
staff in the EUROPAC office who will do their best to answer your questions. Contact 
details for EUROPAC are given on the front of this information sheet. The telephone 
number is 0151 706 4168. If you would rather not deal with the staff in the office, the 
clinical consultant overseeing your care or your General Practitioner (GP) should be 
contacted. If you do not feel that either of these routes is open to you, you could
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complain to the chief executive of the trust where you are being screened and the 
normal NHS complaints procedure would be followed.
Harm
If you were to come to any harm as a result of this study, NHS indemnity and 
insurance procedures apply. In the event that something does go wrong and you are 
harmed during the research and this is due to negligence, you may have grounds for 
a legal action for compensation against the University of Liverpool and the Royal 
Liverpool and Broadgreen University Hospital Trust, but you may have to pay your 
legal costs. The normal National Health Service complaints mechanisms will still be 
available to you. NHS Indemnity does not offer compensation for harm that is not 
the result of negligence.
NHS based research
NHS bodies are liable for clinical negligence and other negligent harm to individuals 
covered by their duty of care. NHS institutions employing researchers are liable for 
negligent harm caused by the design of studies they initiate,
2.4 Will taking part be confidential?
All data handling and storage will be in accordance with Caldicott principles and/or 
the Data Protection Act 1998. All information which is collected about you during the 
course of the research will be kept strictly confidential and any information about you 
which leaves the hospital will have your name and address removed so that you 
cannot be recognised. If you participate, you have the right to check the accuracy of 
data held about you is correct. Data is collected from hospital computer systems and 
casenotes and is stored on the main EUROPAC registry database, which is 
password protected and isolated from the internet. Only the lead scientist, the 
EUROPAC database manager and the EUROPAC research fellow have the 
passwords to access the data. The data will be used to allow statistical analysis for 
any detectable changes in patients that both develop and do not develop pancreatic 
cancer. After the period of this study, data may be retained, subject to further ethical 
committee approval. Any destruction of data will be performed in a secure fashion.
2.5 Involvement of the General Practitioner?
Results would normally be communicated to your GP unless you explicitly state at 
the appropriate point on the consent form that they should not be. As a general 
principle, it is important that your GP has as much information that relates to your 
healthcare as possible. This enables them to make accurate decisions relating to 
your health.
281
Modelling of risk in individuals with a possible genetic predisposition for pancreatic cancer
2.6 What will happen to any samples that I give?
The screening blood tests that are taken will be processed and blood will be stored 
for less than a month afterwards before being destroyed in accordance with NHS 
procedures. Pancreatic juice gathered at ERCP will be stored in the Division of 
Surgery & Oncology at Liverpool University for ten years. If changes were detected 
in your pancreatic juice you may be asked for a further blood sample for research, 
which will be stored for a maximum of 10 years. This blood sample would be used to 
see if the changes detected in your pancreatic juice could be found in your blood. It 
is very unlikely that this will have any immediate consequence for you, but it may 
allow us to develop improved screening systems that could be applied later. If you 
were ever to require an operation we would ask for your permission to retain small 
amounts of tissue.
Any tissue or blood storage complies with both the data protection act and the tissue 
act. Information is coded and kept isolated from the internet on password protected 
databases. Destruction of any data will be performed in a secure fashion.
2.7 Will any genetic tests be done?
There will be no genetic (inheritable) testing done as part of this study. If genetic 
tests are available to you this will have been discussed as part of your existing 
membership of EUROPAC. Your eligibility for genetic testing in future will not be 
affected by your inclusion in the screening study and any future discussions between 
you and members of the EUROPAC study group regarding genetic testing will be 
completely independent of the screening study.
The molecular analysis of the DNA in your pancreatic juice is to look for cancer 
related changes; detection of these changes will have no implications for the health 
of your children or other relatives. As these changes will not have been inherited and 
cannot be passed on to your children, tests for these changes would not normally be 
described as genetic tests.
2.8 What will happen to the results of this study?
You will be made aware of the results of your screening blood and imaging 
investigations during the course of the study by your specialist, normally in the 
outpatient clinic. Any results from the molecular analysis of your pancreatic juice 
would only be given to you if you expressly request them. Although these tests may 
be used by your specialist to guide the timing of the other investigations, the 
significance of these test results are not clear at present and they should be 
considered as research data.
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The overall results of the research project will be made available at the end of the 
study (in an anonymised form) via publications in scientific journals and 
presentations at scientific meetings. Once results have been published, copies will 
be available from the EUROPAC office and anonymous non-sensitive information 
may be made available on the EUROPAC website.
2.9 Who is organising and funding the research?
The sponsors of this study are The Royal Liverpool University Hospital and The 
University of Liverpool. The study is being funded by the European Union (EU) and 
Cancer Research UK (CRUK). The research team do not have any financial interest 
in the study and there are no financial payments or inducements of any kind for 
recruiting participants to the study.
2.10 Who has reviewed the study?
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. This 
study has been reviewed and given favourable opinion by the Warwickshire 
Research Ethics Committee. The study was also funded only after review by the EU 
and Cancer Research UK.
This copy of the information sheet and a signed consent form will be yours to keep. 
This is both for your own records and in case of any queries or concerns in the 
future.
2.11 Further Information and contact details
Thank you for taking the time to read this information sheet. Take time to think 
through the issues raised. If you have any questions please contact the EUROPAC 
office and we will be happy to discuss things with you.
Whenever you are in contact with the EUROPAC office, your contact is:
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If you would like to gather information from other sources, you may find these 
resources of interest.
General information about research.
The Medical Research Council: http://www.ctu.mrc.ac.uk/default.asp 
Cancer Research UK: http://www.cancerhelp.orq.uk/default.asp
Specific information about this research project.
Contact the EUROPAC office (0151 706 4168)
Advice as to whether you should participate.
Contact the EUROPAC office (0151 706 4168)
You could discuss the issues with your GP
Contact details in the case of any problem.
The EUROPAC office (0151 706 4168)
The pancreas specialist that is arranging your screening.
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6.2 The Consent Form for the EUROPAC FPC Secondary 
Screening Study
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The European Registry of Hereditary Pancreatic Diseases
EUROPAC Study Co-ordinator, 5th Floor UCD Building, Royal Liverpool University Hospital, Daulby
Street, Liverpool, L69 3GA, UK
Tel: +44 151 706 4168 euroDac@liv.ac.uk www.euroDac-orq.eu Fax: +44 151 706 5826
Consent Form
Secondary Screening in Familial Pancreatic Cancer
MREC Reference 07/H1211/96 
EUROPAC Unique identification Number
PLEASE INITIAL BOX
1. I confirm that I have read and understand the information sheet dated 8th September 2007 ---------
(version 2) for the above study. I have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without my medical care or legal rights being 
affected and without affecting my continued involvement with the EUROPAC registry.
3. I have had the screening study explained to me and understand the timing of 
proposed investigations.
4. I have had the advantages and disadvantages of each part of the screening study 
discussed with me.
5. I understand that I can choose to have any combination of the tests offered.
6.1 agree/I do not agree* to have a blood sample taken and analysed for the presence of 
CA 19-9 (‘please delete as appropriate)
7. I agree/I do not agree* to have a blood sample taken and analysed to measure fasting 
blood Glucose (*please delete as appropriate)
8. I agree/I do not agree* to Endoluminal Ultrasound (EUS) if indicated in the screening 
process (*please delete as appropriate)
9. I agree/I do not agree* to Computerised Tomography (CT) scanning if indicated in the 
screening process (*please delete as appropriate)
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10.1 agree/I do not agree* to Pancreatic Juice collection via Endoscopic Retrograde 
Cholangio-Pancreatography (ERCP) if indicated in the screening process 
(*please delete as appropriate)
11.1 agree/I do not agree* that a blood sample may also be used for molecular testing 
(see section 2.6 and 2.7 of the information sheet dated 8th September 2007, version 2). 
(*piease delete as appropriate)
12.1 understand that relevant sections of my medical notes and data collected during the 
study, may be looked at by individuals from the EUROPAC study group; from regulatory 
authorities; or from the NHS Trust, where it is relevant to my taking part in this research.
I give permission for these individuals to have access to my records.
13.1 understand that the results of the ongoing trial will be collated on a database. All data 
will be stored in accordance with the Data Protection Act 1998.
14.1 understand that anonymous data from this screening may be used for medical and 
scientific purposes and that it is intended to publish the findings in the scientific literature.
15. I agree to my GP being informed of my participation in the study.
16. I agree to my GP being informed of significant clinical findings that may arise from 
the study.
17. I understand that this is a research study and is not proven as a screen for detecting 
pancreatic cancer.
18. I agree to take part in the secondary screening study. I understand that I can change 
the consents recorded on this form at any point in the future.
Name of Patient Signature Date
Name of Person taking Consent Signature Date
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in medical notes
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